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CHAPTER I 
INTRODUCTION AND 
REVIEW OF THE LITERATURE 
A. Objectives 
In recent years it has become evident that en-
dogenous compounds are produced from the condensation 
of catecholamines (CAs) with aldehydes or a-keto acids 
in several pathological conditions. Of interest in 
this dissertation are the simple, 1-alkyl, CA-derived 
condensation products, the tetrahydroisoquinolines 
(THIQs) which are associated with ethanol (EtCH) 
metabolism. The close structural similarities be-
tween CA-derived THIQ alkaloids and CA neurotrans-
mitters (NTs) suggests that these alkaloids may be 
uniquely qualified to modify biogenic amine function 
and metabolism. 
Little is specifically known about catechol-
THIQ metabolic routes in the nervous system and 
to what extent these pathways differ from conven-
tional CA metabolic routes. It is believed that a-
methylation and, possibly, conjugation are the major 
metabolic routes for THIQs. However, it is not known 
whether the in vivo a-methylation of isoquinolines is 
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similar or identical to that of their open-chain precur-
sors, or whether significant stereoselective differences 
might exist between isoquinolines and CAs. These factors 
were investigated in this dissertation. 
A second possible alternative mode of THIQ metab-
olism, oxidation to isoquinolines, was surveyed in vivo 
as a route to the potential formation of intermediates 
which could bind covalently to cellular nucleophiles. 
In view of known formation of THIQs and lack of 
knowledge about the metabolic consequences of these now-
recognized endogenous CA derivatives, studies of their 
effects on the steady state levels of biogenic amines 
and acid metabolites in vivo also were pursued. 
In order to study THIQ metabolism and to evaluate 
the pharmacodynamic events initiated by the presence of 
THIQ alkaloids and their possible metabolites, highly 
sensitive and specific assays were developed for rou-
tine, rapid, analysis of THIQs, biogenic amines and 
their respective metabolites in vivo. 
In summary, the purpose of the work described in 
this dissertation is to elucidate with greater clarity 
the discrete metabolic consequences of THIQs in mamma-
lian systems, with the underlying hypothesis that these 
condensation products may have neuroregulatory and/or 
neuropathological effects. 
B. Background 
1. Nonenzymatic Condensations: Introduction and 
Overview 
Recent experimental findings demonstrate that 
non-enzymatic, bimolecular condensation reactions are 
definite occurrences in mammalian homeostatic and di-
sease states. These reactions, first characterized 
in plants, can be generally defined as multistep 
processes involving an amine or amino acid and a 
carbonyl compound, in equilibrium with the first 
product, an imine (Schiff's base), which, if the amine 
is derived from a CA, undergo an irreversible intra-
molecular cyclization to form a second heterocyclic 
product, a THIQ molecule (Fig. 1). 
Increased levels of catecholamine-carbonyl 
condensation products are evident in at least three 
pathological conditions in man: phenylketonuria, 
Parkinson's disease, and alcoholism. The products 
have been suggested to be involved in some way in 
the sequelae and etiology of these disease states, but 
their involvement is not specifically known. 
Parkinson's disease, a progressive neurological 
disorder, is characterized by degeneration of the sub-
stantia nigra and associated subnormal striatal dopa-
mine (DA) levels. The clinical characteristics of 
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tr~r, bradykinesia and rigidity can be relieved to 
varying degrees by oral L-3,4-dihydroxyphenylalanine 
(L-DOPA) treatment in conjunction with peripheral L-
DOPA-decarboxylase inhibitors. In 1973, Sandler 
et al. (1) unequivocably demonstrated in vivo bio-
synthesis of THIQs in Parkinsonian patients under-
going L-DOPA treatment who were given test doses of 
EtOH. Both salsolinol (SAL.), the DA/acetaldehyde, 
(AcA} condensation product, and tetrahydropapaveroline 
(THP), the DA/3,4-dihydroxyphenylacetaldehyde (DHPAcA) 
condensation product, were found in significant amounts 
(Fig. 2). 
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Further evidence for THIQ synthesis was the finding of 
tetrahydroprotoberberines (THPBs) in the urine of 
Parkinsonian patients undergoing L-DOPA treatment (2). 
THPB alkaloids are suggested to be further "condensa-
tion" products derived from in vivo enzymatic con-
version of THP via a liver s-adenosyl-methionine-N-
methyl transferase, followed by apparent oxidation 
and ring closure (2, 4) (Fig. 3). 
In 1977, Coscia et al. (3) found yet another 
group of THIQs associated with L-DOPA treatment and 
Parkinsonism. The condensation of DA with phenyl-
pyruvates yielded the two 1-benzyl-1-carboxyl-THIQs, 
norlaudanosolinecarboxylic acid (NLCA) and 3-0-
methylnorlaudanosolinecarboxylic acid (MNLCA) (Fig. 4). 
Interestingly, MNLCA was found to be a normal constit-
uent in control urines as well as in human and rat 
brain (3). 
Phenylketonuria (PKU) is a well-known disease 
resulting from a genetic deficiency in functional 
phenylalanine hydroxylase. As a result, large amounts 
of phenylalanine, phenethylamine (PEA) and phenylpyru-
vate accumulate in the tissues and body fluids of PKU 
individuals (5). Initial studies by Y.H. Loo (6) in 
1967 characterized an aldimine condensate of phenethy-
lamine and pyridoxal in the urines of human PKU pa-
tients and in the brain and urines of rats made "phen-
ylketonuric" (Fig. 5). 
In 1979, Lasala and Coscia, utilizing compu-
terized gas chromatography (GC)/mass spectrometry (MS), 
quantitated significant levels of the phenylpyru-
vate/DA condensation product, 3,4-deoxynorlaudano-
solinecarboxylic acid (DNLCA) (Fig. 6), in the urine of 
PKU children and in the urine and brains of rats with 
experimentally-induced hyperphenylalaninemia (7). 
In 1979, Collins and coworkers reported the 
first evidence for the endogenous formation of 
THIQs in alcoholic humans with the finding of SAL 
and a-methylated SAL (isomer unknown) in the urines 
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of patients undergoing detoxification (Fig. 7) {8, 9). 
consistent with these findings, Borg et al. (10) have 
recently found SAL and a-methylated SAL (isomer un-
known) in the urine and lumbar spinal fluid of alco-
holic patients during and after prolonged intoxica-
tion. Earlier work by Collins and Bigdeli provided 
evidence for the formation of SAL in DA-rich brain 
regions in acute EtCH-intoxicated rats pretreated 
with pyrogallol, a potent catechol-0-methyl trans-
ferase (COMT) and aldehyde dehydrogenase inhibitor 
(11, 12). Hamilton et al. provided important addi-
tional evidence for in vivo CNS formation of THIQ 
alkaloids with his finding of a-methylated SAL 
(isomer unknown) in the corpus striatum of mice 
chronically exposed only to EtOH vapors (13), and 
no other pharmacological agents. 
In summary, non-enzymatic products of CA/car-
bonyl condensation reactions are apparently present 
normally in human metabolism. However, during vari-
ous pathological conditions their levels appear to 
be elevated (14). The possible physiological and meta-
bolic roles of these compounds are the central ques-
tions addressed in this dissertation and will be 
discussed in detail. Of particular interest are the 
simple catechol isoquinolines formed during acute 
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and/or chronic alcohol ingestion. 
2. Metabolic Considerations of EtOH Ingestion 
EtOH is an unusual psychoactive drug because 
of its significant interactions and contributions to 
cellular metabolism (15). The primary metabolic fate 
of ingested EtOH is conversion to acetate, which is 
then available to enter cellular metabolism at sev-
eral portals (16). EtOH is primarily oxidized in the 
liver by a cytosolic, nicotinamide-adenine-dinucleo-
tide (NAD+) dependent alcohol dehydrogenase (ADH) 
(17- 19) (Fig. 8). AcA produced during the oxidation 
of EtOH in the liver is metabolized to acetate by mi-
tochondrial NAD+ dependent aldehyde dehydrogenase 
(ALDH) (20- 23). Although the liver has the enzyma-
tic capacity to metabolize EtCH-derived acetate to 
carbon dioxide (co 2), most of the acetate is released 
into the circulation to be metabolized by other organs 
(24, 25). 
Concomitant with the oxidation of EtOH, cyto-
solic NAD+ is reduced to NADH by cytosolic ADH. Most 
of the peripheral metabolic changes associated with 
chronic EtOH ingestion can be traced back to the sub-
stantial decreases in the free NAD+/NADH ratio 
(18, 26). 
The decrease in the free NAD+/NADH ratio in 
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hepatocytes has been shown to have profound effects on 
the intermediary metabolism of these cells (19, 27). 
This change in redox potential during chronic EtOH 
metabolism has been implicated as the cause of de-
creased lipid oxidation, increased fatty acid synthesis 
(28), hyperlactacidemia (29), decreased glucose utili-
zation (30) and diminished activity of the citric acid 
cycle (TCA) (31). Under these conditions the reoxida-
tion of NADH to NAD+ (the requisite cofactor for cyto-
solic ADH) in the mitochrondria is rate-limiting with 
regard to in vivo oxidation of EtOH (32). 
In lieu of these findings, it is interesting 
to note that chronic ingestion of EtOH by rats 
(27, 33) and humans (34) results in an increased 
ability to oxidize EtOH. Although ADH is the major 
enzyme for the oxidation of EtOH in vivo (18, 19), at 
least two other enzyme systems, microsomal EtOH oxi-
dizing system (MEOS) and catalase are thought to con-
tribute to the oxidation of EtOH to AcA. Inducible 
changes in the activity of MEOS and catalase have 
been proposed to be responsible for the increases in 
EtOH oxidation associated with chronic EtOH inges-
tion (35, 36). 
In addition to the metabolic consequences re-
sulting from the oxidation of EtOH to AcA, many of 
8 
9 
the pharmacological effects associated with EtOH inges-
tion have been ascribed to direct effects of AcA in ani-
mal tissues. Most AcA generated in the liver (as well 
as other tissues) is metabolized to acetate by ALDH 
(37- 39). In normal individuals given a moderate 
test dose of EtOH, a relatively small portion of AcA 
escapes metabolism in the liver and enters circulation 
where it is quickly converted to acetate by other organs 
(40, 41). Circulating AcA levels are maintained at a 
steady-state level by a balance between the rate of 
production and catabolism (42). 
Chronic consumption of EtOH has been observed 
to alter these "steady-state" levels of AcA in humans 
and animals. It has been suggested that these ob-
served changes are the consequence of adaptive in-
creases in EtOH metabolism with concomitant decreases 
in AcA metabolism (35, 43). Chronic, elevated AcA 
levels have been shown to produce structural damage 
in mitochondria which in turn leads to a decreased 
capacity for the metabolism of AcA (43, 44). 
Human alcoholics have been found to have sig-
nificantly higher circulating AcA levels compared to 
controls given a test dose of EtOH (40, 45). These 
observations led to the proposal that a "vicious" 
metabolic cycle may develop during chronic alcohol 
abuse (Fig. 9), where, chronic EtOH ingestion leads to 
induced EtOH metabolism and concomitant decreases in 
AcA metabolism (26, 44). Subsequently, tissues of the 
body are perfused with increasing levels of AcA. High 
AcA levels are believed to contribute not only to the 
pathology at the primary site of AcA metabolism (i.e., 
the liver), but also in other peripheral tissues (46) 
and possibly the brain. 
Little oxidation of EtOH occurs in brain tissue 
due to very low ADH activity (1/4000 of liver activity) 
(47 - 49). However, EtCH-derived metabolites and 
products (AcA and acetate) produced in the periphery 
are metabolized by brain. AcA is primarily metabolized 
to acetate by brain ALDH which has been noted in the 
cytosol, mitochondria and microsomes of brain tissue 
(50). Brain ALDHs located in the parenchymal cells 
of capillaries, glia and neurons are even suggested 
to form a metabolic blood-brain barrier to AcA (51, 
52). Support for this concept comes from data which 
reveal multiphasic increases in brain AcA content 
corresponding to the saturation of various brain ALDHs 
~ by AcA (52, 53) as blood AcA levels increase. 
3. Neuroamine Condensation Products and EtOH: 
Pertinent Theories 
Recently several hypotheses have attempted to 
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relate the potential biosynthesis of CA/aldehyde con-
densation products or their biotransformed products in 
mammalian tissue to some of the actions mediating the 
autonomic and behavioral effects of chronic EtOH in-
gestion. It has been proposed that these compounds 
may also take part in the underlying biochemical me-
chanisms of EtOH tolerance and dependence (54). 
The first hypothesis envisions EtOH, through 
its active metabolite, AcA, inducing alterations in 
the metabolism of CAs to produce complex aberrant 
metabolites (alkaloids) having unique pharmacological 
activities (55, 56). The biogenesis of the proposed 
complex alkaloid products would be the result of the 
known competitive inhibition of aromatic ALDH (57, 
58) by elevated AcA levels (40, 45) generated during 
chronic EtOH ingestion. The inhibition of NAD+ 
linked ALDH would result in a localized increase 
in the highly reactive biogenic aldehydes generated 
by monoamine oxidase (MAO) in tissues rich in CAs. 
Deprived of their normal metabolic route(_s}, the cate-
chol-aldehydes would be available for condensation 
with parent amines (Fig. 10). 
This hypothesis is based on the formation of 
THP. THP is the requisite intermediate in the bio-
synthesis of morphine in the opium poppy Papaver 
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somniferurn (59). As early as 1938, Holtz and Heise (60) 
speculated that biogenic amines and their aldehyde de-
rivatives may condense in animal tissues. In 1964, 
Holtz et al. provided evidence for the in vitro forma-
tion of THP in rat liver homogenates incubated with 
DA (61}. Davis and Walsh, the major proponents of the 
complex-THIQ theor~ utilizing 14c-DA, provided evidence 
for THP formation in rat brainstem homogenates and 
showed that formation was enhanced by addition of in-
creasing amounts of AcA to preparations (55, 62). In 
similar experiments, Davis et al. (63) incubated 14-c-
norepinephrine (NE) in rat brainstem homogenate and 
isolated a substance which apparently had the physical 
characteristics of a 4-hydroxylated-THP. Product for-
mation was enhanced by the addition of barbiturates 
to the incubate. Further evidence to support complex 
alkaloid formation, as mentioned in section A., Back-
ground, came from the biotransformation of administered 
THP to complex THPBs in rat brain and liver 
preparations, and the detection of THPBs in the urines 
of Parkinson's patients undergoing L-DOPA therapy (64). 
Stimulated by these initial findings, numerous 
investigators have studied the possible relationships 
between the actions of opiates and that of EtOH (65 -
68). However, experiments involving THIQ interactions 
with opiate systems (through quantitation of naloxone 
displacement and analgesic effects) have yet to pro-
vide consistent data which would elucidate an accepted 
connection between the molecular mechanisms underlying 
EtOH and opiate "addiction." 
Independently, but simultaneously, Cohen and 
Collins (69 - 71) put forth a second hypothesis de-
lineating the relationship between THIQ formation and 
alcohol ingestion. The major premise of this hypoth-
esis was that AcA, in competition with rapid oxida-
tion and binding to macromolecules, can condense 
directly with CAs to form simple 1-alkyl-THIQ alka-
loids (Fig. 11). The similarity in structure be-
tween the THIQs and parent CAs gave rise to the pos-
sibility that THIQs could interact with mechanisms 
that normally regulate the physiological properties 
of CAs. In this way the THIQs, acting as "false" 
NTs, might contribute to the development of EtOH 
dependence and/or to the general pharmacological 
effects of EtOH ingestion (72). 
Although the remainder of this dissertation 
will not deal further with the hypothesis concerning 
"morphine-like" alkaloids and alcoholism, THP and 
other 1-benzyl-THIQs will be included in the dis-
cussion on the properties and interactions of THIQs 
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with biogenic amine systems. 
4. Tetrahydroisoquinoline Alkaloid Synthesis and 
Biosynthesis 
a. Plant Synthesis of THIQs 
The THIQ alkaloids are naturally occurring 
products in plants; many are known to exhibit phar-
macological actions on mammalian nervous and cardio-
vascular systems (73). Examples of naturally occur-
ring THIQs are anhalamine and salsoline, which are 
found in desert cacti (74), and the saguaro alkaloid 
gigantine, which causes hallucinogenic reactions in 
squirrel monkeys and cats (75) (Fig. 12). In plants, 
the formation of THIQ alkaloids is believed to be the 
result of the reaction of a-keto acids with an amine 
followed by decarboxylation (76). Morphine biosyn-
thesis in the opium poppy passes through the 1-benzyl-
THIQ,THP (77). It is believed that THP is formed 
from the condensation of DA with DHPAcA followed by 
enzymatic decarboxylation (78) to a 3,4-dihydroiso-
quinoline (DHIQ) . The DHIQs and their quaternary 
equivalents are established intermediates in the 
biosynthesis of plant alkaloids; chirality is de-
veloped through asymmetric reduction at this stage 
(79) (Fig. 13). Morphine and codeine are subse-
quently formed by a series of ring closures and 
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methylations followed by partial reduction of the DA-
derived benzene ring. 
SAL and THP formation in mammalian systems by 
the THIQ-1-carboxylic pathway is an interesting pos-
sibility in light of the finding of several 1-carboxy-
THP derivatives in the urine of Parkinsonian and PKU 
individuals (3, 7). 
b. General Synthesis and Biosynthesis In Vitro 
As early as 1934 researchers showed that DA and 
epinine would undergo a spontaneous condensation with 
AcA under physiological conditions to form THIQ alka-
loids (80). The formation of THIQs from the condensa-
tion of phenethylamine derivatives and aldehydes (or 
a-keto acids) is characterized by the Pictet-Spengler 
condensation reaction (81) (Fig. 1). Usually, strong 
acid and heat have been used to catalyze the reaction 
(82). Pictet-Spengler condensation reactions of CAs 
(DA, NE, L-DOPA, and epinephrine; EPI) under physio-
logical conditions with various aldehydes such as 
formaldehyde (HCHO) (70), AcA (83), DHPAcA (62), 
and pyridoxal phosphate (84) have been studied. 
When a phenolic substituent is located para to the 
site of ring closure, the reaction was known to 
occur at ambient temperature and neutral pH (69, 80). 
This facilitation is negligible under physiological 
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conditions if the hydroxyl group is a-methylated or meta 
to the site of ring closure (84). 
THIQ synthesis has been studied in tissue homog-
enates (62, 85), isolated intact cells, and organ prep-
arations (70, 86). Perfusion of cow adrenals with AcA 
or HCHO yielded the corresponding THIQs of NE and EPI 
(70, 86). When high concentrations of HCHO were used, 
total conversion of EPI and NE to THIQs was observed 
(69). THIQ synthesis has also been observed when per-
fusion with AcA was in the range of that seen in the 
blood of human subjects ingesting EtOH (87). 
5. Biogenic Amine Biosynthesis and Metabolism 
Before discussing interactions of THIQs with 
biogenic amine metabolism, biogenic amine biosynthesis 
and metabolism will be considered. In the mammalian 
CNS the CAs, EPI, NE •and DA and the indoleamine, sero-
tonin (5HT~ are putative neurotransmitters. 
a. Catecholamines 
Tyrosine is the only dietary amino acid precus-
sor of DA, NE, and EPI (88). Phenylalanine through 
its conversion in the liver to tyrosine by phenylala-
nine hydroxylase can also contribute to CA biosynthe-
sis (89). The rate limiting step in the biosynthesis 
of CAs is the conversion of tyrosine to L-DOPA by ty-
rosine hydroxylase (TH) (90). THis a cytoplasmic 
enzyme requiring reduced biopterin (91) as a cofactor, 
and is under metabolic feedback inhibition by CA prod-
ucts (92). L-DOPA is rapidly decarboxylated to DA by 
L-DOPA decarboxylase (DDC) (93, 94). Because of its 
low specificity for aromatic amino acids, DDC has 
been given the name aromatic acid decarboxylase (AAD) . 
It is known to decarboxylate a variety of aromatic 
amino acids such as 5-hydroxytryptophan, phenylalanine, 
tryptophan and tyrosine. 
DA is converted to NE by the enzyme DA-B-hy-
droxylase (DBH) (95), an ascorbate -requiring, copper 
containing oxygenase (96) • NE is converted to EPI 
by the action of phenylethanolamine-N-methyl-trans-
ferase (PMNT) utilizing S-adenosyl-L-methionine 
(SAM) as a methyl donor (97). Evidence is accumu-
lating that EPI is a putative neurotransmitter in 
the brainstem (98) . 
The only appreciable endogenous metabolites of 
DA in vivo are 3,4-dihydroxyphenylacetic acid (DOPAC), 
homovanillic acid (4-hydroxy-3-methoxy-phenylacetic 
acid, HVA) and 3-0-Methyl-DA(3M-DA) (100 - 102). By 
use of GC, the endogenous occurrence of 3-methoxy-4-
hydroxyphenylethylene glycol (MOPEG) and 3,4-dihydro-
xyphenylethylene glycol (DOPEG) have been demonstrated 
as the CNS metabolites of NE in vivo in many species 
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(99, 103}. Little is known about central metabolism of 
EPI. The main metabolites of intraventricularily admin-
istered 3H-EPI were metanephrine (MET} and vanillylman-
delic acid (3-methoxy-4-hydroxy-mandelic acid, VMA} 
(260). CAs are oxidatively deaminated to their corres-
pending catechol-aldehydes by a multiform, mitochrondrial 
bound enzyme, MAO. Investigators have been able to 
distinguish two forms of this enzyme by the use of 
the selective-irreversible inhibitors clorgyline and 
deprenyl (104, 105}. These studies indicate that 
specific substrates for the A species of the enzyme 
include SHT, NE and normetanephrine (NORMET} whereas 
benzylamine and PEA are the substrates for the B 
species and DA is acted on by both. The aldehydes 
are converted by the actions of aromatic aldehyde 
dehydrogenases or reductases to corresponding acids 
or alcohols. 
In addition to oxidative dearnination, a-methyl-
ation plays a role in the metabolism of CAs. COMT 
catalyzes the transfer of a methyl group preferen-
tially to the "meta" hydroxyl of substrates containing 
the catechol moeity, in the presence of SAM as the 
methyl donor and magnesium ions (Mg++} as activator 
(106). To a very limited extent para a-methylation 
of endogenous substrates is seen in vivo (107). 
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Para 0-methylation of CAs has been shown to be increased 
in such pathological conditions as Parkinson's disease 
(108), neuroblastoma (109, 110) and pheochromocytoma 
(111). COMT shows low specificity, having as some of 
the physiological substrates, EPI, NE, DA, L-DOPA, 
DOPEG, and DOPAC (112). Summaries of possible meta-
bolic routes of NE and DA can be found in Figures 14 
and 15, respectively. 
b. Serotonin (5HT) 
Tryptophan is the immediate precursor of 5HT 
and is converted by the enzyme tryptophan hydroxylase 
to 5-hydroxytryptophan {5HTP) (113). 5HT synthesis 
is controlled at the level of tryptophan hydroxylase. 
5HTP is converted to 5HT by AAD. The main metabolic 
route for 5HT in the CNS and periphery appears to be 
deamination (MAo-A) and subsequent oxidation to 5-hy-
droxyindoleacetic acid (5HIAA) (114). However, fol-
lowing ingestion of large amounts of EtOH, a shift 
in peripheral 5HT metabolism is observed. Increases 
in the reductive metabolism of 5HT to 5-hydroxytryp-
tophol (5HTOL) with a concomitant decrease in 5HIAA 
are seen in the liver and urine, indicating probable 
inhibition of aromatic aldehyde dehydrogenase by 
AcA (115) (Fig. 16). 
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c. General Neurotransmitter Events 
In general the biogenic amine NTs are stored in 
high concentrations in selective areas of the peripheral 
and central nervous systems. They are actively se-
questered into dense-granular vesicles located in the 
presynaptic endings of neurons. Stimulation of the 
nerve releases only those transmitters bound within 
the dense-core vesicles. NTs released into the synap-
tic cleft (interneuronal space) can react with speci-
fic post-synaptic receptor sites, initiating a sequence 
of molecular events leading to a post-synaptic response. 
Inactivation of NTs occurs rapidly, primarily due to 
reuptake into the pre-synaptic nerve terminal (>80%). 
Neuronal uptake is an unidirectional, sodium-ion (Na+) 
dependent, stereospecific, energy requiring mechanism 
which follows Michaelis-Menten saturation kinetics. 
After reuptake across the neuronal membrane, NTs can 
be reincorporated into dense-core vesicles. Those 
NTs not stored become available for catabolism by 
MAO and COMT. 
6. Transmitter-Like Properties of THIQs 
The similarities between THIQ and CA structure 
led to the theory that the THIQs may act as "false" 
NTs (69 - 71). The THIQs would then exert their in-
fluence by interacting with mechanisms that normally 
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regulate the physiological properties of CAs. In sup-
port of this theory, investigators have noted that 
THIQs interact with axonal and vesicular transport 
systems leading to their uptake and storage in CA 
neurons, are released from nerve terminals along with 
CAs, and interact with pre- and post-synaptic receptors. 
THIQ alkaloids have been shown to block the up-
take of CAs by rat synaptosomes and tissue slice prep-
arations. The addition of THIQs to rat brain synapto-
somes or tissue slices incubated with 3H-CAs resulted 
in an efflux of 3H-CAs, probably due to displacement 
of the 3H-CAs from storage vesicles (116 - 118). 6,7-
dihydroxytetrahydroisoquinoline [6,7-(0H) 2THIQJ has 
been shown to be taken up and stored in sympathetic 
neurons of rat iris (119, 120). Similarly, THIQs were 
shown to be taken up by rat heart, salivary gland, 
iris, and mouse adrenal (121), by capillary endothe-
lial cells, unidentified neuronal components of rat 
hypothalamus and hypophysis (122), and by synapto-
somal fractions of rat brain (123) • THIQs have also 
been shown to be weak inhibitors of 5-HT uptake into 
rat brain slices (124, 125). Uptake was blocked by 
traditional inhibitors of the axonal membrane such 
as cocaine and desmethylimipramine (119 - 121). 
These results suggest that THIQs and CAs compete with 
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each other for transport sites on the neuronal presynap-
tic membrane (126). 
THIQs formed during the perfusion of cow adrenals 
with AcA and HCHO were retained in the gland and were 
actually found to be stored in the CA-binding vesicles 
(127, 128). 6,7-(0H) 2THIQ was shown to be stored in 
the CA-binding vesicles of the rat iris and pineal 
gland (129). THP was found to be incorporated into 
small granular vesicles when incubated with rat caudate 
slices (130). Vesicular storage of THIQs inCA-binding 
vesicles has been shown to be by a reserpine-resistant 
mechanism both in vitro (119, 129) and in vivo (120). 
Reserpine blocks CA uptake into storage vesicles but 
does not affect the axonal uptake mechanisms. There-
fore, THIQs apparently share axonal transport mechan-
isms with CAs but binding to storage vesicles occurs 
by a mechanism which differs from endogenous amine 
binding (131). 
THIQs have been shown to be released upon nerve 
stimulation via the same mechanisms that control re-
lease of endogenous NTs. EPI and NE condensation 
products formed during perfusion of cow adrenals with 
AcA were released with endogenous EPI and NE upon 
stimulation with acetylcholine or succinylcholine 
(132, 133). In a classical experiment, Mytilineou 
et al. demonstrated the release of 6,7-(0H) 2 THIQ from 
NE nerve terminals in rat iris upon electrical stimu-
lation in vivo (120) . Rats were first depleted of en-
dogenous stores of NE by pretreatment with a-methyl-
para-tyrosine methyl ester and reserpine. Subsequently 
rats received intravenous injections of 6,7-(0H) 2THIQ 
which was shown to accumulate in NE nerve terminals 
within the CA-binding vesicles. Electrical stimula-
tion of the preganglionic fibers of the superior 
cervical ganglion showed depletion of the THIQs from 
the storage vesicles and caused retraction of the 
upper eye lid, protrusion of the eyeball and dila-
tion of the pupil, indicating activation of post-
synaptic adrenergic receptors. 
The THIQs have been shown to interact with CA 
receptors both in vitro and in vivo. This is not 
surprising considering the structural similarities, 
for example, between THP and the pharmacological DA 
agonists apomorphine and bulbocapnine (Fig. 17) 
(134, 135). As early as 1910, THP had been shown to 
have S-agonist actions, lowering blood pressure, in-
creasing heart rate, and causing relaxation of 
uterine muscle in cats (136). Several investigators 
have reported potent lipolytic activity for THP 
(137 - 140) and to a less extent SAL (138). The 
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S(-) isomer of both compounds exerted the most potent 
effects on glycerol and free fatty acid release {138). 
THP has been shown to be a moderate DA-depen-
dent adenyl cyclase inhibitor (140 - 142). SAL also 
exerts adenyl cyclase inhibition but to a lesser degree 
(141, 142). The S(-) isomer of both compounds was 
again the more effective configuration. Thus far, 
SAL has demonstrated relatively weak S-agonist effects 
(137, 143, 144). However, this THIQ has shown mod-
erate a-antagonism of NE on aorta and vas deferens 
of rat (145, 146). It has also been shown to block 
the effects of 5HT stimulation of smooth muscle in 
the vas deferens and uterus and block the effect of 
oxytocin and vasopressin on the uterus of rat (147). 
7. THIQ/Enzyme Interactions 
0-methylation of DA- and NE-derived THIQ alka-
loids has been studied in rat brain and liver homog-
enates (148) and with purified rat liver COMT (149). 
The 0-methylation of THIQs is sensitive to inhibi-
tion by pyrogallol, a known COMT inhibitor. Intra-
cerebroventricular (ICV) administration of THP and 
SAL resulted in half life's (T112 's) of 24 and 12 
minutes, respectively (150). These T112 's were 
markedly prolonged by pretreatment with pyrogallol. 
In vitro studies have demonstrated that the 
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radioactivity derived from 14c-SAM is incorporated into 
the molecular structure of THP and SAL following in-
cubation with rat liver CaMT preparations (151) . THIQs 
are both substrates and competitive inhibitors of caMT 
(148, 151 - 153). SAL and THP have been reported to 
be equal or better substrates for in vitro a-methyla-
tion by caMT than the endogenous substrates, DA and 
NE (149, 151, 153). Creveling et al. have reported 
that both the 6-(meta) and 7-(para) hydroxyls were 
a-methylated on two DA derived THIQs by purified rat 
liver caMT (154). Bail et al. (155) has presented in-
teresting preliminary evidence indicating that SAL and 
6,7-(aH) 2 THIQ are largely or exclusively a-methy-
lated on the 7-(para) hydroxyl in rat tissues in vivo. 
Extensive a-methylation on the para hydroxyl is simply 
not observed with "normal 11 catecholamine and catechol 
acid substrates. Meyerson et al. have demonstrated 
that the a-methylation of the complex THIQs, THP and 
THPB, is on both the meta and para hydroxyls in vitro 
(156), the ratio (of meta/para a-methylation) being 
significantly influenced by the optical isomer used. 
Locke et al. demonstrated that a-methylated 
forms of 3H-6,7-(aH) 2DHIQ appeared to be retained in 
sympathetically innervated tissues such as heart 
and salivary glands in amounts greater than or equal 
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to the unmetabolized THIQ (121). As mentioned in sec-
tion I, Collins et al. have found 0-methylated-SAL 
(isomer unknown) in the urines of patients undergoing 
alcohol detoxification (8) and Hamilton et al. (13) 
have found 0-methylated-SAL (isomer unknown) in the 
striata of EtCH-treated mice. In view of the rapid 
formation of a-methylated THIQ alkaloids, it is not 
surprising that O'Neill and Rahwan (157) were unable 
to detect SAL in the brain of alcohol-treated mice, 
in the absence of pretreatment with COMT inhibitors. 
With the exception of earlier work by Hjort 
et al. (158, 159) on the gross peripheral pharmacology 
of phenolic THIQs, little work has been done on the 
physiological and pharmacological properties of 0-
methylated-THIQs, which are probably the primary me-
tabolites of catechol-THIQ alkaloids in vivo. 
To date there is no evidence that the cyclic 
THIQ alkaloids are metabolized by MAO. However, SAL 
and THP have been demonstrated to inhibit competiti-
vely the deamination of 5HT in rat brain and liver 
homogenates (151, 160). A variety of THPBs and 
THIQs were shown to inhibit both type A and B 
species of MAO in rat brain homogenates (161). It 
appears that type A is more sensitive to inhibition 
by these substrates. The THPBs proved to be relatively 
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potent and specific inhibitors of MAO type A. How-
ever, sequential methylation of the hydroxyls on the 
berberine ring system resulted in decreased selec-
tivity and potency of MAO inhibition (161). 
Compared to classical inhibitors of MAO (i.e. 
clorgyline, pargyline, deprenyl, etc.) (162), the 
THIQs appear to be relatively weak to moderate in-
hibitors of MAO in vitro. However, the synaptic 
properties of uptake and vesicular storage provide 
mechanisms for1amplification of THIQ actions. Intra-
neuronal inhibition of MAO has been investigated both 
in vivo and in vitro in the sympathetic nerve plexus 
of mouse heart. Cohen and Katz (163) utilized 6,7-
(0H)2THIQ and demonstrated a 38% increase in 3H-NE 
content with a concomitant decrease in 3H-deaminated-
NE in 3H-NE-treated reserpine-pretreated mice, indi-
eating in vivo inhibition of MAO. In a complementary 
in vitro experiment, Katz and Cohen (164) demonstrated 
intraneuronal inhibition of MAO by both SAL and 6,7-
(OH) 2THIQ. THP did not elicit potent inhibitory ac-
tions, apparently because of poor uptake into the 
nerve plexus. 
In vivo experiments in which large doses of 
THP and SAL were administered ICV provided evidence 
that these THIQ alkaloids were able to alter the 
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steady-state levels of endogenous CA and SHT (165). The 
exact mechanism by which their actions are exerted is 
still unknown. Hannigan and Collins (166) demonstrated 
that acute peripheral administration of 3-carboxy-sal-
solinol (3-CSAL), increases SHT levels in the corpus 
striatum and hypothalamus of rats, whereas chronic 
administration decreased the SHT levels in these tis-
sues. Livra et al. (167) further demonstrated that 
THIQ alkaloids can influence cerebral monoamine me-
tabolism in vivo by the finding that HVA and SHIAA 
levels are raised after acute or chronic intraperi-
toneal (i.p.) injections of THP. In addition, THP 
blocked the L-DOPA-induced increase in HVA as well 
as the p-chlorophenylalanine-induced decrease in 
SHIAA. As there is some question as to whether THP 
can cross the blood-brain-barrier (BBB), these ob-
served interactions with biogenic amine systems could 
depend on a peripheral THP metabolite which enters 
the CNS. 
The THIQ alkaloids have been shown to be weak 
inhibitors of the Na+-Potassium ion (K+) ATPase and 
++ Mg ATPase systems. These membrane-bound, active 
transport systems participate in modulating the 
Na+ and K+ fluxes of excitation and are fundamental 
to the energy-dependent reuptake and storage of NTs 
released at nerve endings (168- 170). 
Evidence indicates that SAL is a good in vitro 
inhibitor of rat brain TH, the rate limiting step in CA 
biosynthesis {171). Little stereo-specificity was 
observed with both the S{-) and R{+) configurations 
inhibiting TH activity nearly equally. The inhibi-
tion was found to be competitive with the pterdine 
cofactor {170). THP proved to be a relatively weak 
inhibitor while 4,6,7-trihydroxy-THIQ [4,6,7-{0H) 3 
THIQ] and 3-CSAL demonstrated moderate inhibition of 
TH activity. However, in vivo experiments utilizing 
SAL, 4,6,7-{0H) 3THIQ and 3-CSAL did not indicate any 
in vivo TH inhibition by these compounds {170). 
Coscia et al. {173) have recently reported on 
the interactions of a variety of NLCA derivatives with 
the enzymes involved in CA metabolism. The NLCAs in-
hibited TH non-competitively with respect to substrate 
and cofactor. DNLCA was shown to inhibit TH both in 
vitro and in vivo. MNLCA proved to be a potent in 
vitro inhibitor of DBH while DNLCA proved less in-
hibitory and NLCA was not effective. NLCA was found 
to be a competitive inhibitor of NE methylation by 
hepatic COMT. The NLCA derivatives showed only minor 
effects on MAO and AAD. 
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8. Possible Oxidative Mechanism For THIQ Metabolism 
A growing amount of evidence derived from human 
and animal alcohol studies now documents that chronic 
EtOH ingestion leads to central and peripheral nerve 
damage despite adequate nutrition (174 - 177). The 
precise mechanisms by which ethanol exerts these 
chronic toxic effects is still unknown. Based on sev-
eral lines of evidence, Collins (178) has proposed a 
discrete chemical mechanism to explain the cytotoxi-
city of ethanol, based on the potential involvement 
of THIQs. Considering the chronic nature of THIQ-re-
lated pathological conditions and attendent excess 
production of these alkaloids, it is conceivable 
that they may have some uniqu~ pat_hological 
effect(s). Supporting this hypothesis are 
experiments by Azevedo and Osswald demonstrating 
that administration of a NE-derived THIQ produced 
selective ultrastructural degeneration of adrenergic 
nerve terminals (179) and hepatotoxicity (180) in 
rats. In addition, Meyers and Melchior (181) dem-
onstrated long-term aberrant behavioral effects (in-
creased ethanol preference) in rats which were in-
duced by ICV administration of THP. 
While the major metabolic routes for cate-
cholic THIQs are probably a-methylation and 
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conjugation, Collins proposed a minor oxidative meta-
bolic route for THIQ metabolism which would lead to 
DHIQs and related N-oxides (Fig. 18). It was suggested 
that the DHIQs, as possible tissue binding agents, may 
play a role in the chronic neurotoxic effects of EtOH. 
The conversion of THIQs to DHIQs is a well-es-
tablished pathway in the aldehyde-induced fluorescence 
method for histochemical demonstration of biogenic 
amines in nerve (182). The decarboxylation of 1-
carboxyl THIQs to afford DHIQs has been accomplished 
by oxidative chemical decarboxylation (183), electro-
chemical oxidation (184), and by horseradish peroxi-
dase enzyme (78). In addition, DHIQs derived from 1-
carboxy-THIQs have been demonstrated as reactive in-
termediates in the biosynthesis of alkaloids in 
plants (79, 185). 
Because of electronic similarities, the me-
chanism by which the DHIQs would exert their neuro-
toxic effects could be analogous to that of 6-hydroxy-
dopamine (60HDA), a potent pharmacological neurotoxin. 
The actions of 60HDA are dependent initially on up-
take into catecholamine neurons and subsequent oxida-
tion to at least two active species, the quinone and 
hydrogen peroxide (186) (Fig. 19). Studies of the 
interactions of 60HDA with various model proteins 
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in vitro (187, 188) and chemical interactions with brain 
tissue in vivo (189, 190) clearly demonstrate that 60HDA 
covalently reacts with and binds nucleophilic groups on 
proteins to form stable covalent bonds (Fig. 20). 
At physiological pH, DHIQs are believed to exist 
predominately at quinoidamine tautomers (191). How-
ever, this is based on studies with formaldehyde-re-
lated DHIQs; the 1-methyl DHIQs in Fig. 19 have not 
actually been studied. Upon examination, the elec-
tronic and structural similarities between DHIQ quin-
oidamines and the oxidized electrophilic quinone of 
60HDA become strikingly apparent (Fig. 19). If two 
DHIQ tautomers share even a degree of the electro-
philic nature of 60HDA, the DHIQs, which are known 
to be taken up and stored in CA neurons (192), should 
be capable of producing neuronal damage via covalent 
attachment to electron-rich cellular ligands (sulfhydryls). 
The DHIQs need not have as extensive electro-
philic and sulfhydryl-binding capabilities of 60HDA 
since they are postulated to form in trace a~ounts 
during chronic ingestion of EtOH. a-methylation of 
THIQs and DHIQs at the meta-hydroxyl (analogous to 
that of the open chain catecholamine precussors) 
would be expected to block the cytotoxic mechanism. 
However, as stated in section 8., evidence now 
indicates that the stereoselective a-methylation pat-
terns of THIQs differs from their catecholamine pre-
cussers (155, 156). 
9. Current Analytical Techniques in THIQ Research 
It has been recognized that available analyti-
cal methods for the neurochemical study of biogenic 
amines and their metabolites are often limited, es-
pecially when dealing with the endogenous levels 
found in small biological samples. This problem is 
exacerbated when dealing with the THIQ alkaloids and 
their metabolites since their levels will always be 
significantly less than their catecholamine precursors. 
Early THIQ research relied heavily on radio-labeled 
precursor studies, with separations by thin layer 
chromatography (TLC), paper chromatography, paper 
electrophoresis and ion-exchange chromatography. 
Detection was by combinations of visualizing stains 
and radioautography (85, 87, 127, 193 - 195). These 
techniques do not offer a very great degree of se-
lectivity, are not generally sensitive (with the 
exception of radio-labeled studies wnich a~~ imprac-
tical for fhe.study of endogenous compounds) and are 
complicated by lorig ardous·isolation procedures. 
More recently, a radioenzymatic method has 
been developed for the detection and quantitation 
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of SAL (196). The principle of this technique is based 
on enzymatic a-methylation of a catechol by CaMT uti-
lizing 14c-SAM as cofactor. Separation is by TLC and 
quantitation by liquid scintillation counting of an 
extract from the developed plate. Although this 
technique is adequately sensitive for the detection 
of endogenous levels of SAL (and probably other THIQs) , 
it is inherently limited by its requirement for ca-
techols. Therefore, endogenous a-methylated or con-
jugated THIQs cannot be assayed directly by 
this approach. 
A significant recent development in the analysis 
of biogenic amines and their congeners is HPLC with 
electrochemical detection. This technique offers an 
inexpensive but sensitive method for the detection of 
picomole concentrations of a range of important phen-
olic and catecholic compounds (197). Initial studies 
utilizing HPLC with electrochemical detection for the 
separation and quantitation of SAL from biological 
samples has proven the efficacy of this technique 
for THIQ analysis. HPLC with electrochemical detec-
tion has been utilized for the detection of NE, DA, 
5HT, SHIAA, HVA and DaPAC in a variety of combina-
tions in discrete brain regions (197). What has not 
been accomplished is the simultaneous assay of all 
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biogenic amines and acids in a given brain structure, 
such as DA, DOPAC, HVA, 5HT and 5HIAA. Separation and 
quantitation of these compounds would give a very com-
plete profile of biogenic amine metabolism within the 
corpus striatum, for example. 
GC/MS is a powerful technique which can con-
elusively identify neuroamines and derivatives present 
in tissue in femtomole amounts. Several investiga-
tors have utilized this technique to identify THIQs 
in discrete brain regions and biological fluids 
(1- 3). This assay, which appears to be the de-
finitive identification step in neurochemical re-
search, is plagued by two serious drawbacks: 1) com-
plicated and sophisticated instruments requiring ex-
pert maintenance and manipulation for both sample 
analysis, data processin~ and interpretation; and, 
5 2) a prohibitive cost ($1.5 - 2 X 10 ) • In lieu of 
these problems, the practicality of GC/MS in the 
average neurochemical laboratory is limited. 
GC with electron capture (EC) detection offers 
a second highly sensitive and specific technique for 
detection of THIQs with picomole/g tissue sensi-
tivity. Several investigators have utilized GC with 
EC detection, with varying degrees of success, to 
determine THIQs in biological samples (8, 11, 13, 155). 
A limiting factor in GC/EC is the ability to separate 
compounds with close structural similarities, which 
is a function of column efficiency. To date the 
separation of geometrical isomers of biogenic amines 
and THIQs on conventional packed GC columns has not 
been accomplished. One possible answer to this 
problem is the use of capillary GC columns. Gen-
erally, capillary columns are those which have in-
ternal diameters less than 1 mm. 
There are three main types of capillary 
columns: 1) micropacked, miniaturized versions of 
ordinary packed columns; 2) support-coated open 
tubular (SCOT), which have small particles of solid 
support adhered to the wall, but have an unrestricted 
flow path; 3) wall-coated open tubular (WCOT) , in 
which the liquid phase is directly coated to the 
inner wall of the column as a thin film. With this 
type of column, the highest efficiency can be at-
tained (>3,000 theoretical plates/m). 
GC/EC utilizing a 25m WCOT capillary chro-
matograph has been utilized for the separation and 
quantitation of the principal_in vitro metabolites 
of prostaglandin endoperoxides (198). Detection 
limits equaled or exceeded those obtained for packed 
column separations and EC detection. The S-antagonist~ 
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alprenolol and oxyprenolo~ have been successfully quan-
titated and separated, after isolation from human blood 
samples, using EC/GC with a 25M X 0.25mm WCOT glass 
capillary column {199). The lowest detectable amount 
of the halogenated {heptafluoracyl) derivatives of 
alprenolol and oxprenolol were 2 pg. Preliminary 
studies utilizing model compounds to represent various 
classes of biogenic amines indicated that fluoracyl 
derivatives of biogenic amines and their metabolites 
could be rapidly separated and quantitated by EC/GC 
with WCOT columns. 
In light of the rapidly accumulating evidence 
of THIQ involvement in pathological conditions and the 
current state-of-the-art for THIQ and biogenic amine 
analysis, highly sensitive and specific assays to 
simultaneously detect these compounds and their me-
tabolites are definitely needed. The requirements 
for the assays are the ability to separate a broad 
spectrum of closely related compounds at picomole 
sensitivity with minimal cost and high reproducibility. 
Assays that would meet these requirements would enable 
the investigator to assess THIQ involvement in human 
pathological conditions. 
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CHAPTER II 
EXPERIMENTAL: MATERIALS AND METHODS 
A. Standard Analytical Methods for the Characteri-
zation of Purity and Identity of Compounds 
Synthesized in Section II 
Identity and purity of synthesized compounds 
were established by co~parison of melting 
points to literature values, co-chromatography with 
authenic samples (when available), infrared (IR) 
spectra and nuclear magnetic resonance (NMR) spectra. 
HPLC, conventional and capillary GC and TLC techniques 
were employed where stated. HPLC and GC techniques 
are discussed in a separate section. 
1. Melting Point 
Melting points were obtained (uncorrected) on 
dried, crystalline samples utilizing a standard melting 
point apparatus (Gallenkamp). 
2. IR Spectrum 
IR spectra were performed by making a potassium 
bromide (KBR; Mallinckrodt) pellet with dried crystals. 
The spectra between 4000 and 400 nm were obtained on a 
grating IR spectrophotometer (Perkin Elmer, model 337). 
38 
3. NMR Spectrum 
NMR spectra were performed utilizing deuterium 
oxide (D 20) solvent. The spectra between 10 and 0 ppm 
(H 2 ) were obtained on a 60 MHz NMR system (Varian 360; 
courtesy Dr. D. Crumrine, Loyola University, Depart-
ment of Chemistry) . 
4. TLC 
TLC was utilized to assess the progress and com-
pletion of synthetic reactions. Two principal proce-
dures were utilized. TLCs of CA-derived THIQs were 
performed by spotting 1 - 5 microgram quantities on 
4 X 10 em silica gel (Whatman) plates. The plates 
were developed in a butanol/acetic acid (HOAc)/water 
(distilled, deionized; dH 20) 4/1/1, (V/V/V) solvent 
system. Starting material, suspected product and a 
mixture of the two were run on the same plate simul-
taneously. Completed plates were air dried and vis-
ualized in an iodine (I 2 ) chamber unless otherwise 
described. 
Mono- and di-methylated THIQs, DHIQs, and CAs 
were separated from their dihydroxylated derivatives 
by utilizing alumin~~ oxide (AL 2o3 ) plates (Macherey-
Nagel) . Development was in a chloroform/methanol 
(MeOH)/dH 2o, 70/50/5, (V/V/V) solvent system. Start-
ing material, suspected product, and a mixture of the 
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two were run on the same plate. Completed plates were 
air dried and visualized in an I 2 chamber, or with a 
K3 Fe (CN) 6 (Mallinckrodt; 0.25 rng/rnl in 0.2 Na2HP0 4 
buffer pH 8-.3} spray which is allowed to dry and then 
counter stained with Fe c1 3 (Mallinckrodt; 2.5% Fe c1 3 
freshly mixed in 1.5 volumes of acetone) (70). 
B. Synthesis of Tetrahydroisoquinolines 
1. Synthesis of 1-Methyl-6,7-Dihydroxy-1,2,3,4-
Tetrahydroisoquinoline (Salsolinol; SAL) HCl 
A solution of 1.87 g (8.0 rnMoles) of DA HBr 
(Aldrich) in 30 rnl of dH2o was adjusted to pH 4.5 
with dilute NH40H (Mallinckrodt). Ice-cold redis-
tilled AcA (J.T. Baker, 0.79 g; 18 rnMoles) was 
added. The reaction was capped and allowed to stir 
slowly at room temperature (RT 0 ). After 3 days, the 
reaction was blown to dryness under a stream of extra 
dry nitrogen (N2Ex) (Benster Welding). The residue 
was dissolved in a minimum vol~.e of hot, absolute 
EtOH (U.S. Industrial Chern.) and brought to the cloud-
point by drop-wise addition of ethyl acetate (EtOAc). 
The suspension was placed in a -20°C freezer over-
night, to yield a primary crop of white needle-like 
crystals. The mother liquor was not recrystallized. 
The crystals were dried over night in a vacuum des-
sicator with phosphorous pentoxide (P 2o5 ) and 
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characterized by NMR, IR, TLC, GC, HPLC and melting 
point comparison (Table 1.) 
2. Synthesis of 1-Methyl-1-Carboxy-6-Hydroxy-7-
Methoxy-1,2,3,4-Tetrahydroisoquinoline (7-0 
MethY-l -1-Carboxy-Salsolinol; 7M-l-CSAL) 
A solution of 0.5 g (2.5 mMoles) of 4-0-Methyl-
dopamine (4M-DA) (HCL salt; Aldrich) and 0.264 g 
(4.4 ~~oles) of pyruvic acid (Sigma) in 10 rnl of 
dH 2o was adjusted with concentrated (cone.) NH 40H to 
pH 4.5 and allowed to stir gently. After 4 days, the 
reaction was seeded by scratching the side of the 
glass vial with a glass rod and was then placed in a 
refrigerator for 1 hr. The crystals which separated 
were filtered and washed with cold dH 2o to remove 
any excess pyruvic acid. The product was dried under 
vacuum in the presence of P2o5 and characterized by 
NMR, IR, TLC, GC, HPLC and melting point comparison 
(Table 1). 
3. Synthesis of 1-Methyl-1-Carboxy-6,7-Dihydroxy 
1,2,3,4-Tetrahydroisoquinoline (1-Carboxy-
Salsolinol; 1-CSAL) 
A solution of 3.0 g (16 mMoles) of DA (HCl 
salt; Sigma) and 1.85 g (42 mMoles) pyruvic acid 
in 10 ml of dH 2o was adjusted to pH 4.0 with cone. 
NH40H. After gentle stirring for 4 days at RT
0
' 
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reaction was seeded by scratching the side of the reac-
tion vial. The reaction mixture was placed in a re-
frigerator for 1 hr. The white powdery crystals which 
separated were isolated over a sintered glass filter 
and washed with cold dH 2o to remove excess pyruvic 
acid. The product was dried overnight under vacuum 
in the presence of P 2o5 and characterized by NMR, IR, 
GC, HPLC, TLC and melting point comparison (Table 1). 
4. Synthesis of 6,7-Dihydroxy 1,2,3,4-Tetrahydro-
isoquinoline [6,7-(0H) 2THIQ]HBr 
A suspension of DA(HBr salt; 0.233 g; 1 mMole) 
in 5 ml of dH2o was adjusted to pH 4.5 with dilute 
NH 40H. HCHO (37% solution; Mallinckrodt; 1.23 ml) 
was added and the reaction mixture was sealed and 
allowed to stir gently at ~0 • After 24 hr, the re-
action mixture was brought to dryness under a stream 
of N2Ex The residue was dissolved in a minimum 
volume of hot, absolute EtOH and brought to the 
cloud-point by dropwise addition of EtOAc. This 
suspension was placed in a -20°C freezer overnight 
yielding a primary crop of white needle-like crystals. 
The mother liquor was not recrystallized. The crystals 
were dried over night under vacuum in the presence of 
P2o5 and characterized by NMR, IR, TLC, HPLC, GC, and 
melting point comparison (Table 1). 
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s. Conversion of 1-Methyl-6,7-Dimethoxy-3,4-Dihydro-
isoquinoline (l-ME-6,7DMDHIQ) HCl to 1-Methyl-6, 
7-Dihydroxy 3,4 Dihydroisoquinoline (1-ME-6,7-
DHIQ) HBr 
1-methyl-6,7-dimethoxy-3,4-dihydroisoquinoline 
HCl (1-Me-6,7-DMDHIQ; synthesized by A. Hashmi, 1978; 
1 g; 4.2 m Moles) was placed in a 20 ml screw top vial. 
Borontribromide (BBr 3 ; 10 ml; Aldrich) was added, the 
vial was capped with. a plastic-lined top and the solution 
was stirred at ~o for 3 hr. The reaction mixture was 
Ex blown to dryness in a hood under a stream of N2 . 
The residue was brought up in a minimum volume of hot, 
absolute EtOH and brought to the cloud-point by drop-
wise addition of EtOAc. The suspension was placed in 
a -20°C freezer overnight to yield a crop of yellow 
crystals. The mother liquor was not recrystallized. 
The product was dried over night under vacuum in the 
presence of P 2o5 and characterized by NMR, IR, TLC, 
HPLC, GC and melting point comparison (Table 1). 
6. Conversion of 1-Methyl-6-Methoxy-7-Hydroxy-
3,4-Dihydroisoquinoline (l-Me~6M-DHIQ) HCl 
to 1-ME-6,7-DHIQ HBr 
1-methyl-6-methoxy-7-hydroxy-3,4-dihydroiso-
quinoline (HCl salt; 0.5 g; 2.2 m Moles; synthesized 
by A. Hashmi, 1978) was placed in a 20 ml screw top 
vial. BBr3 (10 ml) was added, the vial was capped 
with a plastic lined top, and the reaction was 
stirred at ~0 • After 3 hrs, the reaction was taken 
Ex to dryness under a stream of N2 and the residue 
was brought up in a minimum volume of hot, absolute 
EtOH. The solution was brought to the cloud point 
by drop-wise addition of EtOAc. The suspension 
was placed in a -20°C freezer overnight to yield 
a crop of yellow crystals. No effort was made to 
recrystallize the mother liquor. The crystals 
were dried overnight, under vacuum, in the presence 
of P2o5 and characterized by NMR, IR, TLC, GC, HPLC 
and melting point (Table 1). 
A summary of selected physical data for the syn-
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thesized compounds in section B. can be seen in Table 1. 
C. Techniques for Animal Studies 
Compounds utilized in the studies in this disser-
tation were dissolved in sterile, isotonic saline and 
administered to male Sprague-Dawley rats (King; 100 +Sg) 
either centrally by stereotaxic injections into the la-
teral cerebral ventricles or peripherally by intraperi-
toneal injection. Stereotaxic coordinates (200) were 
bregma +0, lateral +1.4 from the midline suture and 
verticle +1.4 from the point of entry. Initial experi-
ments utilizing black I.ndia ink dye confirmed that the 
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injections were in the lateral cerebral ventricles. So-
dium pentobarbital (Abbott) was utilized as the surgical 
anesthesia. It was injected (50 mg/Kg i.p.) 10 minutes 
prior to central injections. At specified time points 
after central injections, experimental rats and their 
paired saline injected controls were sacrificed by de-
capitation. Brain areas and peripheral parts of in-
terest were quickly dissected out according to Holman 
et al. (201) and placed in plastic weigh boats on dry 
ice. The samples were weighed by difference and placed 
in plastic centrifuge tubes for extraction. 
D. Extraction of Biogenic Amines, THIQs and Their 
Metabolites From Tissue 
To each plastic centrifuge tube (7 ml) con-
taining a tissue sample was added 100 ~1 of dH 2o con-
taining 200 ng of an appropriate internal standard. 
The solvent of choice (acid or aqueous EtOH, vide 
infra) was added to the plastic centrifuge tube 
(5 ml/g) and the sample was homogenized with a 20 sec 
burst of a (Tekmar) Tissue-mizer. The blades of the 
Tissue-mizer were washed with an equal volume of sol-
vent, the washings were combined and the homogenate 
then was centrifuged in a Sorvall refrigerated (4°C) 
centrifuge at 30,000 X g for 20 min. The blades of 
the Tissue-mizer were scrupulously washed with dH 2o 
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and wiped dry between each tissue sample to avoid cross-
contamination of samples. 
1. Acid Extraction 
Tissue samples were homogenized in either lN HCl 
or 0.4N HClo 4 (5 ml/g tissue). After homogenization 
and centrifugation as described (vide supra) , the super-
natants were decanted into 20 ml screw-top vials, and 
the pHs were adjusted to 5.5 with 2.0N NaOH followed 
by 0.2N NaOH. The neutralized samples were then fro-
zen, lyopholized and stored at -20°C until cation 
column isolation and/or direct HPLC analysis. 
2. Ethanol Extraction 
Tissue samples were homogenized in aqueous 75% 
EtOH (5 ml/g) which had been stored at -20°C. After 
homogenization and centrifugation as described (vide 
supra) the supernatants were decanted into 20 ml 
screw-top vials and the volumes were doubled with 
dH2o. These solutions were then frozen, lypholized, 
and stored at -20°C until cation column isolation 
and/or HPLC analysis. 
3. Strong Cation-Exchange Column Chromatography 
Isolation Procedure 
a. Resin Preparation 
Dowex AG50-WX, 200/400 mesh (Bio-Rad Labs) 
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(H+ form) was stirred with 4 volumes of dH2o. Small par-
ticles were removed from the suspension by allowing the 
resin to settle and aspirating any suspended particles 
along with the dH 2o layer. This procedure was repeated 
until the supernatant was clear, thus indicating a ho-
mogenous resin bed. The aqueous layer was then removed 
and replaced with 4 volumes of 2 N NH 40H. The slurry 
was allowed to stir for 1 hr after which it was poured 
into a sintered glass filter (coarse-pore) and washed 
with dH2o until the pH of the effluent was 4.0. The 
resin was resuspended in 4 volumes of 2N HCl and 
stirred 1 hr. It was again washed as described (vide 
supra) with dH2o until the effluent pH was 4.0. Ion 
exchange columns (2.50 mx 0.6 em) were prepared in 
plastic columns equipped with sintered plastic fil-
ters (Isolabs). The columns were washed with 5 ml of 
4N HCl/MeOH, 1/1, (V/V) and with dH 20 until pH 4.0. 
b. Column Procedure (Dowex) 
The supernatants from acid-precipitated tissues 
or solutions of standards (prior to neutralization 
and lypholization) were decanted directly onto the 
resin and the columns were allowed to drain. Subse-
quently, the columns were washed with 25 ml of dH 2o, 
5 ml of 40/60 dH20/MeOH (V/V) and eluted with 5 ml of 
4N HCl/MeOH, 1/1 (V/V). The acid/MeOH elution was 
then lyophilized to dryness. The dried residue was 
stored at -20°C for subsequent analysis by HPLC, or 
was derivatized and analyzed by GC. 
c. Weak Cation Exchange Column Chromatography 
Isolation Procedure 
1. Resin Preparation 
BioRex-70, 200/400 mesh, Na+ form (Bio-Rad Labs) 
was sized and washed by repetitive stirring and aspira-
tion in 4 volumes of dH2o. Once the supernatant was 
clear of all fine particulate, the aqueous layer was 
removed and replaced with 4 volumes of 3N HCl. The 
resin was stirred for 1 hr, decanted over a sintered 
glass funnel (coarse-pore) and washed to pH 5.0 with 
dH 2o. The resin was then resuspended in 5 volumes 
of 3N NaOH and allowed to stir for 1 hr, transferred 
to a sintered glass funnel (coarse-pore) and washed 
to pH 5.0 with dH 2o. The resin was then suspended 
in a O.lM Na 2HP0 4)NaH2Po 4 buffer (8.Zg NaH 2Po 4 · 
H2o, 5.68g Na2HP0 4 ; pH 6.5) containing 10% Na 2EDTA. 
2.5 em X 0.6 em resin columns were prepared utilizing 
plastic support columns equipped with plastic sin-
tered filters (Isolabs) . Prior to utilization the 
columns were washed with 5 ml of dH 2o. 
2. Column Procedure 
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The supernatants from neutralized acid-percipitated 
or EtOH-percipitated samples were pipetted onto the 
resin and allowed to drain into 20 ml screw top (scin-
tillation) vials. The columns were then washed with 
2 ml of 0.02 M Na2HP0 4/NaH 2Po 4 buffer (1.66 g NaH 2 
po 4 ·H 2o, 1.14 g Na 2HP0 4 ; pH 6.5) followed by 5 ml of 
dH 2o. The primary elution plus buffer and dH 2o 
washes contained all acid and amphoteric compounds, 
with no detectable amine constituents as ascertained 
by HPLC analysis. The amine compounds were then 
eluted with 5 ml of l.ON HCl. Both fractions were 
frozen in a dry-ice/acetone bath and lyophilized 
to dryness. Dried sample residues, after dissolving 
in appropriate solvent, were analyzed directly by 
HPLC, or were derivatized and analyzed by GC. 
E. Gas Chromatographic Analysis of Catecholamines, 
THIQs and Their Metabolites 
Quantiation of the isolated catecholamines, 
THIQs and respective 0-methylated metabolites were 
carried out by EC/GC employing either capillary or 
conventional packed columns. A Varian model 3700 
gas chromatograph with 63Ni detector (pulsed mode) 
was utilized. 
Wall coated, open tubular (WCOT) , glass 
capillary columns (10M X 0.25 mm i.d.; Alltech 
Assoc.) coated with polyphenylmethylsiloxane (OV-17) 
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were employed. The splitter at the injection port was 
adjusted to a ratio of 10/1. Head pressure of the 
0 F 2 
carrier gas, N2 , oxygen free (N2 2 ) was 0.8 kg/ern • 
peak areas and retention times were obtained with a 
varian CDS-lllC computing integrator. 
Conventional, packed, stainless steel columns 
were prepared in our laboratory. The liquid phase 
of choice was a 3% polydirnethylsiloxane (OV-101; ap-
plied Sci. Labs.) coated over a Gas Chrorn G, H.P. 
100/120 mesh solid support ( ALltec~.Assoc.) by a sol-
vent evaporation technique, utilizing a rotary flash 
evaporator. Column lengths varied from 1 ft to 5 ft. 
Prepared columns were conditioned at their maximum 
operating temperature for 48 hr prior to use. Peak 
areas and retention times were obtained utilizing 
a Varian CDS-lllC computing integrator. 
1. Preparation of Fluoracyl Derivatives for GC 
a. Fluoroacyl Derivatives of Non-Carboxylated 
Catecholarnines, THIQs and Their 0-Methylated 
Metabolites 
Initial studies were undertaken with several 
types of acylating agents to determine which agent 
would give maximum EC responses, completeness of 
reactions, derivatives with good stabilities and 
optimum separations. To 1 rng of crystalline compound 
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or lyophilized tissue residue in a 20 ml screw-top vial 
were added 500 ~1 of sequanal grade acetonitrile (ACN; 
pierce) and 50 ~1 of either heptafluorobutyric anhy-
dride (HFBA), pentafluoropropionylanhydride (PFPA), 
or trifluoroacetic anhyhydride {TFAA) (Pierce). Each 
vial was sealed with a plastic lined cap and allowed 
to react at ~o for 30 minutes. The solutions were 
brought to dryness in a hood with a stream of N2Ex. 
The residues were taken up in 1 ml of sequanal grade 
toluene (Pierce). 0.5 ml of 1M (NH 4 ) 3Po 4 buffer 
(pH 5.8) was added, the mixture vortexed for 60 sec 
and centrifuged in a clinical centrifuge for 5 min. 
b. Formation of Fluoroacyl Derivatives of Carboxyl-
ated THIQs and Their a-Methylated Metabolites 
To 1 mg of crystalline carboxylated compound 
or lyophilized tissue residue in a 20 ml screw-top 
vial was added 0.2 ml of hexafluoroisopropanol (HFIP; 
Pierce) and 0.05 ml of PFPA. Each vial was sealed 
with a plastic-lined screw-top cap and allowed to 
react at ~o for 20 min. The solutions were blown 
Ex dry under a stream of N2 . The residue was treated 
with 0.5 ml of ACN and .05 ml of PFPA for 20 min in 
sealed vials. The samples were again brought to 
dryness with N Ex 2 I toluene ( 1 ml) was added, and the 
solution was washed with (NH 4 ) 3Po 4 as described above. 
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rmmediately following centrifugation, the toluene phase 
(1 ~1) was injected directly into the GC system. 
F. HPLC Methodology 
Lyophilized tissue extracts were brought up in 
o.OlN HCl (0.5 ml) and chromatographed on BioSil, c18 , 
reverse phase; 25 CM columns (Bio-Rad Labs) using 
electrochemical detection (B.A.S.; 0.79 volts). Vari-
ous buffer systems were employed for optimum separa-
tions and sensitivity of detection. The mobile phase 
flow rate utilized was generally 1.0 ml/min, as indi-
cated in Results. 
1. Paired-Ion Buffer System 
Degassed dH20(-850 ml), 1.1 g (8 mM) heptane-
sulfonic acid (HSA; waters) and 9.7 ml of glacial 
HOAc were mixed and adjusted to pH 3.5 with NH 40H, 
if necessary. MeOH (Baker Reagent grade), 100 ml, 
was then added and the mobile phase was then brought 
to 1 liter with dH2o. 
2. Ionic-Suppression Buffer System 
The ionic-suppression buffer consisted of 
0.1 M NaH 2Po4 with 1 mM Na 2 EDTA. The pH was ad-
justed to precisely yield optimum separation (pHs 
4.7- 5.2). 
3. Reverse Phase HPLC Column Regeneration 
Repeated injections of tissue samples lead 
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to loss of separation of isolated compounds even in the 
presence of a guard pre-column (Altex). Reverse phase 
columns were cleaned of absorbed tissue com-
ponents and paired-ion reagent by the technique of 
Hannigan (202). After disconnecting the electrochem-
ical detector, the column was washed successively 
with 25 ml of 10 mM oxalic acid (pH 3.5 with concent-
rated NaOH; Sigma); 25 ml MeOH/dH 20 1/1 (V/V); 25 ml 
• 
methylene chloride/tetrahydrofuran, 1/1 (V/V), 25 ml 
MeOH and 25 ml MeOH/dH 2o, 1/1 (V/V). The mobile phase 
of choice ·t.hen .was run through the column for 30 
min, the detector reconnected, and allowed to stabi-
lize before use. 
G. Procedure for In Vivo Studies on Stereoselective 
0-Methylation of Catechol Isoquinolines 
A variety of catechol isoquinolines were inves-
tigated to represent various combinations of catechol-
amine-carbonyl condensation products. Compounds 
utilized (Fig. 21) were SAL, 1-CSAL, 3-CSAL, 4,6,7-
(0H)3 THIQ and 1-Me-6,7-DHIQ, a compound which could 
theoretically form from the oxidation of SAL or oxi-
dative decarboxylation of 1-CSAL. A group of rats 
were pretreated with the MAO inhibitor pargyline 
(50 mg/Kg, i.p. 2 hr pre-DA}, anesthetized and in-
jected bilaterally in the lateral cerebral ventricles 
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with DA. Separations and quantitations of isoquinolines 
and their respective 6- and 7-0-methylated metabolites 
were carried out by EC/GC on a WCOT glass capillary col-
umn and reverse phase HPLC with electrochemical detec-
tion, as described (vide supra) . 
Male Sprague-Dawley rats (100 + 5 g) were anes-
thetized and stereotaxically injected bilaterally (ICV) 
with 50 ~g (25 ~g/ventricle; 12.5 ~g/~1; free base) in 
isotonic saline. Control rats were given equal volumes 
of isotonic saline. 50 min after the ICV injections, 
rats were sacrificed by decapitation and the hypothal-
amus, corpus striatum and hippocampus were removed. 
They were weighed, homogenized in 75% aqueous EtOH 
with 200 ng of dihydroxybenzylamine (DHBA, internal 
standard) and centrifuged as described at 30,000 X g, 
4°C for 20 minutes. The supernatants volumes were 
doubled with dH2o, were decanted onto Bio Rex-70 cation 
exchange columns and differentially eluted for acid 
and amine constituents as described. All fractions 
were frozen on dry ice and lyophilized to dryness. 
The residues were taken up into O.OlN HCl and analyzed 
by HPLC utilizing the ionic suppression buffer system 
with electrochemical detection. An aliquot of each 
fraction was taken lyophilized and depending on the 
isoquinoline to be assayed differentially derivatized 
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for acids (PFPA/HFIP) or amines (HFBA) . 
Confirmation of peak identity was determined by 
comparison of retention times of authentic standards on 
both HPLC and GC as well as co-chromatography with 
authentic standards added to derivatized tissue samples. 
Regional brain parts of saline-injected controls were 
analyzed for the presence of interfering peaks on both 
HPLC and GC. 
H. Procedure for Study of the Uptake of Peripheral 
Salsolinol Into CNS 
Male Sprague-Dawley rats were administered 
5 - 20 mg/Kg (i.p.) of SAL (HCl). At 0.5, 2.0, 5.0, 
and 10 hr post-administration, rats were sacrificed 
by decapitation. The hypothalamus, corpus striatum, 
and hippocampus were removed, weighed, homogenized 
in 0.4N HCL0 4 with 200 ng of DHBA (as internal stand-
ard) and centrifuged at 30,000 X g, 4°C, for 20 minutes. 
The pH of the su?ernatant was adjusted to 5.5. The 
supernatan'c the11 was. decanted onto Bio Rex-70 cation 
exchange columns and differentially eluted for acid 
and amine constituents. The amine fraction was lyo-
philized, the residue derivatized with HFBA/ACN, and 
analyzed by capillary GC with EC detection for the 
possible presence of SAL, 7-o-MethyrSAL (7M-SAL) and 
6-0-Methyl•SAL ( 6M-SAL) . 
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r. Acute ICV Administration of Catecholic Isoqunino-
lines for Studies on Effects on Endogenous SHT 
and Acid Metabolites of Biogenic Amines 
Male Sprague-Dawley rats were anesthetized with 
Na+ pentabarbital (50 Mg/Kg, i.p.) and stereotaxically 
injected ICV bilaterally with 50 ~g (25 ~g/ventricle; 
free base; 12.5 ~g/~1) of SAL, 4,6,7-(0H) 3THIQ, 1-CSAL, 
3-CSAL 1-Me-6,7-DHIQ, orDAin isotonic saline [rats 
given DA were pretreated with 50 mg/Kg pargyline (i.p.) 
2 hr earlier]. Control animals were given equal vol-
umes of isotonic saline ICV. 50 min after central 
administration the animals were sacrificed by decapi-
tation and the hippocampus, hypothalamus, and corpus 
striatum were removed, weighed, homogenized in 75% 
aqueous ethanol (containing 200 ng of DHBA as internal 
standard), and centrifuged at 30,000 X g, 4°C, for 
20 min. The supernatant volumes were diluted with 
an equal volume of dH 2o, decanted onto Bio Rex-70 
cation exchange columns and differentially eluted 
for acid and amines constituents. The acid fractions 
were lyophilized to dryness, taken up in 0.5 ml of 
0.01 N HCl and analyzed for DOPAC, SHIAA, and HVA in 
the corpus striatum and hypothalamus, and for SHIAA 
in the hippocampus utilizing paired-ion, reverse 
phase HPLC with electrochemical detection. Amine 
fractions were lyophilized to dryness. Hippocampal 
samples were analyzed for SHT as above. Hypothalamus 
and corpus striatum samples were derivatized with 
HFBA/ACN and analyzed for further verification of 
stereoselective a-methylation of amine isoquinolines, 
possible decarboxylated products of carboxylated 
isoquinolines, and DA levels. However, due to con-
taminated derivatizing reagents from Pierce Chemical 
co., these samples were lost. 
J. Procedure for Study of the Half-Life of 7 M-SAL 
In the Rat CNS 
Male Sprague-Dawley rats were anesthetized with 
Na+ pentobarbital and stereotaxically injected ICV as 
described with 5 vg/ventricle (5 vg/vl) bilaterally 
with 7M-SAL (HCl salt). Control rats were given equi-
valent volumes of isotonic saline. 1, 3, 6, 12, 24, 
57 
and 48 hr after central administration, rats were sacri-
ficed by decapitation and the hippocampus, hypothalamus 
and corpus striatum were removed and weighed. They 
were homogenized in 75% aqueous EtOH containing 200 ng 
DHBA as internal standard and centrifuged at 30,000 X 
g, 4°C for 20 min. The supernatant volumes were 
doubled with dH 2o. AJ iquots of the hypothalamus and 
corpus striatum were placed on Bio Rex-70 weak cation 
exchange columns and differentially eluted for amine 
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and acid constituents. The amine fraction was lyophi-
lized to dryness, derivatized with HFBA/ACN, and analyzed 
for the presence of 7M-SAL. The remainder of the 
supernatants were lyophilized and the dried residues 
were taken up in 0.5 ml of 0.01 N HCl and analyzed by 
reverse phase HPLC with electrochemical detection. 
Utilizing the ionic suppression buffer, simultaneous 
separations and quantitations of DA, DOPAC, 5HT, 5HIAA, 
HVA, and 7M-SAL were performed. 
K. Procedure for Study of Peripheral 1-CSAL 
Metabolites 
Male Sprague-Dawley rats were injected with 
1-CSAL (100 mg/Kg, i.p.) daily for 6 days. On the 
7th day, the single dose was increased to 300 mg/Kg 
i.p. Control rats were given equal i.p. volumes of 
isotonic saline. Rats were sacrificed by decapita-
tion 3 hr after the last injection. Livers, hippo-
campi, hypothalami and corpus striata were removed , 
weighed, homogenized in 0.4N HCl04 containing 200 ng 
of DHBA as internal standard, and centrifuged at 
30,000 X g, 4°C, for 20 minutes. The supernatants 
were adjusted to pH 5.5 with NaOH and decanted onto 
Bio Rex-70 weak cation exchange columns. The columns 
were differentially eluted for acid and amine con-
stituents. All fractions were frozen on dry ice and 
lyophilized to dryness. The residue was taken up in 
o.Ol N HCl and an aliquot was analyzed by reverse phase 
HPLC with electrochemical detection for the presence 
of 1-Me-6,7-DHIQ, SAL and their respective 6- or 7-
o-methylated metabolites. Two different HPLC condi-
tions were utilized. A mobile phase consisting of 
0.1 M Na 2HP0 4 , 1 mM Na 2EDTA titrated to pH 7.4 with 
0.1 M citric acid, followed by dilution with MeOH 
(10% V/V), was employed for DHIQ analysis. Samples 
were analyzed for SAL and its 0-methyl metabolites 
with the mobile phase consisting of 0.1 M NaH2Po 4 , 
1 mM Na 2EDTA pH 5.5, with 5% (V/V) methanol. pH 
adjustments on the mobile phases were made prior to 
the addition of methanol to avoid organic solvent-
induced pertuberations in pH. 
The remainder of the O.OlN HCl-suspended sample 
was lyophilized to dryness. HFB-derivatives were pre-
pared and analyzed by capillary GC with EC detection 
for the presence of SAL, 1-Me-6,7-DHIQ and their 
respective 0-methylated metabolites. 
L. Spectrophotometric Studies of a Series of 1-
Methyl-6,7-Substituted 3,4-Dihydroisoquinolines 
1-Me-6,7-DHIQ, 1-methyl-6-hydroxy-7-methoxy 
3,4 dihydroisoquinoline (l-Me-7M-DHIQ}, l-Me-6M-DHIQ, 
and 1-Me-6,7-DMDHIQ (HCl salts) were prepared by 
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dissolving the appropriate compound (1.0 mg/ml) in dH2o 
and storing it at -20°C. u.v. absorption spectra were 
obtained on a Perkin-Elmer model 320 spectrophotometer 
between 220 and 500 nm~ Excitation and emission spec-
tra were determined at pH 7.0 utilizing and Aminico-
Bowman scanning Spectrophotofluorometer. The spectra 
were examined in O.lN HCl, 0.01 N NaOH, O.lN NaOH and 
0.1 M buffers (acetic acid-acetate, pH 3.0 - 5.0; Na+ 
phosphate, pH 6.0 - 8.0; glycine-NaOH, pH 9.0 - 11.0) 
over a pH range of 2 - 13. All substances studied 
exhibited significant fluorescence quenching above 
1 ~g/ml. Therefore, the solutions examined were at 
concentrations of 1 ~g/ml or less where fluorescence 
intensity was proportional to concentration. Solu-
tions were examined for fluorescence and absorption 
immediately after they had been prepared, and fluores-
cence intensity was always determined at ~o within 
10 - 20 seconds after exposure to exciting light, 
to avoid possible photodecomposition and temperature 
effects. 
M. Cyclic Voltammetry of DHIQs 
Cyclic voltammetry was performed on a direct 
current voltammetry instrument (B.A.S.) utilizing 
a three electrode linear sweep between +1.2 and -1.2 
volts. The reaction cell was constructed in our 
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laboratory from a 20 ml screw top vial. A teflon-lined, 
screw-top cap was modified to accommodate a carbon paste 
working electrode, reference electrode (B.A.S.) and 
auxillary electrode. Cyclic voltammograms were re-
corded on an x-y recorder at pH 3.0, 5.0, and 7.4 uti-
lizing a Na+-phosphate-citrate buffer. The change in 
voltage was monitored by use of a voltmeter (Westronics). 
All voltammetric studies were done with concentrations 
of between 2.0 and 5.0 ~g/ml (free base), scan speed 
200 mv/sec at a sensitivity of 2 ~A/em. Scans were 
repeated and verified by Dr. Peter Kissinger at the 
Bio-Analytical Systems (B.A.S.) Laboratories in West 
Layafette, Indiana. 
N. Attempted Synthesis of Glutathione-DHIQ Adducts 
Two different DHIQs, 1 Me-6,7-DHIQ HBr (250 mg, 
0.95 mMoles) or l-Me-7M-DHIQ HCl (250 mg, 1.17 mMoles) 
were each dissolved in 10 ml of dH 2o containing gluta-
thione (GSH; 921 mg, 3.00 rnMoles). The pH was ad-
justed to 7.4 with 1.0 M NH40H. The reaction mix-
tures were placed into a warm water bath (37°C) and 
gently shaken. After 10 hr the solutions were frozen 
on dry ice and lyophilized to dryness. 5 ~g/~1 samples 
of the reaction mixture was spotted on an 4 em X 10 em 
silica gel plate along with standards of GSH and appro-
priate DHIQs. The plates were developed in a butanol/ 
HOAc/dH 2o, 4/1/1 (V/V/V) and visualized by irradiation 
under fluorescent light for DHIQs, and ninhydrin (pep-
tide reagent) for GSH. NMR spectra of the reaction 
mixtures were performed in D2o on a varian 360 NMR 
spectrophotometer (courtesy of Dr. Dr. D. Crumrin, 
Loyola University, Dept. of Chemistry). HPLC analysis 
of the reaction mixture was performed utilizing a .1M 
Na 2HP0 4 buffer titrated to pH 7.4 with O.lM citric 
acid in 20% (V/V) MeOH. Combinations of electro-
chemical/U V or electrochemical/fluorescence detec-
tion were utilized to attempt detection of a reaction 
product. 
o. Gas Chromatographic Analysis of Ethanol and AcA 
EtOH and AcA were analyzed on a Varian 2400 
gas chromatograph equipped with a flame ionization 
detector. The column utilized was a 1/8 in X 6 ft 
coiled glass column packed in our laboratory with 
Porapak QS, 80/100 mesh (Alltech Assoc.). Empty 
glass columns were cleaned by successively drawing 
through hot soapy water, acetone, and methanol under 
vacuum. Columns were then dried with N2Ex. Deacti-
vation of glass surfaces was accomplished by treat-
ment with Glass-Treet (Alltech Assoc.). Excess rea-
gent was removed by rinsing with anhydrous MeOH 
(25 ml). Columns were stoppered at one end with a 
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glass wool plug and were packed under vacuum by injec-
tion of Porapak QS into the open end. They were vi-
brated during the packing procedure with an engraving 
gun. The columns were then conditioned for 48 hr at 
200°C. 
P. Procedure for the Determination of AcA and EtOH 
in Human Blood During Alcohol Detoxification 
Blood samples (3 - 5) ml were drawn from con-
senting male adults (ages 37 - 54) admitted to the 
Alcohol Detoxification Unit at Hines Veterans Admin-
istration Hospital. Non-alcoholic controls were in 
the same age range and were psychiatric in-patients 
at the hospital. Both groups were on the same daily 
diet and between-meal consumption of foods was re-
stricted. The blood samples were stored in citrated 
tubes in a freezer (-20°C) until preparation for 
analysis (6 - 48 hr). Aliquots (0.2 ml) of blood 
were added to 15 ml vacutainers containing 0.5N 
HClo 4 (1.0 ml) with 25 rnM thiourea and 50 mg/dl 
N-propanol as an internal standard. Prior to use, 
the vacutainers were washed with hot soapy water, 
treated with chromerge (S/P), treated further with 
hydrogen fluoride (5% solution), rinsed well with 
dH2o and dried under vacuum at 100°C. The blood 
mixtures (0.2 ml) were immediately mixed and frozen 
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over liquid N2 , blown for -15 sec with N2Ex, capped, and 
equilibrated at 37°C for 20 min. Head space samples 
(1 - 2 ml) were taken with a gas-tight syringe (Hamilton) 
and analyzed for EtOH, AcA and N-propanol on a PoraPak 
QS column (prepared as described in section 0.; Tc = 
125°C). Standard curves were prepared with AcA, EtOH, 
and N-propanol added to normal bloods. Control bloods 
showed negligible formation of AcA during work up pro-
cedure. Standard curves were expressed as concentration 
of EtOH or AcA versus the ratio of peak areas of EtOH or 
AcA/N-propanol. 
CHAPTER III 
RESULTS 
.. A. Synthesis of THIQs 
Selective physical data for synthesized compounds 
is summarized in Table 1. NMR and IR spectra were con-
sistent with expected structures. GC and HPLC analysis 
determined purity of all synthesized compounds to be 
greater than 99%. TLCs of reaction mixtures verified 
that the reactions had gone to completion. 
B. Extraction and Recovery Studies of Biogenic 
Amines, THIQs and Their Acid Metabolites 
Dihydroxybenzlamine (DHBA) proved to be a good 
internal standard, consistently reflecting the recovery 
of a variety of compounds. This verifies the utility 
of this compound as an HPLC (203) and GC internal 
standard. Recoveries of all compounds of interest 
correlated within 5 - 7% of DHBA recovery. The ex-
ception was 5HT, whose recovery varied greatly with 
the isolation tech~ique employed. 
Acid extraction utilizing 0.4 N HClo 4 followed 
by lyophilization caused almost total loss of isolated 
compounds as determined by HPLC analysis. This loss 
could be avoided if the supernatant was adjusted to 
65 
66 
pH 5.5 prior to lyophilization. When 1.0 N HCl was uti-
lized as the homogenizing medium, no neutralization was 
necessary; however, 5HT recovery was only 50% of DHBA 
recovery. When the 1.0 N HCL was adjusted to pH 5.5, 
the recovery of DHBA directly reflected 5HT recovery. 
overall recovery as determined by HPLC of THIQs, bio-
genic amines, and their metabolites for the neutralized 
acid (1.0 N HCl) extraction technique ranged from 80 -
85%. Recoveries were calculated from known standards 
added to cerebellar homogenates, which were then carried 
through the extraction procedures and compared to iden-
tical neat standards by HPLC. 
EtOH extraction of tissue samples had the added 
advantage of not having to adjust the pH prior to lyo-
philization or addition to weak cation-exchange columns. 
Doubling the volume of the EtCH-extracted supernatant 
with dH2o yielded a solution of pH 5.5. Utilization of 
this technique gave 5HT recoveries by HPLC which were 
directly reflected by the recovery of DHBA. Overall 
recoveries of THIQs, biogenic amines and their metabo-
lites after EtOH extraction, lyophilization and direct 
HPLC analysis ranged between 85 - 89%. Recoveries 
were calculated, as above, from addition of known 
standards to cerebellar homogenates. 
The aforementioned extraction techniques 
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utilizing HCl, HCl04 , or EtOH, homogenization, pH or 
volume adjustment and lyophilization provided reasonable 
HPLC chromatograms (see section D). However, GC anal-
yses utilizing these abbreviated isolation techniques 
were unsuccessful. Attempts to chromatograph the lyo-
philized residues (following derivatization of samples 
isolated utilizing any of the three simple extraction 
techniques) yielded chromatograms with solvent peaks 
exceeding 25 min. Therefore, a rapid sample "clean-
up" technique using ion-exchange columns was sought. 
The use of a strong cation-exchange resin, 
Dowex-50, for the separation of amines, acids, and 
amphoteric constituents from acid or EtOH extracted 
tissue samples had limited success. The 4N HCl/MeOH 
which was necessary for the removal of bound amines 
apparently caused significant destruction of the bio-
genic arnines prior to analysis, as indicated by low 
recoveries after (and discoloration during) sample 
lyophilization. In order to increase recoveries, 
lower concentrations of acid could be utilized. How-
ever, this would become impractical due to the large 
volume necessary for elution. Overall recoveries of 
THIQs, biogenic amines and their a-methylated metabo-
lites after Dowex, ranged between 25 and 40%, as de-
termined by both HPLC and GC analysis. These low 
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recoveries and the wide range discouraged the use of this 
oowex ion-exchange technique. 
When the samples were passed through columns con-
taining a weak cation-exchange resin (BioRex-70) which 
allowed for selective isolation of amines, acids, and 
amphoteric constituents, GC analyses of these fractions 
were possible. The use of BioRex-70 for these isola-
tions was adapted from procedures by Holman (201) and 
Barchas (204). Eightyfive% of·the~carboxylated THIQs and 
and acid metabolites (HVA,5HIAA,DOPAC) of biogenic amines 
were detec.ted in the ·primary eluate. An additional 2 ml 
of 0.02 M sodium phosphate buffer eluted an additional 
10% of the carboxylated compounds with no detectable 
cross contamination from amine constituents. Non-car-
boxylated THIQs, 5HT, the CAs, and their a-methylated 
amine metabolites remained bound to the columns until 
elution with 1.0 N HCL. Overall recoveries of non-
carboxylated THIQs, CAs, and their a-methylated metabo-
lites, directly reflected by the HPLC or GC recovery 
of DHBA, were within 83 - 85%. 5HT recovery (HPLC 
analysis) was consistently 75%. A suitable internal 
standard was not found for the acid fraction. The 
recoveries for all acid constituents, which were ob-
tained by addition of standards to cerebellar tissue 
homogenates and carried through the column procedure, 
were consistently high, ranging from 93 to 95%. 
c. Gas Chromatography of CAs, THIQs, and Their 
Metabolites: Results of Studies on Derivative 
Formation and GC Separation Conditions 
In general, the HFB-derivatives of non-carboxyl-
ated THIQs, CAs, and their respective a-methylated me-
tabolites yielded the higher responses, more symmetri-
cal peaks and better isomer separations, when compared 
with the TFA-derivatives. PFP-derivatives actually 
gave EC responses equivalent to HFB-derivatives, but 
GC separation of the structural amine isomers (a-me-
thylated metabolites of SAL, 4,6,7,-(aH) 3 THIQ, and 
DA} was not achieved following PFPA derivatization. 
The a-methylated isomers of carboxylated THIQs were 
separable, however, when PFPA was used in combination 
with HFIP. 
69 
It was found absolutely necessary to wash the de-
rivatives, taken up in toluene, with an aqueous buffer 
solution just prior to capillary GC analysis. The 
aqueous washing apparently removed residue fluoro-
anhydrides and other derivatized volatile compounds 
which were contributing significantly to a large 
tailing solvent front. This novel step was accom-
plished with a 1M NH 4 H2 P0 4/(NH 4 ) 2 HPa 4 buffer, 
pH 5.8 - 5.9. The aqueous buffer presumably 
hydrolyzed any unreacted fluoroanhydride, and fluoro-
acids were extracted by the aqueous ammonia. The 
fluoroacyl esters of phenols are reportedly stable 
in H20 at pH~6.0 (205), and the results with THIQs 
and CAs indicated this to be true (vide infra) . 
+ The use of aqueous NH 4 phosphate to wash the 
toluene samples is demonstrated in Figure 22. Recovery 
experiments, in which derivatized standards were washed 
up to 5 times with the aqueous buffer and injected im-
mediately afterward, showed no significant change in 
peak heights, areas, symmetries or retention times. 
However, extended storage (72 hrs) of toluene solutions 
of derivatized THIQs or CAs in the presence of the 
aqueous NH4 phosphate resulted in a 90 - 100% decrease 
in derivative peak heights. 
A comparison of capillary versus conventional 
column separation of a standard mixture of DHBA, DA, 
SAL, 3M-DA, 4M-DA, 6:r-~-SAL, and 7M-SAL can be seen in 
Figure 23. The conventional 6 foot X 1/4 inch i.d. 
packed column was unable to resolve the isomers of 
3-M- and 4-M-DA and 6-M and 7-M SAL, despite 
various combinations of temperature, pressure, and 
liquid phase. Packed columns of longer length tended 
to lose efficiency, as demonstrated by excessive 
peak widths of long retention time compounds, and 
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required temperatures which neared or exceeded maximum 
operating temperatures of the columns. Capillary col-
umns were found to separate easily. the 6- and 7..0-Hethyl 
isomers of DA, SAL (Fig. 24), 4,6,7,(0H) 3 THIQ (Fig. 25), 
l~AL (Fig. 26), 3-CSAL (Fig. 27) and 1-Me-6,7-DHIQ 
(Fig. 28). A summary of capillary chromatographic con-
ditions, retention times, and minimum detectable quan-
tities is shown in Table 2. 
D. High Performance Liquid Chromatography (HPLC) 
of Biogenic Amines, THIQs, and Their Metabo-
lites 
The use of paired-ion HPLC permitted simultan-
eous quantitation of either the acid components or 
their corresponding amines in a single injection, but 
separation of amines and acids in the same mixture 
was not achieved in these studies. Separation of a 
standard mixture of DOPAC, SHIAA and HVA by paired 
ion chromatography is seen in Figure 29. Figure 30 
shows the separation of NE, DHBA, DA, SAL, and SHT. 
Although paired-ion HPLC was able to separate the 
6- and 7-C-Methyl. isomers of I'HIQ~. the separations 
were not adequate enough for precise quantitation. 
Small adjustments in paired-ion content, % MeOH and 
flow rate were necessary to accommodate the column 
degeneration associated with repeated usage. 
The use of the 0.1 M Na 2Pa4-l mM Ha2 EDTA buffer 
(ionic-suppression buffer) allowed for the simultaneous 
separation and quantitation of the biogenic amines and 
their acid metabolites. The pH, now an important pa-
rameter, was manipulated to achieve the best separa-
tions. Because ionic-suppression buffers have pHs of 
between 4 and 7, electrochemical oxidation of most bio-
logical molecules is easily achieved. Figure 31 demon-
strates the simultaneous separation of NE, DHBA, DA, 
oaPAC, 5HT, 5HIAA, and HVA utilizing the ionic-sup-
pression buffer system. Utilization of this buffer 
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system in combination with a C reverse phase (25 em) 
column easily separated the following catechol THIQs 
and their respective 6-0- and 7-0-methylated isomers: 
SAL (Fig. 32), 467-(aH) 3THIQ (Fig. 33), 1-CSAL (Fig. 
34), and 3-CSAL (Fig. 35). With a slight modification, 
1-Me-6,7-DHIQ and its two a-methylated derivatives 
were also separated (Fig. 36). A summary of reten-
tion times and selected HPLC parameters is found in 
Table 3. 
E. In Vivo Studies of the Stereoselective Brain 
a-Methylation of a Variety of catechol Iso-
quinolines and DA 
Electron capture responses for HFB-derivatized 
samples of SAL, 467-(aH) 3THIQ, 1-CSAL, 3-CSAL, 
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1-Me-6,7 DHIQ, DA and their a-methylated isomers were 
all excellent. Minimum detectable quantities were in 
the range of 2 - 10 picomoles~l. GC recoveries of 
all compounds of interest, after EtaH extraction, 
Bio Rex-70 isolation, derivatization, and sample clean-
up with NH 4+ phosphate buffer, ranged from 80 - 85%. 
Representative chromatograms of HPLC and GC separa-
tions of SAL/DA (Fig. 37), 4,6,7-(aH) 3 THIQ (Fig. 
38), 1-CSAL (Fig. 39), 3-CSAL (Fig. 40), and their 
respective a-methyl-metabolites are actual tissue-
extracted results. Regional brain chromatograms of 
saline-injected controls showed no interfering com-
ponents at the retention times of any compounds of 
interest. 
As can be observed in chromatograms, Figures 
37 and 39, SAL and 1-CSAL were almost exclusively 
0-methylated on the para -7- hydroxyl. Figures 38 
and 40 qualitatively show that 4,6,7-(aH) 3 THIQ and 
3-CSAL had mixed stereospecificity to a-methylation 
with peaks for both "meta" -6- and "para" -1- a-me-
thyl products. 1-Me-6,7-DHIQ was not a-methylated 
to any detectable extent in the 50 minute period fol-
lowing central injection. DA, injected ICV into 
six pargyline-pretreated rats, was apparently a-me-
thylated exclusively in brain on the meta -3-
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hydroxyl (Fig. 37}; if 4M-DA was present, levels were less 
than 4 - 5 ng/g striatum. This result insured that the 
7-a-methylation seen with catecholic isoquinolines was 
not an artifact of administration. The quantitative 
distribution of brain isoquinoline a-methylation can be 
seen in Figure 41. 
Tables 4, 5, and 6 show the % stereoselective 
a-methylation, % of a-methylation and levels of cate-
chol isoquinoline precursors present in the corpus 
striatum, hypothalamus, and hippocampus, respectively. 
In the corpus striatum (Table 4} the levels of all ca-
techol isoquinoline presursors were statistically the 
same (P>.05}. However, the% a-methylated [=total 
a-methylated products/catechol isoquinoline presursor 
(+} total a-methylated products] are significantly 
different. SAL and 4,6,7-(aH} 3THIQ are statistically 
a-methylated to the same extent, while 1-CSAL and 3-CSAL 
are a-methylated 67% (P<.Ol} and 33% (P<.Ol} of SAL, 
respectively. 
In the hypothalamus (Table 5) the levels of'the 
carboxylated THIQs were 2 to 3 fold as high as SAL and 
4,6,7-(aH) 3THIQ. The% a-methylation for 4,6,7-(aH) 3 
THIQ, 1-CSAL, and 3-CSAL are statistically the same 
being an average of 70% of the % SAL a-methylation. 
In the hippocampus (Table 6) the levels of SAL, 
4,6,~(aH) 3THIQ and 3-CSAL (1-CSAL was not assayed in 
this brain part) were statistically the same as were 
the% a-methylation for 4,6,~aH) 3THIQ and SAL. How-
ever, the % a-methylation for the carboxylated THIQ 
3-CSAL was 36% (P<.Ol) of SAL % a-methylation. 
F. Survey of Salsolinol Uptake into the Rat CNS 
After Intraperitoneal Administration 
This experiment was undertaken to determine 
whether the levels of THIQs found in the CNS after 
EtaH administration could have originated in part 
from a peripheral source such as liver, heart, or 
adrenals, via the cerebral circulation. GC/EC pro-
vided a means by which the presence of picomole quan-
tities of SAL and a-methylated SALs could be detected 
in brain (minimum detectable quantities, 15 - 30 
pmoles/g tissue). The results indicate that at SAL 
doses between 5 and 20 mg/kg i.p. SAL and a-methy-
lated SALs were not detectable in the corpus stria-
tum, hypothalamus or hippocampus (data summarized 
in Table 7). The efficacy of GC/EC assay was checked 
by the measurements of endogenous DA, which fell 
within literature values. Dopamine levels in the 
hypothalamus and corpus striatum were not signifi-
cantly changed at any SAL dose or at any time point 
(not shown). These results indicate that at doses 
75 
of 20 mg/Kg or less (assumed possible physiological 
range), SAL, a representative, simple catechol THIQ, 
does not significantly cross the blood/brain barrier. 
G. Effects of Acute ICV Administration of Cate-
chol-Isoquinolines on the Levels of 5HT and 
Acid Metabolites in Various Rat Brain Regions 
In Tables 9, 10, and 11, the actual values for 
5HT, 5HIAA, DOPAC, and HVA in the hypothalamus, hip-
pocampus and corpus striatum in control and isoquino-
line (or pargyline/DA) treated animals are tabulated. 
In the hippocampus (Table 9, summary Table 8 
and Figure 42) where only 5HT and 5HIAA were assayed, 
only 1-CSAL failed to significantly increase the 
levels of 5HT. The three THIQs, SAL, 3-CSAL, and 
4,6,7-(0H) THIQ, and the DHIQ all increased the 
hippocampal levels of 5HT to 145 - 185% of control 
(P<.Ol); 5HIAA levels were altered (increased 27%; 
P<.Ol) only by 4,6,7-(0H) 3 THIQ. Pargyline/DAde-
creased 5HIAA to 26% (P<.Ol) of control as expected. 
In the striatum (Table 10, summary Table 8 and 
Figure 42), where DOPAC, HVA, and 5HIAA levels were 
assayed, 1-CSAL significantly increased both DOPAC 
(P<.Ol) and HVA (P<.Ol) 160 and 116% respectively. 
3-CSAL significantly lowered 5HIAA levels to 83% of 
control (P<.Ol) but did not effect the levels of 
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DOPAC or HVA. Likewise, 4,6,7-(0H) 3THIQ significantly 
lowered SHIAA to 82% of control (P<.OS), but had no effect 
on the other acid metabolite levels. On the other hand, 
sAL did not alter the steady-state levels of any of 
the acid metabolites in the corpus striatum. 
In the hypothalamic tissue (Table 11, summary 
Table 8 and Figure 42) DOPAC, HVA, and 5 HIAA were as-
sayed. A number of significant changes occurred due 
to the isoquinolines. First, levels of the SHT metabo-
lite, SHIAA, were observed to be increased 127% - 178% 
(P<.Ol) of control by four of the five isoquinolines, 
the exception was SAL. The levels of the catechol 
acid, DOPAC, were lowered to 67% - 79% (P<.Ol) of con-
trol values by each of the four THIQs, and additionally, 
3-CSAL also decreased HVA levels to 63% of control 
(P<.Ol). Finally, 1-Me-6,7-DHIQ significantly reduced 
HVA levels by 26% (P<.Ol). 
Thus, it appears that diverse neurochemical 
changes occur after large (50 ~g) ICV injections of 
catechol isoquinolines, depending on the brain area 
examined. For example, SHIAA levels were changed 
(increased) almost exclusively in the hypothalamus 
but not in the other two brain areas [slight signi-
ficant decrease in corpus striatum by 3-CSAL and 
4,6,7-(0H) 3THIQ] by all the isoquinolines except SAL. 
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Hypothalamic DOPAC levels are decreased by all four 
THIQs, but in the striatum, only 1-CSAL affected DOPAC 
levels, and this was a 60% increase above control levels. 
HVA was only affected by one THIQ in the hypothalamus 
(a 37% decrease in its levels by 3-CSAL), and by 1-CSAL 
(16% increase) in the striatum. The DHIQ, l-Me,6,7-
DHIQ had a consistent effect on HVA, decreasing it 
20% - 25% in both regions measured. 
H. Half-Life and Effects of 7-Methoxy-Salsolinol 
Following Acute ICV Injection 
The half life (T 1/2) of ICV administered 7M-SAL 
was determined by following its disappearance from se-
lected brain parts. Analysis by HPLC and GC showed 
its T 1/2 to be 133 minutes. This was calculated from 
T 1/2 = 0.693/R; R is equal to the slope of the line 
generated from the plot of log 7MSAL (~g/g tissue) 
versus time (hr) (Fig. 43). 
In tables 12 and 13 the actual values for DA, 
SHT, DOPAC, HVA and SHIAA in the hypothalamus, hippo-
campus and corpus striatum in control and 7M-SAL 
treated rats were tabulated. 
In the hypothalamus (Table 13A summarized 
Figure 44) there is no observed significant change 
in SHT levels over the 48 hr period assayed. How-
ever, SHIAA levels were increased significantly at 
12 hr (P<.OS), 24 hr and 48 hr (P<.Ol). The increases 
in SHIAA were 120% 137% of control values. The 
initial reciprocal changes (1 hr - 6 hr) seen in the 
SHT and SHIAA levels were not significant. 
In the hippocampus (Table 13B, summarized in 
Figure 44), SHT and SHIAA levels were assayed. 7~1-SAL 
significantly increased SHIAA levels 130% - 143% from 
6 hr to 48 hr (P<.Ol) while initially (1 hr) lowering 
SHIAA 19% (P<.OS). SHT levels were significantly 
affected at 3, 6, 12, and 48 hr after ICV injection. 
At 3 hr and 48 hr SHT levels were increased 17% and 
29% over control values, respectively (P<.Ol), while 
at 6 hr and 12 hr the SHT levels are decreased 17% 
and 11% respectively (P<.02) 
In the corpus striatum (Table 12, summarized 
in Figure 44) DA, DOPAC, HVA, SHT, and SHIAA were 
assayed. Striatal SHIAA was significantly increased 
3, 6, and 12 hr (114% - 139%; P<.OS) post ICV injec-
tion, while 5HT levels were significantly decreased 
only at the 12 hr time point (23%; P<.02). On the 
other hand, Striatal HVA was significantly increased 
133% - 192% over central at 1, 3, 12 hr (P<.OS). DA 
levels were decreased 24% at the 48 hr time point 
(P<.02) and DOPAC levels were increased 25% at the 
3 hr time point (P<.OS). 
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Thus, it appears that consistent neurochemical 
changes occur after moderate (10 ~g) ICV injections of 
7M-SAL in all three brain parts assayed. For example, 
SHIAA was observed to be· increased as was HVA and to 
some extent DOPAC in the hypothalamus, hippocampus, 
and corpus striatum. The biogenic amines, SHT and DA, 
have scattered changes with the hippocampus having the 
most significant SHT alterations. Examination of the 
graphed results (Fig. 44) indicates that the general 
trend is an increase in the acid metabolites of the 
biogenic amines (DOPAC, HVA, and SHIAA) over time 
with no concomitant, consistent changes in DA or SHT 
steady-state levels over time. 
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I. Results of Chronic Intraperitoneal Administration 
of 1-Carboxy-Salsolinol for Determination of In 
Vivo Formation of Dihydroisoquinolines froma 
Simple 1-Carboxylated THIQ 
After chronic 1-CSAL administration, the acid 
eluates of Bio Rex-70 isolation columns (amine fraction) 
of liver, corpus striatum, hypothalamus and hippocam-
pus were examined for the presence of 1-Me-6,7,-DHIQ, 
6- and 7-0-Methy~l-Me-DHIQ, SAL and the two a-methy-
lated SALs. There was no chromatographic evidence for 
the presence of these compounds which could, in theory, 
form from the (oxidative) decarboxylation and/or 
a-methylation of 1-CSAL. Minimum detectable quantities 
for DHIQs were 12 - 24 ng/g. Excellent recovery (85 -
87%) of the internal standard and biogenic amines in-
sured the integrity of the assay. Addition of 1-Me-
6,7 DHIQ and its 6- and 7-0-methylated isomers to cere-
bellar tissue passed through the BioRex-70 column pro-
cedure showed that they were exclusively eluted in 
the amine fraction. Qualitative examination of the 
+ primary elution plus 2 ml of .02M Na phosphate (acid 
and amphoteric fraction) confirmed the presence of 
1-CSAL and its 7-0-methylated (carboxylated) metabo-
lite in all regions examined. No endogenous amines 
were found in this fraction. These results indicate 
no substantial formation of DHIQs from 1-carboxy-SAL 
in these rat tissues in vivo after chronic i.p. admin-
istration of the THIQ. 
J. Spectrophotometric Studies on a Series of 
1-Methyl-6,7-Substituted 3,4-Dihydroisoquino-
lines 
The proposed neurotoxicity of dihydroisoquino-
lines is dependent on the structural similarities be-
tween the quinoidamine conformation of the DHIQs and 
that of the oxidized quinones of 60HDA and of other 
related compounds (i.e. 6-amino-dopamine, acetamino-
phen) . pH dependency of DHIQs was studied to determine 
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the tautomeric form of the DHIQs under physiological 
conditions (Fig. 45). 
1. 1-Methyl-6,7 Dihydroxy-3,4-Dihydroisoquinoline 
(I) and 1-Methyl-6-Hydroxy-7-Methoxy-3,4-Dihydro 
Isoquinoline (II) 
The UV absorption spectra of (I) and (II) were 
practically identical throughout the entire pH range 
tested (Fig. 46). Between pH 2 and 4 the spectra were 
unchanged; however above pH 5.0 they went through 
characteristic and similar changes for both substances. 
The most prominent change was the appearance of an ab-
sorption peak at 384 .nm which reached a maximum of 
about pH 9.0. With a further increase of pH up to 
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13, the absorption at 384 nrn was considerably diminished. 
Compound (I) had very weak fluorescence in the Ph 
range of 1 to 5. However, above pH 5.0 a fluorescence 
maximum at 455 appeared which gradually increased with 
increasing pH. The maximum activation peak was at 
380 nrn. The fluor~:scence intensity reached a maximum 
at approximately pH 8.0; above this pH, the emission 
intensity weakened, falling to a small value at higher 
pH's (Figures 47 and 48). Even at pHs 1 to 5, corn-
pound (II) exhibited a fairly strong fluorescence 
with a main excitation maximum at 380 nrn and an emis-
sion peak at 465 nrn. Maximum fluorescence intensity 
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was attained at about pH 8.0. The fluorescence decreased 
with increasing pH above pH 8.0 (Figures 47 and 48). 
2. 1-Methyl-6,7-Dimethoxy-3,4-Dihydroisoquinoline 
(III) and 1-Methyl-6-Methoxy-7-Hydroxy-3,4-Di-
hydroisoquinoline IV 
Compounds III and IV had almost identical U V 
spectra at all pHs tested (1 to 13). The spectra 
were practically identical between pHs 1 to 7 and 
in this range they also resembled the spectra of com-
pounds I and II between pHs 1 and 5 (Fig. 49). Above 
pH 8.0 they underwent reversible and typical changes. 
The absorption peak at 350 nm gradually decreased and 
disappeared (Fig. 49). 
Compound III showed a high fluorescence inten-
sity from pH 1.0 to pH 7.0 with these spectral charac-
teristics: the main fluorescence excitation peak was 
at 350 nm and the main emission maximum was at 450 nm 
(Fig. 50). Above pH 7.5 the fluorescence intensity 
decreased, disappearing at higher pH values (Fig. 51). 
Compound IV exhibited very weak fluorescence 
compared to the other DHIQs tested. In order to ob-
tain accurate readings the concentrations had to be 
increased 10-fold. 
K. Cyclic Voltarnmetry Studies on a Series of 1-Me-
thyl-6,7-Substituted-3,4-Dihydroisoquinolines 
Cyclic vol tarnmograms were generated from 1-Me-
6,7-DHIQ, l-Me-7M-DHIQ, and l-Me-6M-DHIQ at pHs of 
3.0, 5.0, and 7.4. The results of the cyclic voltam-
metry for these three dihydroisoquinolines can be seen 
in Figures 52, 53, and 54, respectively. The voltam-
mograms are strikingly dissimilar from those generated 
from CAs, THIQs and 60HDA-like compounds. The DHIQs 
exhibit no reversible reduction peak. The voltammo~ 
grams generated do exhibit characteristic shifts in 
oxidation potentials from higher oxidation potentials 
to lower oxidation potentials as the pH is increased 
from 3.0 to 7.4. These shifts indicated an increase 
in the ease of oxidation as the pH increased. The 
lack of the reversible reduction peak would indicate 
electrochemical oxidation to a compound which is sta-
bilized against reduction. Further interpretation 
of these results are reserved for the discussion sec-
tion of this dissertation. A summary of pH versus 
oxidation potential is shown in Table 14. 
L. Attempted Synthesis of Glutathione-Dihydroiso-
quinoline Adducts 
TLC analysis of the reaction mixtures of the 
dihydroisoquinolines and glutathione indicated that 
84 
85 
no adduct formation had occurred. Silica Gel TLC plates, 
developed with butanol/HOAc/dH20(4/l/l), showed only 
one fluorescence spot whose RF (= distance compound 
from origin/distance solvent front from origin) was 
identical to the respective DHIQ utilized as starting 
material. Staining of the plates with ninhydrin (pri-
mary amine)-reagent to visualize the location of the 
glutathione demonstrated one spot whose RF was iden-
tical to that of GSH and was substantially different 
from that of the respective DHIQs. No spot appeared 
having both fluorescence and ninhydrin staining which 
would indicate adduct formation. The NMR spectra of 
the two lyophilized reaction mixtures indicated no 
loss of the 5 or 7 position aromatic protons [as seen 
in 60HDA-glutathione adduct formation (206)] which 
are the expected sites of sulfhydryl addition. HPLC 
analysis of the reaction mixture utilizing combina-
tions of electrochemical/ UV and electrochemical/ 
fluorescence detection also indicated no adduct forma-
tion. 
M. GC Analysis of Acetaldehyde (AcA) ana Ethanol 
(EtOH) in Human Blood 
Routine separation of the compounds of in-
terest, AcA, EtOH, and the internal standard N-pro-
panol can be seen in Figure 55. Standard curves 
prepared with AcA and EtOH were linear for both corn-
pounds through their physiological ranges, (EtOH, 2.0 
to 500 rng/dl, AcA, 0.04 to 1.0 rng/dl). Recoveries 
ranged from 60 - 70%. Blood AcA and EtOH levels in 
blood samples were not changed by storage at -20°C 
for at least 72 hours. 
Table 15 shows mean concentrations of EtOH and 
AcA in the blood of thirteen male subjects ages 37 -
54, on admission (day 0) and days 1 - 4. Blood EtOH 
concentrations ranged from 110 to 420 rng/dl in these 
subjects, with a mean of 229.7 rng/dl. The mean EtOH 
concentration dropped to 5.0 rng/dl one day after ad-
mission and was undetectable on successive days. Our 
subjects' blood AcA concentrations on admission had a 
range of 0.06 to 0.70 rng/dl and averaged 0.350 rng/dl. 
Blood AcA in our studies were somewhat lower than 
those previously reported by Magrinat et al. (207), 
but our subjects' average EtOH concentrations were 
also less. 
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CHAPTER IV 
DISCUSSION 
A. Introduction 
-
These studies have been concerned with several 
related aspects of THIQ metabolism. The metabolic 
aspects were studied in vivo to determine in situ 
involvement of THIQs with the important CA-rnetabo-
lizing enzymes, COMT and MAO. First, the cerebral 
a-methylation pattern of several 1-alkyl catechol-
isoquinolines related to the CAs and their effects 
on DA, SHT and the acid metabolites of biogenic arnines 
were studied. Since 7M-SAL was the predominant O-rne-
thylated product of SAL in those studies, and since 
both of these THIQs form in vivo during alcoholism, 
the half-life and effects of 7M-SAL (ICV) ,on endogen-
ous DA, SHT, DOPAC, HVA and 5HIAA levels in various 
rat brain regions were determined. Third, prelirni-
nary investigations on a possible, novel, oxidative 
pathway for brain THIQs were initiated. Analytical 
characterization of the possible oxidative products 
of this pathway was undertaken. Simple but highly 
sensitive and specific analytical techniques were 
developed in order to pursue the above neurochemical 
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studies. The technical achievements in this disserta-
tion include improved GC/EC and HPLC/ED methods for 
the simultaneous separation and quantitation of bio-
genic amines, THIQs and their respective metabolites. 
Lastly, a procedure for the analysis of EtOH and AcA 
in human blood was modified and endogenous AcA levels 
were quantitated in alcoholics during detoxification 
at Hines V.A. Hospital. 
The discussion that follows is organized into 
sections headed by a statement of principle which des-
cribes the results to be discussed in that section. 
B. Improved Methods 
1. Direct Ass~y of Tissue Supernatants by HPLC 
with Electrochemical Detection Proves to Be 
a Rapid, Facile, and Versatile Way to Measure 
Biogenic Amines and Acids in Small Brain Samples 
Simultaneous separation and quantitation of DA, 
DOPAC, HVA, SHT and SHIAA in small brain parts allows 
for direct assessment of the neurochemical consequences 
of administered agents. Comparing control values of 
the biogenic amines and acid metabolites obtained by 
the HPLC techniques developed in this dissertation 
with literature values obtained by a variety of ana-
lytical methods, the efficacy of our rapid HPLC assay 
system can be seen (Table 16). All results fall well 
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within established literature values. The ability to 
do simple EtOH or HCl extraction and direct analysis 
of the supernatant allows for a rapid profile of brain 
regions and constitutes a useful and inexpensive ad-
dition to the neurochemists' repertoire of analytical 
tools. 
Reverse phase (RP) is a special case of parti-
tion chromatography. In the case of RP-HPLC, the or-
ganic phase is a permanently bond non-polar stationary 
phase. For our purposes we utilized a 18-carbon alkyl 
side chain covalently attached to silica beads. The 
aqueous phase is represented by the buffer system uti-
lized to make the mobile phase. 
The separations using this system are achieved 
because of the different degrees of interaction of a 
compound with both the non-polar stationary phase 
and the polar mobile phase. Compounds with a charged 
ionic moiety partition preferentially in the aqueous 
phase and move through the column quickly. Compounds 
which are neutral (uncharged) tend to interact with 
the hydrophobic phase of the column and to be re-
tained. 
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The biogenic amines and their acid metabolites 
represent a group of ionic compounds whose charge 
species are the amine and carboxylic acid, respectively. 
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For these ionic species the following equilibrium 
. - + ~ + 
exists; RCOOH~RCOO +H ; RNH 3~RNH 2+H . By adjusting 
the pH of the buffer system in the mobile phase, 
the equilibrium can be driven to favor a particular 
species. This technique is called ionic-supression 
HPLC chromatography. 
Paired ion chromatography (PIC) utilizes a 
large organic counter-ion added to the mobile phase 
which forms a reversible ion-pair complex with the 
ionized sample; this complex behaves as an electroni-
cally neutral, non-polar compound. The use of octane 
sulfonic acid (OSA) or heptane sulfonic acid (HSA) 
as the paired-ion adds a high degree of hydrophobic 
character to the sample through the paired-ion com-
plex. 
In order to assure a high paired-ion sample 
interaction, the pH of the mobile phase must be 
such that the sample is present in its ionic form. 
The extent to which the ionized sample and the 
counter-ion form an ion-pair complex affects the 
degree of retention on the column. 
In the separation of biogenic amines by PIC 
with alkyl sulfonates, the pH of the mobile phase 
should be around 3.5 for best ionic interactions. 
Maintaining a pH of around 3.5 ensures that both 
strong and weak bases will be in their ionic forms and 
any weak acids will be primarily in the non-ionic 
species. 
With the use of the electrochemical detection 
a second important pH-dependent reaction must be con-
sidered. The oxidations of the phenolic hydroxyls 
of the biogenic amines and their metabolites are 
also pH dependent. The lower the pH the higher the 
oxidation potential which must be applied. While 
the CAs and catechol isoquinolines and acid metabo-
lites are sufficiently detectable at low pHs (-3.5) 
using moderate(+.5-+.8 DC Volts) oxidation potentials, 
their a-methylated metabolites have a poor response 
at these potentials. Raising the applied potential 
to a value which would allow for detection of a-me-
thylated compounds results in increased oxidation 
of buffer components and a general loss in oxidative 
specificity. Increasing the pH of a strong paired-
ion mobile phase to above pH 4.5 results in a low 
efficiency of paired-ion-complex formation, thereby 
frustrating separations. 
For our investigations a HPLC system was de-
veloped which utilized a combination of ion-sup-
pression/ion-paired chromatography for the simul-
taneous separations of DA, DaPAC, 5HT, 5HIAA, HVA, 
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a number of THIQs, and their a-methylated metabolites 
(208). The buffer system of 0.1 M Na H2Pa4 utilized 
1 mM Na 2EDTA as the weak complexing paired-ion. EDTA 
is an unusual paired-ion because of its four ionizable 
carboxylates with PKa's of 2.0, 2.67, 6.16, and 10.26 
(209). The wide range of PKa's allows for this mole-
cule to be utilized as a paired-ion over a broad 
spectrum of pHs. 
In our studies, the pH which gave maximum 
separation and detection within the shortest time 
period was determined by titration with concentrated 
nitric acid (HNa 3) and found to be between 4.7 and 5.2. 
Between these pHs the ability to detect the whole 
spectrum of biogenic amine NT components was excellent. 
Separation of these compounds were dependent on pH ad-
justments as little as 1/10 of a pH unit. pH adjust-
ments were made to accommodate column deterioration 
and THIQs and their a-methylated metabolites which 
were present. 
Therefore, several significant advantages of 
the system developed in this research can be noted: 
1) with small change in pH a wide variety of sample 
mixtures could be routinely separated and quantitated; 
2) the moderate pHs allowed for quantitation of a-
methylated compounds; 3) the expense of costly 
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paired-ion reagents was eliminated; buffer systems can 
be made from conventional laboratory reagents. 
2. Capillary GC with EC Detection: A Very Selec-
tive and Extremely Sensitive Approach to the 
Estimation of Biogenic Amines and THIQ Stereo-
isomers in Discrete Brain Regions 
The use of a 10 M, WCOT column in combination 
with EC detection yielded the separation of geometri-
cal isomers with sensitivity as low as 3ng/g tissue. 
These results are comparable, in terms of sensitivity, 
with those generated by GC/MS. The use of short 
glass capillary columns allowed for unequivocal de-
termination of isolated compounds. The quantitation 
of endogenous brain DA levels and the assessment of 
in vivo THIQ metabolism had never been exploited by 
glass capillary GC/EC before this work was initiated. 
The development, therefore, represents the breaking 
of new ground in the field of analytical neurochem-
istry. The DA values generated by this technique 
compare favorably with established literature values 
(Table 16). Conversion of a conventional EC/GC to 
a capillary system is a relatively inexpensive in-
vestment (·$380). However, the result of this modi-
fication is the addition of a highly versatile and 
sensitive instrument, without prohibitive cost, to 
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the average neurochemistry laboratory. 
c. A Peripherally-Circulating DA-Related THIQ, SAL, 
Does Not Enter the Rat CNS 
Utilizing the highly sensitive (minimal detec-
table quantity for SAL and a-methylated products, 3 -
5 ng/g) GC/EC assay developed in this dissertation, 
it was found that low peripheral doses (5 - 20 mg/Kg) 
of SAL were not taken up into the CNS. This is not 
surprising, considering various CAs, including DA, 
the SAL precursor, also do not readily cross the 
BBB (217). The results here are additional support 
that SAL (11) and a-methylated-SAL (13), detected in 
the CNS of experimental animals after EtaH adminis-
tration, were derived in situ and were not the result 
of peripheral formation followed by uptake. 
SAL can be rapidly a-methylated by caMT with 
a Km equal to such accepted physiological substrates 
as DA and NE (151 - 153). The greatest activity for 
caMT is found in the liver (218) with activity also 
found in the spleen, intestines, adrenal gland (219) 
and blood (220 - 221) as well as other peripheral 
tissues. Peripherally formed SAL therefore would be 
rapidly a-methylated. Neither of the a-methylated 
SAL geometric isomers, Meta-6- or para-7- , were 
found in the CNS tissue assayed. 
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Peripheral metabolism of SAL could be envisioned 
as analogous to that of the THIQ trimetoquinol which 
like the sympathomimetic isoproterenol, is metabolized 
by a combination of a-methylation and conjugation with 
glucuronic acid (222). Because of these results, our 
general approach was to study the interactions of ca-
techol-isoquinolines on the biogenic amine systems 
after ICV administration. 
D. Centrally-Administered Isoquinolines Signifi-
cantly Affect the Levels and Turnover of Re-
gional Brain Arnines and Acid Metabolites to 
Differing Degrees, Depending on the Isoquino-
line 
1. Hippocampal SHT is Increased with Little Change 
in SHIAA Levels 
The results of this dissertation indicate that 
hippocampal SHT levels are increased significantly when 
measured 50 min following ICV administration of a ca-
techol isoquinoline (with the exception of 1-CSAL) , 
but SHIAA levels are unchanged (Fig. 42). These find-
ings agree with those of Hannigan and Collins (166) and 
Patel and Collins (223) that acutely administered THIQs 
cause increases in SHT with no increase in SHIAA in 
rat brain. 
The experiments in this dissertation show 
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that a variety of THIQs have this effect indicating 
that as a class catechol-isoquinolines can interact 
with SHT-systems. One plausible explanation for in-
creases in SHT without immediate and concomitant 
changes in SHIAA would be inhibition of SHT-specific 
MAO. In light of this, these results can be compared 
to the in vitro work by Meyerson et al. (161), who 
demonstrated that MAO type A, the SHT specific en-
zyrne, was more sensitive to inhibition by isoquino-
lines that MAO type B. 
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A second possible interpretation of these results 
could be blockade of SHT postsynaptic receptors, thereby 
increasing steady-state levels of SHT through in-
creased SHT reuptake and storage. Evidence for THIQ 
interactions with SHT receptors was found by Hamilton 
et al. (146) who demonstrated that SAL antagonized 
the effects of SHT on smooth muscle. 
It is quite possible that catechol-isoquino-
lines exert their effects at both the level of re-
ceptor and as a metabolic inhibitor. These effects 
would be synergistic and could account for increases 
in SHT with little or no changes in levels of SHIAA. 
What is apparent, is that the catechol-iso-
quinolines interact with SHT neurons. It is parti-
cularly relevant and interesting that catechol 
derived isoquinolines can influence SHT-systems. The 
isoquinolines could thus serve as a neuro-modulatory 
bridge between CA-systems and SHT systems. The fact 
that isoquinolines have effects on SHT steady-state 
levels and are known to inhibit SHT uptake (124) 
would reflect their ability to be taken up into SHT 
neurons in vivo. Once taken up, they could act as 
"false" SHT-NTs. The presence of isoquinolines in 
SHT-neurons, possible release and receptor interac-
tions and the potential to inhibit SHT deamination, 
could lead to aberrant SHT metabolism. 
Abnormal SHT metabolism was proposed long ago 
by Mcisaac (224) as an etiological factor in some 
forms of mental disease. One feasible hypothetical 
situation could occur during chronic EtOH intoxica-
tion, where the formation of the THIQ, SAL, within 
the CNS has been documented. THIQ interactions with 
SHT-systems would lead to elevated intracellular SHT 
levels. This in turn would lead to increased SHT 
and tryptophan condensations with free aldehydes 
(AcA) , resulting in the formation of harmaline-like 
tetrahydro-S-carboline (THBC)-alkaloids. THBCs are 
themselves potent SHT antagonists and MAO A inhib-
itors (225) as well as benzodiazepine receptor 
blockers (226). Such harmaline compounds have 
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recently been reported in vivo in untreated and alcohol 
treated rats (227). Therefore, the initial formation 
of catechol-isoquinolines within CA neurons specula-
tively could result in a self-perpetuating stimula-
tion of SHT dynamics. In this way, small quantities 
of THIQs generated during chronic EtOH ingestion could 
augment their pharmacodynamic effect by generating a 
second {possibly more potent) psycho-active agent. 
This situation could be described very well by 
Thudichum, a pioneer in brain chemistry, who wrote 
with foresight in 1884, "many forms of insanity are 
unquestionably the external manifestations of the 
effects upon brain substance of poisons fermented 
within the body" {228). 
2. A 6-Hydroxy-Dihydroisoquinoline Quinoidamine 
Significantly Decreases Hypothalamic and Stri-
atal HVA Levels Without Changes in DOPAC 
1-Me-6,7-DHIQ lowered HVA levels with no con-
comitant changes in DOPAC in both the corpus stria-
tum and hypothalamus (Fig. 42). These results may 
be due to in vivo inhibition of COMT which was seen 
only with 1-Me-6,7-DHIQ. The unique aspect of this 
molecule which may be responsible for this possible 
action is its quinoidamine tautomer {vide supra, 
section G) which appears to be the predominant 
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conformation at physiological pH (Fig. 45). In the 
quinoidamine conformation the catechol moiety no longer 
exists; it is an aromatic keto-enol substituent and 
closely resembles compounds such as tropolones, 
the tropolone-like pyrones, and pyridones, which are 
regarded as isosteric with catechol (Fig. 56). 1-Me-
6,7-DHIQ would appear to be isosteric with these in-
hibitory compounds. The tropolones, pyrones and pyri-
dones represent a class of short lived, but highly 
potent COMT inhibitors. In vivo, the tropolones ex-
hibit more potency of inhibition than do any catechol 
or catechol-derivative inhibitors (229). It is then 
reasonable to assume that the specific affect of 1-
Me-6,7-DHIQ on the levels of HVA are due to its tro-
polone-like activity (230). Further support of this 
suggestion is presented in section E of this dis-
cussion. 
3. SHIAA Levels Are Increased and DOPAC Levels Are 
Decreased in the Hypothalamus by Four of the 
Five Catechol Isoquinolines Examined 
The decreased hypothalamic DOPAC with increased 
5HIAA, which was potentiated by all the isoquinolines 
tested with the exception of SAL, reflects differing 
effects of catechol isoquinolines within SHT- and DA-
neurons (Fig. 42). The increase in SHIAA could be 
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explained by displacement of SHT from binding vesicles, 
again with an increase in SHT turnover (therefore, no 
change in SHT levels). Either case would require that 
the catecholic THIQ would be taken up into SHT neurons. 
This is further evidence of a structure-activity re-
lationship between SHT and isoquinolines. 
DOPAC levels in the hypothalamus were decreased 
by all of the THIQs (but not the DHIQ) examined, with 
generally no change in HVA levels, the exception being 
3-CSAL, which also decreased hypothalamic HVA. One 
would suspect that these decreases reflect inhibition 
of DA turnover. Inhibition of TH, the rate limiting 
step in CA synthesis, by isoquinolines have been demon-
strated both in vitro and in vivo (171 - 173). If MAO 
---
inhibition were responsible for DOPAC decrease, one 
would expect to see a concomitant decrease in HVA as 
seen in the case of pargyline pretreatment (Table 8) . 
4. Carboxylated Isoguinolines Cause Opposite Ef-
fects on DOPAC and HVA in the Hypothalamus and 
Corpus Striatum 
1-CSAL, .causes a corpus striatum-specific (23) 
increase in DOPAC and HVA. These concomitant in-
creases may reflect an increase in DA turnover. 
3-CSAL on the other hand causes significantdecreases 
in both DOPAC and HVA in the hypothalamus. This, as 
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stated above, could reasonably be due to inhibition of 
MAO or a decrease in DA turnover in the hypothalamus. 
5. Summary 
This study shows that various isoquinolines 
have remarkably different effects on the levels of 
SHIAA,DOPAC and HVA. Moreover, the isoquinolines in-
duce different changes in the three brain regions 
studied. Further studies of isoquinoline interac-
tions with biogenic amine systems will help to in-
terpret the mechanisms by which these interactions 
occur. 
E. The Brain 0-Methylation Patterns of Catechol-
Isoquinolines Are Remarkably Different from 
Those of Their Parent Amines 
The in vivo stereoselective a-methylation of 
the catechol isoquinolines differed dramatically 
frpm their parent amines, demonstrating significant 
( para) 7-0~ethylation. These studies on the ster-
eoselective enzymatic a-methylation of simple cate-
chol isoquinolines by brain COMT are particularly 
relevant, because they were performed in vivo. In 
vitro experimental studies seldom permit the liberty 
to quantitatively relate the actions of an extracted 
enzyme to its activity in the intact system. To 
date, methods used to study the stereoselective 
a-methylation of THIQs by caMT have usually involved 
the enzyme being isolated from cell extracts, "puri-
fied," and studied in an artifical medium. 
Among the many problems associated with extra-
polating in vitro results back to in vivo systems are 
the differences seen between in vitro and in vivo 
stereoselective a-methylation patterns of physiologi-
cal substrates of CaMT (DOPA,Epi, NE, DA, D~PAC, 
DHPG, etc.) (229, 231). In vivo results have demon-
strated almost exclusive formation of the meta (3-0CH 3) 
derivative (232) while conversely, in vitro results 
have shown meta/para ratios that varied significantly 
. h . h . ++ . d w1t m1nor c anges 1n pH, Mg concentrat1ons, an SAM 
cofactor concentrations (231- 236). 
The reasons for the anomaly between different 
isomeric ring substitutions in vivo and in vitro are 
not known. It has been suggested that the differences 
could be due to the cellular disruption which could 
alter the native conformation of COMT. The direct 
in vivo investigations in this dissertation circum-
vent these complications by allowing substrate-en-
zyme interactions to occur while maintaining the mi-
croenvironment of the biological system under inves-
tigation. 
The catecholic THIQs have been shown to interact 
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with CaMT as competitive inhibitors in vitro (151 - 153) 
and in vivo (153, 237), and, furthermore, undergo a-me-
thylation (148, 151, 153). However, the elucidation of 
the a-methylated products in vivo had not been accom-
plished. In vitro studies, utilizing purified rat 
liver CaMT to determine the stereoselective a-methy-
lation of 6,7-dihydroxy THIQ, N-Methyl 6,7 dihydroxy 
THIQ (154}, THP and THPB (156}, demonstrated signifi-
cant para (7-aca3 ) a-methylation. In light of the 
known lack of agreement between in vivo and in vitro 
CA results, these findings with THIQs have to be 
viewed with caution in regard to their physiological 
relevance. 
To date, the only studies on in vivo a-methyla-
tion of THIQs in tissues, particularly brain, was for-
warded by Bail et al. (155). Their studies presented 
chromatographic evidence indicating that the a-methy-
lation of (+) SAL and (+) 6,7(aH) 2 THIQ in the rat CNS 
were predominantly on the "para" (?-position) hydroxyl. 
These results were unexpected because, as reviewed, 
endogenous CAs are primarily or exclusively a-methy-
lated in vivo on the meta (3-aH) hydroxyl. Bail 
et al. were unable to definitively separate and 
quantitate the two a-methylated SAL and 6,7-(aH) 2 
THIQ products due to lack of chromatographic 
resolution. 
Our results unequivocably demonstrate that the 
a-methylation of THIQs in vivo follows discrete pat-
terns that are very different from the CAs. In fact, 
no catechol substrates have ever shown the high de-
gree of p-a-methylation like SAL and 1-CSAL. DA a-
methylation was observed to occur exclusively on the 
meta (3} hydroxyl, thus confirming literature indi-
cations and insuring that the "variant" a-methyla-
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tion of the THIQs was not an artifact of administration. 
The reasons for the observed differences in the 
stereoselective site for a-methylation between precur-
sor CAs and product THIQs in vivo are worth consider-
ing at this point. Much evidence suggests that a 
single enzyme catalyzes the formation of both a-methy-
lated products from catechols (229}. Extensive purifi-
cation of CaMT did not affect the meta/para ratio of a 
variety of substrates, providing further evidence that 
only one enzyme is involved in both meta and para a-
methylation of catechols (238}. 
The ratio of meta and para a-methylated products 
in vitro was found to be strongly dependent on the na-
ture of the aromatic substrate and the pH of the reac-
tion medium. Meta-(3}-0-methylated isomers predomi-
nated with substrates which contained highly polar 
substituents [as is the case with physiological sub-
strates (154)], while substrates with non-polar sub-
stituents had ratios close to unity. 
There are at least two possible explanations for 
the negative effects of polar substituents on p-0-me-
thylation by COMT (231): a) Catechols containing sub-
stituents with highly polar moieties are bound by means 
of this highly polar substituent in an orientation that 
favors transfer of the methyl group to the meta (3) po-
sition, or, b) A hydrophobic region is present in the 
active site of COMT which prevents random binding of 
polar substrates by repulsive interactions so that 
binding occurs primarily (as is the case of physiolog-
ical substrates) in a conformation which favors meta 
a-methylation. Since the apparent affinity of polar 
substrates for COMT does not differ markedly from 
those of non-polar compounds, and since both anonic 
and cationic polar substituents have the same effect 
on p-methylation, the latter explanation is favored. 
The presence of a non-polar region in the ca-
techol binding site of COMT would then militate the 
orientation of binding, directly influencing 
meta/para ratios. The meta/para ratios obtained 
with amine substrates would be due to the presence 
of the ionized ammonium function in the side chain 
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being oriented away from this non-polar region. Simi-
larly, studies utilizing analogues of DA and NE sug-
gest meta/para ratios as a function of side chain in-
teractions with hydrophobic centers on COMT (239). 
charged species on the substrate molecules would be 
steered away from the hydrophobic centers, resulting 
in binding orientations which would result in a stere-
ospecific a-methylation reaction. 
Application of these in vitro findings to the 
in vivo results on THIQ stereoselective 0-methylation 
can help to provide an explanation for the patterns 
observed. The THIQs, although structurally very 
similar to CAs (having several structure-activity 
relationships~ have one major structural dissimi-
larity. The amine substituent is not flexible but 
is fixed within a heterocyclic ring in the THIQ. 
This limits the freedom of rotation of the amino 
functional group (as well as other side chain sub-
stituents) and restricts the number of orientations 
which the side chain can accommodate. This restricted 
movement of ionizable groups adds another parameter 
to the binding orientation of THIQs to COMT. 
Figure 57A illustrates the manner in which a 
hydrophobic region adjacent to the active site of 
COMT could influence binding orientation of 
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physiological substrates. The hydrophobic area orients 
the ionized side chain such that binding of substrate 
best accommodates the charge species outside of the 
hydrophobic area. Binding such that the para hydroxyl 
is a-methylated is possible but involves overcoming 
hydrophobic forces. The THIQs would be particularly 
susceptible to hydrophobic steering of their ionizable 
substituents because of the additional loss of rota-
tional freedom due to the heterocyclic ring. The 
most favored orientation would, as in the case of CAs, 
place charged substituents outside this hydrophobic 
area (Fig. 57b). 
Utilizing the above rationale, the observed 
stereoselective binding of the THIQs assayed in this 
dissertation can be understood. 
R2=cH 3), which was a-methylated to a major (95%) ex-
tent on the para-7- hydroxyl, had to bind in an up-
side-down orientation in relation to CA binding. 
Thus, the charged amine was positioned away from the 
hydrophobic center while the hydrophobic region of SAL's 
ring was oriented into the hydrophobic center. The 
5% meta binding observed may be due to R1 (cH 3) being 
able to interact with the hydrophobic region thus 
deferring some of the hydrophobic repulsion forces. 
This is a tenable explanation in light of 
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the results with (+} 1-CSAL (R1=COOH, R2=CH3 , R3-R4=H}. 
The presence of carboxylic acid moiety on the R1 sub-
stituent eliminates a "meta-wobble" and militates 
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strict (100%} "para" (7-0H) 0-methylation. Binding 
orientation places both the charge amine and carboxylic 
acid away from the hydrophobic center, thereby position-
ing the para-hydroxyl for methylation. 
4,6,7-(0H) 3 THIQ (R1=R2=R 3=H, R4=0H) has polar 
substituents located in a meta orientation to one 
another and may therefore represent a class of THIQ 
substrates with intermediate binding specificity. 
Binding in either the meta or para orientation posi-
tions places a polar moiety within the hydrophobic 
region. This is reflected in the observed (55% meta/ 
45% para) randomized product ratio. Similarly, (-) 
3-CSAL (R1-cH 3 ,R2R4=H R3=COOH) has two (2) polar 
moieties (located ortho to one another). Binding of 
the substrate in the para orientation brings the car-
boxylic moiety in close proximity to the hydrophobic 
region. Binding in the meta position would bring 
the amine within proximity of the hydrophobic region 
but also positions the R1 methyl group in a favorable 
position for overlap with the hydrophobic center. The 
binding is randomized but favors the accommodation of 
the methyl group overlap and yields 60% meta/40% para 
results. 
1-Me-6,7-DHIQ represents a novel finding in that 
it appears not to undergo a-methylation to any de-
tectable extent. As described (vide supra in section 
D2) this compound resides in a quinoidamine con-
formation and resembles the tropolone-like inhibitors 
of COMT. The tropolone-like inhibitors compete with 
CAs for the active site of caMT, but are not metabo-
lized (233, 240) (Fig. 56). The lack of a catechol 
moiety at physiological pH is no doubt responsible 
for the inert nature of these compounds toward enzyma-
tic a-methylation. 
An additional set of interesting observations 
can be gleaned from these results. In Tables 4, 5, 
and 6 the % a-methylation and the levels of catechol 
isoquinolines (~g/g brain region) are given 
as found in the corpus striatum, hypothalamus and hip-
pocampus, respectively. The levels of the catechol 
isoquinolines appear to be similar in both the corpus 
striatum and hippocampus. However, the % a-methyla-
tion for the carboxylated-THIQs is consistently 
lower. In the corpus striatum (Table 4) 1-CSAL is 
66% of SAL while 3-CSAL is 33% of SAL. In the hypo-
thalamus (Table 5) the levels of carboxylated THIQs 
are 2 - 2.5 fold that of the noncarboxylated THIQs 
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and the % a-methylation is found to be approximately the 
same. In the hippocampus (Table 6) the levels of 3-CSAL, 
sAL, and 4,6,7-(0H) 3 THIQ are similar. However, the% 
a-methylation for the carboxylated THIQ is 37% of the 
non-carboxylated THIQs. These results may reflect a dif-
ference in the Km's between the carboxylated and non-
carboxylated THIQs. These results again reflect signi-
ficant differences between the THIQs and the open chain 
catecholic substrates which bear acidic, neutral, and 
basic constituents whose Km's are not markedly differ-
ent (231). If this is the case, the presence of a car-
boxylic acid moiety on the side of a THIQ would result 
in an extended T 1/2. The consequence of this increase 
in T 1/2 would be a similar increase in the duration 
of the pharmacological effect. 
F. a-Methylation of a Catechol Isoquinoline In-
creases Its Half-Life in Brain Over 10-Fold 
and Alters Its Effects on Biogenic Amine Systems 
1. Centrally Administered 7M-SAL Significantly 
Affected the Levels and Turnover of Regional 
Brain Biogenic Amines and Acid Metabolites 
The phenolic isoquinoline 7M-SAL tended to in-
crease SHIAA without increasing SHT in hypothalamus 
and hippocampus over the entire 48 hr period assayed 
(Fig. 44). Striatal increases in SHIAA, HVA, and 
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oOPAC levels were restricted to the first 24 hr. These re-
sults, increased acid metabolites with no concomitant in-
creases in biogenic amine levels, indicates that 7M-SAL 
increased biogenic amine turnover in all three tissues 
assayed. This represents an obvious change in the pharma-
codynamics of SAL upon a-methylation. The most signifi-
cant effect is on striatal HVA levels within the first 
12 hrs after ICV administration. In contrast to SAL 
whose main effect is on 5HT neurons, 7M-SAL appears to 
effect both 5HT and DA neurons, not as inhibitor of bio-
genic amine metabolism, but as an activating agent. 
These effects indicate that the production of endogenous 
catechol isoquinolines, followed by metabolism to their 
phenolic "metabolites," would result in a complex array 
of metabolic consequences. 
2. 0-Methylation of a Catechol Isoquinoline In-
creases Its T 1/2 in Brain Over 10-Fold 
ICV administered 7M-SAL had a calculated T 1/2 
of 133 minutes as measured from its disappearance from 
the corpus striatum and hypothalamus. This repre-
sents a 10.6 fold increase in the T 1/2 of SAL in 
the rat CNS. SAL rapidly disappears from the CNS 
with aT 1/2 of 12.5 min (150). The T 1/2 was doubled 
when pyrogallol, a known inhibitor of COMT, was ad-
ministered, indicating that the disappearance of SAL 
is the result of conversion to an a-methylated metabo-
lite. Hamilton et al. (13) provided the chromato-
graphic evidence for a-methylated SAL (isomer unknown) 
in the CNS of mice treated with chronic EtOH. In light 
of the relative inertness of SAL to enzymatic oxida-
tive degradation, a-methylation appears to be a major 
metabolic pathway. The consequences of a-methylation 
in the case of SAL do not appear to be deactivation. 
In fact, a growing body of evidence is challenging 
the initial premise that a-methylation is totally 
a deactivation process. Recent findings have demon-
strated that 3M-DA, the primary in vivo product of DA 
a-methylation by COMT, is not pharmacologically-
inactive compound. Rats treated with 3M-DA exhibited 
psychomotor effects which mimic those of DA treatment 
in combination with MAO inhibitors, conditions re-
sulting in increased 3M-DA formation (241). 
G. Catecholic and Phenolic 1-Me-DHIQs: Spectro-
photometric, Fluorescence and Voltarnrnetric 
Investigations Provide Interesting Results 
1. Spectrophotometric and Fluorescence Assays In-
dicate that 6-0H-DHIQs Are in the Quinoid-
amine Conformation at Physiological PH 
At physiological pH (7.4), 1-Me-6,7-DHIQ and 
l-Me-7M-DHIQ are totally in the quinoldamine 
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conformation. The interpretation of U V and fluores-
cence results on 1-Me-DHIQs obtained in this disserta-
tion were based to a large extent on the work of G. 
Jonsson with HCHO generated DHIQs (lacking the 1-Me-
thyl group) (242, 243). 
Jonsson's U V and fluorescence results utiliz-
ing 6-hydroxy-DHIQ are identical to those generated 
in this dissertation for 1-Me-6,7-DHIQ and l-Me-7M-
DHIQ. Jonsson found that at pH 2.0, 6-hydroxy-3,4-
DHIQ showed two absorption peaks, one at 236 nm and 
the other at 323 nm (242). Above pH 6.0 - 6.5 the 
spectra showed typical drastic changes with an appear-
ance of a strong absorption peak at 365 nm. This peak 
increased with increasing pH, reaching a maximum at pH 
8.0 - 9.0. Above pH 9.0 the absorption gradually 
decreased and at pH 13 the absorption characteristics 
were similar to those of pH 2.0. The 6-hydroxy-3,4-
DHIQ exhibited only weak fluorescence at low pH's 
but fluorescence increased with increasing pH, reach-
ing a maximum at around pH 8.0. Above pH 8.0, the 
fluorescence intensity fell, becoming very weak above 
pH 12.0. 
The 6-hydroxyl-3,4-DHIQ, lacking a 7-position 
hydroxyl, by default, must form a tautomeric quinone 
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whose structure resembles form B (Fig. 45). l-Me-7M-DHIQ, 
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with a blocked 7-hydroxyl, behaves like its dihydroxy 
derivative, which in turn behaves like 6-hydroxy-3,4-
DHIQ. All three compounds show identical pH dependent 
spectral changes. The disappearance of long wavelength 
absorption above pH 8.0 is probably due to the ioniza-
tion of the hydroxyl group in the 6 position (Fig. 58A). 
1-Me-6,7-DM DHIQ and l-Me-6M-DHIQ both have the 
6-hydroxyl group blocked and behave almost identically. 
Their typical spectral changes prevalent above pH 7.5 
are probably due to addition of water across the imine 
double band to form a carbinolamine (Fig. 58b) (244). 
Therefore, these results demonstrate that 1-Me-
6,7-DHIQ and l-Me-7M-DHIQ at physiological pH and am-
bient temperature exist in a quinoidamine conforma-
tion which bears structural similarities to the oxi-
dized (apparent neurotoxic) form of 60HDA (Fig. 19). 
Previous results (section E) indicate that 1-Me-
6,7-DHIQ does not undergo a-methylation and that its 
possible THIQ precursors (SAL and 1-CSAL) are both 
0-methylated predominantly on the 7-position hy-
droxyl. Therefore, even if the dihydroisoquinolines 
were to be formed after a-methylation of the precur-
sor THIQs, quinoidamine formation would not be blocked 
by a-methylation. 
2. Cyclic Voltammetry of 1-Me-6,7-DHIQ l-Me-7M-DHIQ 
and l-Me-6M-DHIQ Indicate that They Are Irrever-
sible Oxidized 
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Cyclic voltammograms of the DHIQs, 1-Me-6,7-DHIQ, 
l-Me-7M-DHIQ and l-Me-6M-DHIQ demonstrated irreversible 
oxidation throughout a range of pHs. This is strik-
ingly different from the cyclic voltammetry of CAs, 
THIQs, or 60HDA-like compounds, and suggests that the 
electrochemical oxidation of DHIQ leads to the forma-
tion of an "atypical" product. In order to facilitate 
the interpretation of the results of the cyclic volt-
ammetry of the compounds of interest, a brief discus-
sion of cyclic voltammetry follows. 
In voltammetry, a varying potential (Eapp) is 
applied between a working electrode and a reference 
electrode immersed in a quiet (non-stirred) solution 
containing an electroactive component suspended in 
a buffer. The buffer, a supporting (background) 
electrolyte is simply one which can provide overall 
high conductance, while not being electroactive in 
the region of interest. The cut-off potential for 
any voltammetric analysis is that potential where 
general electrolysis of solvent begins to occur. 
The working electrode is an inert surface which 
serves as a source or sink of electrons. As Eapp 
varied, molecules near the electrode surface can either 
gain electrons from the source (cathodic reduction) or 
loose them to the sink (anodic oxidation) . Diffusion 
occurs as a result of the concentration difference de-
veloped between the electrode surface and the bulk of 
the solution as soon as electrolysis is initiated. 
Diffusion is the predominant form of mass-transport 
in quiet (standing) solution voltammetry. 
When a working electrode is placed in a quiet 
solution and Eapp is varied in a linear fashion (a 
linear potential sweep) the response is a peak voltam-
mogram (Fig. 59a) . Figure 59a represents a model com-
pound whose oxidation occurs at Ep of 0.42 volts and 
the magnitude of Ip is directly proportional to the 
concentration of the compound in solution. By con-
vention, oxidation currents are plotted downward 
from the zero current line and the potential, E, is 
increasing anodic or oxidizing, from right to left. 
Potentials in voltammetry are usually referred di-
rectly to the experimental reference electrode, in 
the case of our work, an Ag-AgCl electrode. 
When a peak voltammetry is seen and the poten-
tial sweep is rapidly and reproducibly reversed, a 
cyclic voltammogram is generated (Fig. 59b). Since 
the solution is quiet and the time interval between 
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sweep reversals is short, the products generated in the 
oxidation are available near the electrode for reduc-
tion as the potential sweep reverses. In a simple, 
rapid electron transfer, with no chemical complica-
tions, one obtains oxidation and reduction peaks whose 
potentials are separated by a small increment as de-
fined by equation: 
- E 
Pred 
= 
0
·
57 
volts (245} N (Eq. 1} 
The reversibility of any electron transfer can 
be qualitatively judged by the separation of the oxida-
tion and reduction peaks (Fig. 60}. Figure 60a illus-
trates a fast (reversible} electron transfer; B, a less 
reversible (quasi-reversible} transfer; while C, a slow 
electron (irreversible} transfer. 
In Figure 59b, the theoretical voltammogram for 
a pure reduced species in solution is shown. As can 
be observed, it represents a reversible electron trans-
fer system. The potential sweep is initiated in an 
anodic (oxidizing} direction at some arbitrary point. 
During the time interval of peak b, the originally 
fully reduced compound is oxidized. At an arbitrarily 
chosen point, the potential is reversed and peak a is 
generated and represents the re-reduction of the com-
pound. With no intervening chemical reactions, the 
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properly measure ratio of a/b currents is unity (246). 
All the adrenergic NTs and their metabolites 
(247), as well as the THIQ alkaloids, SAL and 0-Me-SAL 
(248), possess electrochemical activity with their 
voltammograms showing that they are quasi-reversible 
systems. 60HDA, on the other hand, is a model com-
pound for cyclic voltammetry and displays near per-
fect reversibility (246). It was unexpected to dis-
cover that the cyclic voltammograms of 1-Me-6,7-sub-
sti tuted- 3, 4·-DHIQs resembled neither the THIQs nor 
CAs, their purported precursors, or 60HDA, to which 
they bear some structural resemblance, at any of the 
pHs tested. Rather, the cyclic voltarnmograms of the 
DHIQs demonstrated an irreversible electron transfer 
system which could only undergo oxidation. (The re-
duction peak is so negative and flat it could not be 
distinguished over the reduction of the support sol-
vent.) The interpretation of these results possibly 
would constitute detailed information regarding the 
possible reactions and metabolic degradation of DHIQs 
at the molecular level. 
Aside from the pH-dependent decrease in oxida-
tion potential (Table 14}, the cyclic voltammograms 
were idential for all three DHIQs tested. This would 
indicate that upon electrochemical oxidation they are 
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all being converted to the same product. The primary 
step of the oxidation was probably conversion to the 
ortho-quinone similar to what is seen with CA oxida-
tion. One possible explanation is that the orthoquin-
one is an unstable intermediate which undergoes spon-
taneous intramolecular oxidation/reduction to yield 
a fully aromatic, heteroaromatic molecule (Fig. 61}. 
This would be similar to the internal oxidation re-
duction of cyclized 60HDA to form 5,6-dihydroxy-
indole (249}. Attempts to reduce the fully aro-
matic molecule would be futile, owing to its internal 
reduction upon aromatization. Any attempts to reoxi-
dize the "fully aromatic" heteroQaromatic species 
would probably require very high electrochemical oxi-
dation potentials to overcome the loss of aromaticity 
upon oxidation. This would account for the lack of 
a new oxidation peak when repetitive sweeps were run 
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at applied potentials between (+} 1.2 and (-) 1.2 volts. 
H. Oxidative Decarboxylation of 1-CSAL to a DHIQ 
or THIQ Appears to be Insignificant in the Normal 
Intact Rat 
As reported in the Results, detectable levels of 
1-methyl-DHIQs were not observed after chronic i.p. 
administration of 1-CSAL. However, recently it has 
been demonstrated that 1-carboxylated THIQs can be 
decarboxylated to their corresponding 3,4-DHIQs by 
anodic oxidation at a low potential (184), prolonged 
aerial oxidation in basic media (183), and exposure 
to plant laccases and peroxidases (78). In all the 
oxidative decarboxylations a free'phenolic group at 
position 6 or 7 of the isoquinoline system is essen-
tial. These reactions are considered to be decar-
boxylations induced by oxidation of the phenolic hy-
droxyl group. To date, no in vivo or in vitro decar-
boxylations of 1-carboxylated THIQs have been reported 
using animal tissue, and initial experiments presented 
here were unsuccessful. This may be due in part to 
rapid a-methylation and conjugation which is known 
to occur with other THIQs. 
a-methylation of 1-CSAL, as reported earlier 
in this work was found to be predominantly on the 
7-hydroxyl in brain (4-hydroxyl of the precursor 
moiety) and was qualitatively observed on the 7-hy-
droxyl in liver. These results imply that a signi-
ficant metabolic route for 1-CSAL is a-methylation. 
Studies utilizing trimetoquinol (TMQ), a cate-
chol THIQ having potent bronchodilating action, demon-
strated that 61% of the excreted TMQ was conjugated 
to glucuronide, 11.5% the free base, and 27.5% as a-
methylated-conjugated TMQ (222). Further studies 
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determined that sulfate conjugation of biogenic amines 
and their acid and a-methylated metabolites is an im-
portant metabolic pathway in their metabolism in the 
eNS {250 - 251). These reactions would tieup the 
free phenolic hydroxyls of THIQs {necessary for oxi-
dative decarboxylation) thereby deactivating the 
THIQs toward oxidative decarboxylation. 
Alternatively, the optimum situation for the 
formation of DHIQs from THIQs in the rat in vivo may 
be after chronic EtOH or barbiturates when microsomal 
oxidizing systems are "induced." In an analogous 
situation, Dajani and Saheb (252) , studying the metabo-
lism of 6-hydroxy- and 6-methoxy-1,2,3,4-tetrahydro-
S-carbolines (THBCs), found that varying metabolic 
conditions favored the formation of a number of oxi-
dized S-carbolines both in vivo and in vitro. These 
findings give rise to yet another alternative explan-
ation, that is, formation of other oxidative products 
such as N-oxides and fully aromatic isoquinolines 
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(Fig. 62). Hamilton and Gause (253) have indicated possi-
ble formation of N-oxides from SAL and 6,7-(0H) 2-THIQ 
after incubation in mild aqueous alkaline conditions. 
Results of the cyclic voltammograms generated in this 
dissertation indicate the possible formation of fully 
aromatic isoquinolines upon oxidation of DHIQs. These 
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alternative oxidation products may have formed but would 
not have been detected because those possible products 
were not available as standards. 
r. Simple 6-Hydroxy-DHIQs Do Not Apparently Form 
Glutathione Adducts 
CAs after oxidation to ortho-quinones as well 
as 60HDA, 6-amino-DA (6NH2DA) and their analogues, 
after oxidation to para-quinones, are known to undergo 
irreversible nucleophilic additions of sulfhydroryl 
compounds (190, 249, 254). The addition of thiol 
to carbon-carbon double bonds of a quinone constitutes 
a special case of nucleophilic addition to an ~-S-un­
saturated system (255). The nucleophile in these 
reactions is R-S-H. The reaction occurs rapidly 
when the electron density of the carbon-carbon double 
band is reduced by electron withdrawing substituents 
(256). Electron withdrawal can be either by induc-
tion or resonance, or both. 
We can conclude that simple 1-akyl-6-hydroxy-
7-alkoxy-substituted-3,4-DHIQs, which at physiologi-
cal pH reside as para quinoidamine tautomers, do 
not participate to any detectable extent in sulfhy-
dryl adduct formation. The plausible explanation 
for this lack of reactivity may lie in the low elec-
trophilic character of tautomeric double bands. 
unlike the para-quinones of 60HDA and 6NH2DA which can 
rely on the strong electron withdrawing capacities of 
two electron withdrawing substituents, the DHIQs tested 
have only the proximal catecholic oxygen which cannot 
sufficiently reduce the electron density of the double 
band participating in adduct formation. (The distal 
atom in the para-quinone being the 1-carbon; carbon 
atoms are poor electron withdrawing groups.) However, 
the electrophilicity of the DHIQ tautomers can be en-
hanced if the 1-methyl substituent would be replaced 
with an electron withdrawing group. This is the case 
when dealing with one of the DHIQ products of oxida-
tive decarboxylation of 1-carboxy-1-benzyl THIQs. 
These THIQ compounds, as noted in the introduction, 
are present in various pathological conditions (3, 7), 
and are known to undergo oxidative decarboxyla-
tions under a variety of conditions (78, 183, 184) 
to form ~-keto-'3,'4-substituted-1-benzyl-6,7-substi­
tuted DHIQs. These compounds may be electrophi-
lic enough to undergo adduct formation through the 
enhanced electron-withdrawing capabilities of the 
a-keto and 1-benzyl substituents. If these complex 
DHIQs share even a degree of the electrophilic 
character of 60HDA quinone, they should be capable 
of producing neuronal damage via covalent attachments 
123 
to cellular nucleophiles. 
J. Ethanol and Acetaldehyde in Human Blood 
GC methods for the determination of EtOH and AcA 
are specific, sensitive and rapid. However, an acknow-
ledged problem hindering the precise measurement of AcA 
and EtOH containing samples (blood and tissues) is ar-
tifactual (non-enzymatic) generation of the aldehyde 
(257). It has been reported that addition of 20- 40 
mM thiourea suppressed AcA production from EtOH in de-
proteinated rat blood which was incubated at 65°C, but 
that thiourea was only partially effective when human 
blood was used (258). We found, however, that arti-
factual AcA formation was essentially absent of human 
blood sample in perchloric acid and thiourea were in-
cubated at a lower temperature. As would be expected, 
incubation at a lower temperature lowered AcA and 
EtOH recoveries. However, the recoveries were ade-
quate to permit minimum detection of 0.04 mg/dl of 
AcA. 
The significant importance of this portion of 
the study is that mean blood AcA concentrations did 
not remain elevated throughout the four day detoxi-
fication period. An earlier report by Magrinat 
et al. (207) stated that blood AcA concentrations 
in patients admitted for alcohol detoxification 
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remained at admission day levels over four days as blood 
EtOH dropped to negligible values. Our findings show 
that blood AcA levels drop 70% within one day after ad-
mission and were undetectable on days 2 - 4. The pos-
sible differences in subject population, previous al-
cohol or drug consumption, or nutritional and hepatic 
status should not account for this large disparity 
with regard to blood AcA concentration on days 1 - 4 
of detoxification. A possible conclusion for the 
chronically elevated blood AcA levels reported earlier 
in detoxification is that the workers failed to account 
for artifactual AcA formation during analysis. 
CHAPTER V 
SUMMARY 
In this dissertation, relatively simple, highly 
sensitive, and specific techniques were developed or 
improved for use in neurochemical studies of tetrahy-
droisoquinoline metabolism. A direct assay of tissue 
supernatants by high performance liquid chromatography 
with electrochemical detection was used to measure 
tetrahydroisoquinolines, biogenic amines and acids in 
small brain samples. Capillary gas chromatography 
with electron capture detection proved to be a very 
selective and extremely sensitive approach to the es-
timation of biogenic amines and catechol isoquinoline 
stereoisomers in discrete brain regions. 
Utilizing the highly sensitive (minimal detec-
table quantity for salsolinol and 0-methylated products, 
3 - 5 ng/g) gas chromatography with electron capture 
detection assay developed in this dissertation, it was 
found that salsolinol in low peripheral doses (5 - 20 
mgjkg) was not taken up into the central nervous system. 
These results are additional support that sal-
solinol and 0-methylated-salsolinol, detected in the 
central nervous system of experimental animals after 
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ethanol administration, were derived in situ and were 
not the result of peripheral formation followed by 
uptake. 
Centrally administered catechol isoquinolines 
(10 - 50 ~g) were found to alter the steady state 
levels of biogenic amines and acid metabolites to dif-
fering degrees, depending on the isoquinoline and the 
brain region. Of particular interest was the effect of 
catechol isoquinolines on the serotonergic system. A 
variety of catechol isoquinolines raised the steady 
state levels of serotonin, indicating that as a class 
these compounds can interact, indirectly and/or di-
rectly, with serotonergic systems in vivo. The iso-
quinolines could thus serve as neuromodulating bridges 
between catecholaminergic systems and serotonergic 
systems. 
The a-methylation patterns of several cen-
trally-administered catechol isoquinolines were found 
to be different from those of their parent amines, as 
reflected by the extent of a-methylation on the 7-po-
sition hydroxyl (para position in the parent cate-
cholamine) . Such in vivo studies on the stereoselec-
tive enzymatic a-methylation of simple catechol iso-
quinolines are more relevant than in vitro approaches, 
because substrate-enzyme interactions occur in the 
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endogenous microenvironment of the biological system 
under investigation. 
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The endogenous half-life of centrally adminis-
tered 7-0-methyl-salsolinol (salsoline; the major me-
thylated metabolite of salsolinol in vivo) was deter-
mined to be 133 minutes in two brain regions, the 
striatum and the hypothalamus. This represents a 10.6 
fold increase over the reported half-life of the parent 
isoquinoline salsolinol. In addition, salsoline was 
found to effect the steady state levels of biogenic 
amines and acid metabolites over a 48 hour period. 
These effects, increase in half-life and pharmacological 
activity of an a-methylated metabolite, indicate that 
production of endogenous catechol isoquinolines fol-
lowed by metabolism to phenolic metabolites would re-
sult in a complex array of metabolic consequences. 
Spectrophotometric studies of 1-methyl-6,7-sub-
stituted 3,4-dihydroisoquinolines (potential products 
of tetrahydroisoquinoline oxidative metabolism) indi-
cated that, at physiological pH, those with 6-hydroxy-
substituents are nearly exclusively in the quinoid-
amine conformation (the conformation postulated for 
nucleophilic attack on cellular ligands) . The cyclic 
voltammetry of these dihydroisoquinolines showed that 
upon electrochemical oxidation they become irreversibly 
oxidized, suggesting transformation to a fully aromatic 
species. 1-methyl-6-hydroxy-7-alkoxy-substituted-di-
hydroisoquinolines apparently do not readily form glu-
tathione adducts as such. Also, in vivo synthesis of 
simple 1-methyl-dihydroisoquinoline~ from 1-carboxyl-
salsolinol (injected chronically) by oxidative decar-
boxylation,appeared to be insignificant in the normal 
intact rat. 
These findings represent advancements in our 
knowledge about the discrete metabolic consequences 
of catecholamine-related isoquinolines in mammalian 
systems, advancements which could aid in understanding 
the underlying meaning of condensation product in-
volvement in mammalian homeostasis and disease. 
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Table 1 
Selected Physical Data for Synthesized 
Compounds in Section II 
Compound M0 
Salsolinol HBr (SAL) 264 183 
1-Carboxy-Salsolinol (1-CSAL) 223 233 
7 -0-Hethyl-1-Carboxy-Salsolinol (7M-l-CSAL) 237 205 
6,7-Dihydroxytetrahydroisoquinoline (6, 7-(0H) 2THIQ) HB.r 250 268 
1-Methyl-6,7-dihydroxy-3,4-dihydroisoquinoline 263 230 
(1-Me-6,7-DHIQ HBr) 
"' r.~..WJ = Molecular weight (salt) • 
B o 1' . d . d MP C = me t1ng po1nt egrees centlgra e. 
c% Yield actual yield X lOO. 
theoret1cal y1eld 
MP°CB 
(lit. 182-184) 208 
(lit. 230-235) 208 
(lit. 205)210 
(lit. 267-268) 209 
(lit. 230)259 
% Yieldc 
85 
94 
85 
80 
90 
1-' 
w 
0 
Table 2 
Summary of GC Capillary Parameters for 
Selected Compounds of Interest 
Compound Column Temp 0 c Retention time (min) a Derivative MDQ (b) 
_(ng/m1) 
DHBA 130 4.00 HFBA 
DA 130 6.00 HFBA 0.25 
3M-DA 130 9.50 HFBA 0.45 
4M-DA 130 10.20 HFBA 0.45 
SAL 130 8.40 HFBA 0.25 
6H-SAL 130 21.55 HFBA 0.45 
7M-SAL 130 22.55 HFBA 0.45 
4,6,7(0H) 3THIQ 130 12.05 HFBA 2.00 
6M-4,7(0H) 2THIQ 130 17.64 HFBA 5.00 
7M-4,6(0H) 2THIQ 130 18.80 HFBA 7.00 
1-CSAL 125 6.45 PFPA/HFIP 1.00 
6M-l-CSAL 125 16.20 PFPA/HFIP 5.00 
t-' 
7M-l-CSAL 125 18.16 PFPA/HFIP 5.00 w I-' 
Compound 
3-CSAL 
6M-3-CSA.L 
7M-3-CSAL 
1-He-6,7 DHIQ 
l-Me-6M,70H-DHIQ 
l-Me-7M,60H-DHIQ 
Table 2 (Cont'd) 
Summary of GC Capillary Parameters for 
Selected Compounds of Interest 
Column Temp 0 c Retention time (min)a Derivative 
155 5.40 PFPA/HFIP 
155 16.70 PFPA/HFIP 
155 19.25 PFPA/HFIP 
145 4.55 HFBA 
145 7.10 HFBA 
145 8.50 HFBA 
MDQ (b) 
(ng/ml) 
1.00 
5.00 
5.00 
1. 00 
7.00 
2.00 
alOM X.25mm i.d. OV-17 glass NCOT capillary column N2°2F 0.8 kg/cm
2 detector temperature 
340, injector temperature 250°C. 
b Minimum detectable quantity (equivalent to twice the baseline noise). 
1-' 
w 
N 
Co!" pound 
NE 
DHBA 
DA 
DOPAC 
5HT 
5HIAA 
HVA 
SAL 
6r1-ST•L 
7M-f.:AL 
4,6,7-(0H) 3THIQ 
6M 4,7-(0H) 2THIQ 
7M 4,6-(0H) 2THIQ 
Table 3 
Summary of Retention Timesa and Selected HPLC Parameters 
Retention Times (min) 
6mM Heptane Sulfonic Acid, O.lM NaH 2Po4( l.OmM Na 2EDTA 
10% MeOH, 9.7% HOAct pH 3.5 pH 5.0 
6.2 1.9 
8.1 3.9 
10.4 5.2 
4.9 6.8 
21.8 13.6 
8.1 17.6 
11.3 20.1 
12.0 (8.40)b 8.4 
(27.0)b 22.8 
(23.4)b 22.8 
4.0 
9.2 
f-' 
11.6 w w 
Compound 
1-CSAL 
6!11-l-CSAL 
7M-l-CSAL 
3-CSAL 
6H-3-CSAL 
7M-3-CSAL 
1-Me-6, 7-DHIQ 
l-Me-7M- DHIQ 
1-Me- 61',1- DH IQ 
Table 3 {Cont'd) 
Summary of Retention Timesa and Selected HPLC Parameters 
Retention Times (min) 
6ml'1 Heptane Sulfonic Acid, 
10% MeOH, 9.7% HOAc, PH 3.5 
(12.86)c 
(l8.60)c 
(39.60)c 
.1M _ NaH 2Po 4 ; .lmM Na2EDTA, 
pH 5.0 
4.0 
12.8 
16.2 
4.4 
14.4 
16.0 
1--' 
w 
~ 
Table 3 (Cont'd) 
Summary of Retention Timesa and Selected HPLC Parameters 
Retention Times (min) 
aBiosil c18 reverse phase 25 em column, flow rate 1.0 ml/min. 
bChromatographed using a O.lUN&H2Po4 ,lmM Na~DTA buffer pH 5.5 with 5% MeOH. 
cChromatographed using a O.lMNa~Po4 ,lmM Na2EDTA buffer pH 7.4 with 10% MeOH. 
f-' 
w 
U1 
Compound 
SAL 
4,6,7-(aH) 3THIQ 
1-CSALe 
3-CSAL e 
1-He-6,7-DHIQ 
DAd 
Table 4 
Stereoselective In Vivo a-methylation of Catechol 
Isoquinolines in Rat Corpus Striatuma 
% of Total Methylation 
+ S.E.M. (N = 6) 
Levels of %(b) 
6-a-methylation 7-a-methylation catechol isoquinoline a-methylation 
precursor (+ s.e.m.) 
(~g/g:!:. s.e.m.) -
5 + 1. 5 95 + 1. 5 18.0 + 0.98 18. 0 + 1. 30 
55 + 2.8 45 + 2.8 15.8 + 3.60 17.4 + 0.50 
N.d. (c) 
100 + o.o 19.7 + 3.90 12.0 + 1.60 
60 + 1. 3 40 + 1.3 28.3 + 4.80 6.0 + 0.70 
N.d. N.d. 
(3M-DA 100 ~ 0.0) (4M-DA N.d.) 
I-' 
w 
()) 
a N = 6. 
b % a-methylated 
Table 4 (Cont'd) 
Stereoselective In Vivo a-methylation of Catechol 
Isoquinolines in Rat Corpus Striatuma 
Total a-methylated product X 100. 
= . "'I -- - - • • • .. - • • .. • ... -- - -
c N.d. = Not detectable. 
d Pretreated with pargyline. 
e N = 4 
....... 
w 
~ 
Compound 
SAL 
4,6,7-(aH) 3THIQ 
1-CSALa 
3-CSALa 
1-Me-6,7-DHIQ 
DAd 
Table 5 
Stereoselective In Vivo a-methylation of Catechol 
Isoquinolines in Rat Hypothalamus 
% of Total Methylation 
+ S.F.M. (N = 6) 
6-a-methylation ?-a-methylation Levels of 
6 + 1.1 
57 + 2.0 
N.d. 
61 + 2.0 
N.d. c 
(3M-DA 100 ± 0) 
94 + 1.2 
43 + 1.0 
100 + 0 
39 + 2.0 
N.d. 
(4H-DA N.d.) 
catechol isoquinoline 
precursor 
11g/g :t s.e.m. 
22 + 1.4 
34 + 1.8 
60 + 7.2 
69 + 12.2 
%b 
a-methylation 
<± s.e.m.) 
17 + 2.0 
13 + 3.0 
12 + 1.1 
9.8 + 2.5 
1--' 
w 
co 
Table 5 (Cont'd) 
Stereoselective In Vivo a-methylation of Catechol 
Isoquinolines in Rat Hypothalumas 
a N = 4. 
b ~ 
0 a-methylated Total 0-methylated pr?d~c~ _ _ _ X 100. - . . - - . . . - - . 
c N.o. = Not detectable. 
d Pretreated with pargyline. 
I-' 
w 
~ 
Compound 
SAL 
4,6,7-(0H) 3THIQ 
3-CSALa 
1-Me-6,7 DHIQ 
DAd 
a N = 3. 
Table 6 
Stereoselective In Vivo a-methylation of Catechol 
Isoquinolines in Rat Hippocampus 
% of Total Methylation 
+ S.E.M. (N = n) 
6-0-methylation 7-0-methylation 
3 + .5 97 + . 5 
54 + 1. 7 46 + 1. 5 
60 + 1. 3 40 + 1.3 
N.d. c N.d. 
3M-DA 100 + 0 4M-DA N.d. 
Levels of 
catechol isoquinoline 
precursor 
JJg/g ± s.e.m. 
16 + 2.6 
19 + 2.6 
14.5 + 7.5 
%b 
a-methylation 
(+ s.e.m.) 
19.6 + 2.0 
18.6 + 1.5 
7.0 + 0.42 
1-' 
""" 0 
Table 6 (Cont'd) 
Stereoselective In Vivo a-methylation of Catechol 
Isoquinolines in Rat Hippocampus 
h 
._ % a-methylation = Total 0-methylated 
rT"I I ... rY'IYT"T"" t I I ., - I, .. I ~ ............... - X 100. 
c N.d. = Not detectable. 
d Pargyline pretreated. 
1-' 
~ 
1-' 
Table 7 
Survey Study of SAL Uptake into the Corpus Striatum, 
Hypothalamus and Hippocampus after Intraperitoneal Administration (5-20mg/kg)a 
Brain Region Salsolinolb 
Corpus striatum N.d. e 
Hypothalamus N.d. 
Hippocampus N.d. 
a N = 12. 
b Minimum detectable quantity 3 ng/g 
c Minimum detectable quantity 5 ng/g 
d Minimum detectable quantity 5 ng/g 
e N.d. = Not detectable. 
6M-Salsolinolc 7M-Salsolinold 
N.d. N.d. 
N.d. N.d. 
N.d. N.d. 
(17.3 pmoles/g). 
(28.6 pmoles/g). 
(28.6 pmoles/g). 
Dopamine 
\.19/9 ± s.e.m. 
9.50+ 0.78 
1.90 + 0.31 
N.d. 
f-' 
of:>, 
N 
Table 8 
Levels of 5-HT and Acid Metabolites (Percent of Control) 
in Brain Areas of Rats 50 Min after (ICV) Treatment 
with Various Isoquinolines (50 llg) 
HIPPOCA.111PUS STRIATUM HYPOTHALM1US 
Compound 5-HT 5-HIAA 5-HIAA DOPAC HVA 5-HIAA DOPAC 
--
SAL 186* 110 97 99 93 111 73* 
4,6,7-TIQ 145* 127* 82* 91 94 178* 77* 
1-CSAL 112 94 103 160* 116* 150* 79* 
3-CSAL 160* 92 83* 98 93 127* 67* 
1-Me-6,7-DHIQ 176* 99 89 111 81* 148* 110 
Pargyline/DA -- 26* 18* 29* 55* 39* 39* 
* Significantly different from control (p<0.05) 
HVA 
94 
109 
103 
63* 
74* 
90 
1-' 
""' w
Table 9 
Effects of Catechol Isoquinolines on the Levels of 5-HT and 5-HIAA in the Rat Hippocampus 
]Jg/g tissue + s.e.m. (N = 6) 
c 
Compound 5HT % ~ E. 5HIAA %C E. 
--
Control (saline) 0.352 + .040 -- -- 0. 2 30 + .020 
SAL 0.656 + .090 186 .01* {). 254 ± .040 110 NSD 
4,6,7-(0H} 3THIQ 0.510 + .020 145 . 01* 0.292 + .040 127 . 01* 
1-CSAL 0.359 + .060 112 NSDb 0.217 + .020 94 NSD 
3-CSAL 0. 569 + . 0 80 160 ,01* 0.211 + .020 92 NSD 
Pargyline/DA -- -- -- 0.061 + .010 26 .01* 
1-He-6,7-DHIQ 0.618 ± .080 176 .01* 0.229 + .020 99 NSD 
a t1ale Sprague-Dawley rats were given one dose of catechol isoquinol~ne o~ dopamine 
(50 ug/animal} bilaterally into the cerebral ventricles. All animalS were anesthetized 
with 50 mg/kg of pentabarbital i.p. 
b NSD = Not significantly different. 
c % c = % of control. 1-' 
"'" 
"'" 
a 
Table 10 
Effects of Catechol Isoquinolines on the Levels of Acid Metabolites ef the 
Biogenic Amines in Rat Striatum a 
~g/g tissue ± s.e.m. 
Compound DOPAC % c E 5HIAA %C E HVA %c E 
--
Control (saline) 1.62 + .15 -- -- 0.72 + .03 -- -- 0.85 + .05 
SAL 1.61 + .15 99 NSDb 0.70 + .06 97 NSD 0.79 + .07 93 NSD 
4,6,7-(0H) 3THIQ 1.48 + .18 91 NSD 0.59 + .07 82 .01* 0.80 + .07 94 NSD 
1-CSAL 2.59 + .13 160 .01* 0.74 + .04 103 NSD 0.99 + .04 116 . 01* 
3-CSAL 1.59 + .09 98 NSD 0.60 + .08 83 .02* 0.79 + .08 93 NSD 
Pargyline/DA 0.47 + .10 29 . 01* 0.13 + .02 18 . 01* 0.47 + .07 55 . 01* 
1-Me-6,7-DHIQ 1.81 + .36 111 NSD 0.64 + .09 89 NSD 0.69 + .12 81 .05* 
a Male Sprague-Dawley rats were given one dose of catechol isoquinoline or dopamine 
(50 ~g/animal) bilaterally into the cerebral ventricles. All animals anesthetized 
with 50 mg/kg of pentabarbital i.p. 
b NSD = Not significantly different. 
c ~ C = % control. 0 ~ 
"'" Ul 
Table 11 
Effects of Catechol Isoquinolines on the Levels of Acid Metabolites of 
the Biogenic Amine in Rat Hypothalamus a 
~g/g tissue ~ s.e.m. (N == 6) 
Compound DOPAC % cc E 5HIAA %C E HVA %C E 
-- -- -- --
Control (saline) 0.114 + • 009 -- -- 0.323 + .010 -- -- 0.305 + .020 
SAL 0. 083 + • 008 73 .01* a. 358 + • o3o 111 NSD ().287 ~ .006 94 NSD 
-
4,6,7-(0H) 3THIQ 0.088 + .008 77 .01* o. 57 5 + • 0 4 0 1 7 8 .01* o. 333 + .020 109 NSD 
1-CSAL 0.090 + .004 79 .01* 0. 4 86 + • 0 30 150 • 01 'i• 0. 314 + .020 103 NSD 
-
I 
3-CSAL o. 076 + .009 67 .01* o. 4 10 + • 0 10 12 7 .01* 0.192 + • 040 63 .01* 
Pargyline/DA o. 045 + • 007 39 .01* 0.121 + .010 37 .01* 0. 276 + • 050 90 NSD 
1-Me-6,7-DHIQ 0.125 + • 061 110 NSD 0. 4 71 + • 0 50 14 8 . 0 1 * 0. 2 2 6 + • 0 2 2 74 .01* 
a Male Spraque-Dawley rats were given one dose of catechol is~quinoline or dopamine 
(50 ~g;animal) bilaterally into the cerebral ventricles. All animals were anesthetized 
with 50 mg/kg of pentabarbital i.p. 
b NSD == Not significantly different 
c % c == % of control 1-' 
,j::>. 
0) 
Table 12 
Effect of 7-0-Methyl-Salsolinol (lOug/rat) on the Levels of Biogenic 
Amines and Acid Metabolites in the Rat Striatum 
~g/g tissue ± s .. e.m. (N· = 4) 
Time of Sacrifice (hr) Dopamine a !._£__ P. DOPAC % c P. HVA %C E 
Control 
1 
3 
6 
12 
24 
48 
Time of Sacrifice (hr) 
Control 
1 
3 
8.45 + 1.04 -- NSDbl 1.30 + .20 -- --1 .626 + .036 
8.60 + 0.49 101 NSD I 1.43 + .17 109 NSDI1.202 + .032 192 .01* 
8.80 + 0.64 104 NSD 1.64 + .07 125 .05*11.016 + .088 162 .01* 
8. 40 + 1. 24 99 NSD 1.45 + .09 111 NSDI 0.814 + .172 130 NSD 
8.20 + 0.23 97 NSD 1.51 + .02 115 NSDI 0.836 + .058 133 .05* 
9.30 + 0.67 110 NSD 1.18 + .12 90 NSDI 0.640 + .134 102 NSD 
6.42 + 0.53 76 .02* I 1.17 + .08 90 NSDI 0.504 + .074 80 NSD 
5HT %C p_ 5HIAA %c P. 
0.518 + .052 0.366 + .027 
0.482 + .060 93 NSD 0.351 + .019 96 NSD 
0.544 + .048 105 NSD 0.509 + 0.25 139 .02* f-' 
""' -..J 
Table 12 (Cont'd) 
Effect of 7-0-Methyl-Salsolinol (10 ug/rat) on the Levels of Biogenic 
Amines and Acid Metabolites in the Rat Striatum 
Jlg/g tissue + s.e.m. ~N = 4) 
Time of Sacrifice (hr) 5HT % c E SHIAA % c E 
6 0.516 + .046 99 NSD 0.454 + .042 124 .05* 
12 0.400 + .034 77 .02* 0.418 + .017 114 .05* 
24 0.458 + .050 88 NSD 0.344 + .042 94 NSD 
48 0.454 + .032 88 NSD 0.344 + .046 91 NSD 
----------------------------------------------------------------------------------------
a % e· = % control. 
b NSD = Not significantly different 
1-' 
""" CX> 
Table 13 
Effect of 7-0-Methyl~alsolinol (10 ug/rat) on the Levels of 5-R~ 
and 5-HIAA in Rat Hypothalamus (A) and Hippocampus (B) 
ll gIg tissue + s . e . m . ( N .:. 4 ) 
Hypothalamus (A) 
Time of Sacrifice (hr) 5-HT G % c- p* 5-HIAA % c p* 
Control 0.606 + .034 0.448 + .024 
1 0.644 + .090 106 NSDb 0.444 + .027 99 NSD 
3 0.672 + .076 111 NSD 0.410 + .038 92 NSD 
6 0.548 + .054 90 NSD 0.416 + .028 94 NSD 
12 0.612 + .050 101 NSD 0.538 + 0.57 120 .05* 
24 0.634 + .036 105 NSD 0.613 + .007 137 .01* 
.48 0.584 + .058 96 NSD 0.561 + .035 125 .01* 
Hippocampus (B) 
Time of Sacrifice 5-HT % c p* 5-HIAA % c p* 
Control 0.295 + .011 0.299 + .025 
1-' 
ol:lo 
1.0 
Table 13 (Cont'd) 
Effect of 7-0-Methyl-Salsolinol (10 ug/rat) on the Levels of 5-HT 
and 5-HIAA in Rat Hypothalamus (A) and Hippocampus (B) 
]..lg/g tissue ± s .. e.m. (N = 4) 
Hippocampus (B) 
Time of Sacrifice (hr) 5-HT !.c._ p* 5-HIAA !_c_ p* 
--
1 0.277 + .045 94 NSD 0. 242 + • 017 81 NSD 
3 0.344 + .009 117 NSD* o. 375 + . 091 125 NSD 
6 0.245 + .006 83 .02* 0. 425 + . 045 142 .01* 
12 0.263+.005 89 NSD* 0.428 ± .018 143 .01* 
24 0.318 + .037 108 NSD o. 46 6 + . 04 3 156 .01* 
48 0.381 + .022 129 . 01 - o. 3 8 8 + . 0 2 5 130 . 01 
-----------------------------------------------------------------------------------------
a % c = % control. 
b NSD = Not significantly different. 
1-' 
U1 
0 
Table 14 
Summary of Oxidation Potential vs pH of Three 
1-Methyl-6,7-Substituted-3,4-Dihydroisoquinolines 
Compound pH Oxidation Potential E(+) 
1-Me-6,7-dihydroxy 3.0 +0.64 
3,4-dihydroisoquinoline 5.0 +0.49 
(l-.r.1e-6, 7-DHIQ) 7.4 +0.33 
1-Me-6-hydroxy-7-methoxy 3.0 +0.88 
3,4-dihydroisoquinoline 5.0 +0.65 
(l-Me-7H-DHIQ) 7.4 +0.50 
1-He-6-methoxy-7-hydroxy 3.0 +0.90 
3,4-dihydroisoquinoline 5.0 +0.79 
(l-Me-6M-DHIQ) 7.4 +0.62 
volts 
I-' 
Ul 
I-' 
Table 15 
Blood Acetaldehyde and Ethanol Concentrations (mg/dl ± s.e.m.) 
in Alcoholic Patients on Admission (Day 0) and During Early Detoxification 
DAY 
0 1 2 3 
Acetaldehyde (13) 0.350 + .071 0.104 + 0.42 <0.04 <0.04 
Ethanol ( 13) 229.7 + 29.8 5.0 + 2.0 N.d. N.d. 
Number of individual subjects in parenthes~s. 
N.d. = Not detectable. 
4 
<0.04 
N.d. 
1-' 
Ul 
N 
Table 16 
Comparison of Regional Brain Levels of DA, 5HT and Acid 
Metabolites Obtained in These Studies with Published Values 
Compound Tissue llg/g ± s.e.m. Method Reference 
DA corpus striatum 8.45 + 1.04 (a) HPLC/EDd 
9.50 + 0.78 (c) GC/ED 
8.43 + 0.73 Fluoromett'ie 166 
7.93 + 0.73 Fluorometric 165 
8.78 + 0.89 Fluorometric 201 
DOPAC corpus striatum 1.30 + 0.20 (a) HPLC/ED 
1.62 + 0.15 (b) HPLC/ED 
0.79 + 0.45 Fluoromet ric 210 
0.90 + 0.21 GC/EC 211 
2.25 + 0.37 GC/EC 212 
1.95 + 0.13 HPLC/ED 213 
--------------------------------------------------------------------------------------~ 
Ln 
uv 
Table 16 (Cont'd) 
Comparison of Regional Brain Levels of DA, 5HT and Acid 
Hetabolites Obtained in These Studies with Published Values 
Compound Tissue 
HVA corpus striatum 
5HT hypothalamus 
]lg/g + s.e.m. 
0.63 + .03 (a) 
0.85 + .05 (b) 
0.45 + .01 
0.38 + 0.06 
0.69 + 0.06 
0.66 + 0.16 
0.58 + 0.06 
0.606 + .034 (a) 
o. 707 + • 050 
0.841 + .059 
0.786 + .049 
Hethod Reference 
-
HPLC/ED 
HPLC/ED 
Fluorometric 210 
Fluorometaic 165 
HPLC/ED 213 
GC/EC 211 
GC/EC 212 
HPLC/ED 
GC/EC 214 
HPLC/ED 215 
Fluoromet~ic 201 
I-' 
lJl 
""" 
Table 16 (Cont'd) 
Comparison of Regional Brain Levels of DA, 5HT and Acid 
Metabolites Obtained in These Studies with Published Values 
Compound Tissue 11g/g ± s.e.m. l'lethod Reference 
--
HIAA hypothalamus 0.448 + .024 (a) HPLC/ED 
0.323 + .010 (b) HPLC/ED 
0.771 + 0.35 Fluorometric 166 
0.514 + .057 HPLC/ED 215 
0.400 + .028 HPLC/ED 216 
a HPLC/ED combination paired-ion ionic suppression system developed in this dissertation. 
b HPLC/ED paired-ion system utilized in this dissertation. 
c GC/EC with capillary column developed in this system. 
d ED electrochemical detection. 
I-' 
Ul 
Ul 
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Figure 1. CA condensing with a carbonyl to form a Schiff 
--
base intermediate followed by an irreversible intramolecular 
cyclization to form a THIQ alkaloid. 
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~gure 2. Condensation products of DA found in the urines 
of Parkinsonian patients undergoing L-Dopa treatment. 
158 
* 3 , 4 - Dihydroxyphenyl acetaldehyde 
f-' 
Ul 
1.0 
Figure 3. Suggested pathway for the formation of THPBs 
found in the urines of Parkinson's patients undergoing 
L-DOPA treatment. 
160 
161 
HO liver HO enzyme 
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Figure 4. Condensation products of DA and phenylpyruvic 
-
acids found in the urine of Parkinsonts patients undergoing 
L-DOPA treatment. 
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Figure 5. Phenylalanine and phenethylamine (PEA) condensation 
-
products found in the urines of PKU individuals and in the 
brain and urines of rats made "phenylketonuric". 
I II .. ~C02H HO~ NH 2 
~2H Tyrosine V NH2 B 
Phenylalanine Pyridoxal 
!-co2 
(()H2 A 
PEA 
~-C02 
~ V c~N 
HOOCH20H 
CH3 ~N 
Schiff Base 
1-' 
0'\ 
Ul 
166 
figure 6. DA/phenylpyruvic acid condensation product found 
-in the urines of PKU children and in the brain and urine 
of rats with experimentally induced hyperphenylal~ninemia. 
167 
HO 
. 
DNLCA 
Figure 7. Simple THIQs found in the urines and lumbar 
spinal fluid of human patients during and after ethanol 
intoxication. 
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~gure 8. Representation of liver EtOH oxidation. 
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Figure 9. Possible relationship between EtOH consumption, 
-
altered AcA levels, and mitochondrial impairment. 
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CHRONIC ETHANOL CONSUMPTION 
~ 
INCREASED ACETALDEHYDE CONCENTRATION 
/ ~ 
HITOCHONDRIAL DECREASED ACETALDEHYDE 
IMPAIRMENT METABOLISM 
~gure 10. Proposed pathway for the biosynthesis of THP 
during chronic EtOH ingestion. 
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Figure 11. Formation of simple 1-alkyl-THIQsfrom CAs 
and AcA. 
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Figure 12. Examples of naturally occurring plant THIQs. 
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anhalamine 
figure 13. Proposed pathWa.y for the biosynthesis of THP 
and related THIQs in plants. 
180 
HO~ 
HO.r0 Q ;IH2 
HOOC 
OH 
OH 
181 
Fe l +t-+ 
:Figure 14. Possible metabolic routes for the metabolism 
of NE. 
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Figure 15. Possible metabolic routes for the metabolism 
of DA. 
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!_igure 16. Possible metabolic routes for the metabolism 
of 5HT. 
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Figure 17. Structural similarities between the DA agonists, 
apomorphine and bulbocapnine, and the THIQ, THP. 
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Figure 18. Proposed pathways for the formation of DHIQs 
from THIQs. 
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Figure 19. Structural similarites between the quinoidamine 
tautomer of DHIQs and the oxidized form of 60HDA. 
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Figure 20. Schematic of 60HDA interacting with cellular 
nucleophiles. 
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Figure 21. Catechol isoquinolines studied for their 
stereoselective a-methylation in vivo. 
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Figure 22. GC results of washing toluene solutions of 
gFB-derivatives of NE, DA, SAL, DHBA, 3M-DA, 4M-DA with 
ammonium phosphate buffer, pH 5.9~ A, before treatment; 
B, after treatment. A 0.25 mm i.d. x 10M, OV-17, WCOT 
glass capillary column with electron-capture detector 
was utilized. GC conditions: Column temperature 130°C, 
detector temperature 340°C, injector temperature 250°C, 
N2°2F 0.8 kg/cm
2
, splitter set at 10/1. 
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A 
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Figure 23. Comparison of (A) capillary vs (B) packed 
column GC separations of HFB-derivatives of DHBA, DA, 
SAL, 3M-DA, 4M-DA, 6M-SAL and 7M-SAL. A 0.25 mm i.d. 
x 10M, OV-17 WCOT glass capillary column with electron-
capture detection was utilized. Capillary GC conditions: 
o a Column temperature 130 C, detector temperature 340 C, 
injector temperature 250°C, N2°2F .8kg/cm
2
, splitter 
" setting 10:1. The conventional packed column (1/4 x 
6 stainless steel, 3% OV-101 on Gas Chrom G-HP, 100/120 
0 
mesh) conditions: Column temperature 165 C, detector 
temperature 340°C, injector temperature 250°C and N2°2F 
25 psi. 
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Figure 24. GC chromatogram of a standard mixture of HFB-
derivatives of DHBA, DA, SAL, 3H-DA, 4M-DA, 6~-1-SAL and 
7M-SAL. Analysis was performed on a 10M x 0.25 mm i.d. 
wcoT OV-17 glass capillary column with electron-capture 
detection. Chromatographic conditions: Column temperature 
130°C, detector temperature 340°C, injector temperature 
o 0 F 2 . 250 C, N2 2 0.8 kg/em and spl1tter set at 10/1. 
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Figure 25. GC chromatogram of a standard mixture of 
HFB-derivatives of DHBA, 4,6,7-(0H) 3THIQ, 6M-4,7-(0H) 2THIQ 
and 7M-4,6-(0H) 2THIQ. Analysis was performed on a 
10M x 0.25 mm i.d., WCOT, OV-17, glass capillary column 
with electron-capture detection. Chromatographic 
conditions: Column temperature 130°C, detector temperature 
340°C, injector temperature 250°C, N 02F 0.8 kg/cm2 and 2 
splitter set at 10/1. 
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Figure 26. GC chromatogram of a standard mixture of 
PFP/HFIP-derivatives of 1-CSAL, 6M-l-CSAL and 7M-l-CSAL . 
.Analysis was performed on a lOH x 0. 25 nun i .d. 1 WCOT 1 
OV-17, glass capillary column with electron capture 
detection. Chromatographic conditions: Column temperature 
125°C 1 detector temperature 340°C, injector temperature 
o 0 F 2 . 250 c, N2 2 0.8 kg/em and spl~tter set at 10/1. 
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Figure 27. GC chromatogram of a standard mixture of 
pFP/HFIP-derivatives of 3-CSAL, 6M-3-CSAL and 7M-3-CSAL. 
Analysis was performed on a 10M x 0.25 mm i.d., WCOT, 
ov-17, glass capillary column with electron-capture 
detection. Chromatographic conditions: Column temperature 
0 0 .. 155 c, detector temperature 340C ~n]ector temperature 
o 0 F 2 . 250 C, N2 2 0. 8 kg/em, sol~tter settina 10/1. 
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Figure 28. GC chromatogram of a standard mixture of 
HFB-derivatives of 1-He-6,7-DHIQ, l-Me-6M-DHIQ and 
l-Me-7r1-DHIQ. Analysis was performed on a 10r1 x 0. 25 mrn 
i.d., WCOT, OV-17, glass capillary column with electron-
capture detection. Chromatographic conditions: Column 
temperature 145°C, detector temperature 340°C, injector 
temperature 250°C, N2°2F 0.8 kg/cm
2 
and splitter setting 
10/1. 
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Figure 29. HPLC chromatogram of a standard mixture of 
DOPAC, 5HIAA and HVA. Analysis was performed on a Bio-Sil 
212 
c18 reverse-phase 25 em column with electrochemical detection. 
HPLC conditions: Paired-ion buffer {SmM HSA, 10% MeOH, 1% 
HOAc, pH 3.5) with a flow rate of 1.0 ml/min. 
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Figure 30. HPLC chromatogram of a standard mixture of 
NE, DHBA, DA, SAL, and 5HT. Analysis was performed on a 
· s·1 c 18 h 25 1 'th 1 h · 1 B~o- ~ reverse p ase em co umn w1 e ectroc em1ca 
detection. HPLC conditions: Paired-ion buffer (8mM HSA, 
10% MeOH, 1% ijOAc, pH 3.5) with a flow rate of 1.0 ml/min. 
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Figure 31. HPLC chromatogram of a standard mixture of 
NE, DHBA, DOPAC, 5HT, 5HIAA and HVA. Analysis was performed 
. s '1 18 h 25 1 . h on a B1o- 1 C reverse p ase em co umn w1t 
electrochemical detection. HPLC conditions: Ion-
suppression buffer (0.1 NaH2P04/lmM Na 2EDTA pH 5.0) 
with a flow rate of 1.0 ml/min. 
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Figure 32. HPLC chromatogram of a standard mixture of DA, 
DOPAC, SAL, 5HT, 5HIAA, HVA, 7H-SAL and 6M-SAL. Analysis 
f d . s '1 18 h 25 was per orme on a B~o- ~ C , reverse p ase, em 
column with electrochemical detection. HPLC conditions: 
Ion-suppression buffer (0 .1 M Na.H2Po 4/lwl Na2 EDTA, pH 5. 0) 
with a flow rate of 1.0 ml/min. 
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Figure 33. HPLC chromatogram of a standard mixture of 
4,6,7-(0H) 3-THIQ, 6M-4,7(0H) 2THIQ and 7M-4,6(0H) 2THIQ. 
1 . f d . '1 18 h Ana ys~s was per orme on a B~o-s~ C , reverse p ase, 
25 em column with electrochemical detection. HPLC 
conditions: Ion-suppression buffer (0.1 M NaH2Po4/l roM 
Na2EDTA, pH 5.0) with a flow rate of 1.0 ml/min. 
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Figure 34. HPLC chromatogram of a standard mixture of 
1-CSAL, 6M-l-CSAL and 7M-l~CSAL. Analysis was performed 
· ·1 c18 h 25 1 · h on a B~o-s~ , reverse p ase, em co urnn w~t 
electrochemical detection. HPLC conditions: Ion-
suppression buffer (0.1 M NaH2Po4/l mM Na 2EDTA, pH 5.0) 
with a flow rate of 1.0 ml/min. 
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Figure 35. HPLC chromatogram of a standard mixture of 
3-CSAL, 6H-3-CSAL and 7M-3-CSAL. Analysis was performed 
. '1 18 h 25 1 . h on a B1o-S1 C , reverse p ase, em co umn w1t 
electrochemical detection. HPLC conditions: Ion 
suppression buffer (0.1 M NaH 2Po4/lmM Na2EDTA pH 5.0) 
with a flow rate of 1.0 ml/min. 
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Figure 36. HPLC chromatogram of a standard mixture of 
1-Me-6,7-DHIQ, l-Me-6M-DHIQ and l-Me-7M-DHIQ. Analysis 
was performed on a Bio-Sil c18 , reverse phase, 25 em 
column with electrochemical detection. HPLC conditions: 
226 
Ion-suppression buffer (0.1 M Na2HP04/l mM Na2 EDTA adjusted 
to pH 7.4 with 0.1 M citric acid, 10% MeOH) with a flow 
rate of 1.0 ml/min. 
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Figure 37. (A) Representat~ve GC chromatogram of a corpus 
striatum extracted with 70% aqueous EtOH and isolation on 
BioRex-70 from a rat injected ICV with SAL or DA (---). 
After Iyophflization. samples were derivatized with HFBA 
and analyzed on a 10M x 0.25 i.d., OV-17, WCOT, glass 
capillary column with electron-capture detection. GC 
conditions: Column temperature l30°C, detector tenperature 
340, injector temperature 250°C, N2°2F 0.8 kg/cm
2 
splitter 
set at 10/1. 
(B) Representative HPLC chromatogram of a 
corpus striatum from a rat injected ICV with SAL. Tissues 
228 
were extracted with 70% aqueous EtOH, isolated on BioRex-70 
lyophilized and taken up in 0 .. 1 N H.Cl. P..nalysis 'toTas 
f d . '1 18 h 25 1 per orme on a B1o-S1 C reverse p ase, em, co umn 
with electrochemical detection. HPLC conditions: Ion-
suppression buffer (0.1 M NaH 2Po4/1 ~1 Na2EDTA, pH 5.0) 
with a flow rate of 1.0 ml/min. 
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Figure 38. (A) Representative GC chromatogram of a corpus 
striatum from a rat injected ICV with 4,6,7-(0H) 3THIQ. 
Tissues were extracted with 70% aqueous EtOH, isolated on 
BioRex-70, lyophilized and derivatized with HFBA. Analysis 
was performed a 10M x 0.25 ~m i.d. OV-17 WCOT glass 
capillary column with electron-capture detection. GC 
conditions column temperature 130°C, detector temperature 
340°C, injector temperature 250, N2°2F 0.8 kg/cm
2 
and splitter 
set at 10/1. 
(B) Representative HPLC chromatogram of a corpus 
striatum from a rat injected ICV with 4,6,7-(0H) 3THIQ. 
~issues were extracted with 70% aqueous EtOH, isolated on 
BioRex-70, lyophilized and taken up in O.OlN HCL. Analysis 
was performed on a Bio-Sil c18 reverse phase column with 
electrochemical detection. HPLC conditions: Ion-suppression 
buffer (0.1 M NaH 2Po4/l rnt-1 Na2EDTA pH 5.0) with a flow rate 
of 1. 0 ml/min. 
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Figure 39. (A) Representative GC chromatogram of a 
hypothalamus from a rat injected ICV with 1-CSAL. Tissues 
were extracted with 70% aqueous EtOH, isolated on BioRex-70 
lyophilized and derivatized with PFPA/HFIP. Analysis was 
performed on a 10M x 0.25 mm i.d. OV-17, WCOT, glass 
capillary column with electrochemical detection. GC 
conditions: Column temperature 125°C, detector temperature 
340°C, injector temperature 250°C, N °2F 0.8 kg/crn2 and 2 
splitter set at 10/1. 
{B) Representative HPLC chromatogram of a 
hypothalamus from a rat injected ICV with 1-CSAL. Tissues 
were extracted with 70% aqueous EtOH, isolated on BioRex-70, 
lyophilized and taken up in 0 .rn N' HCl. ·Analysis was 
f d . '1 18 h 25 1 . per orme on a B1o-S1 C , reverse p ase em co umn w1th 
electrochemical detector. HPLC conditions: Ion-suppression 
buffer (0.1 M N'aH2Po4/l mM Na2EDTA, pH 5.0) with a flow rate 
of 1. 0 ml/min. 
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Figure 40. (A) Representative GC chromatogram of 
hypothalamus from a rat injected ICV with 3-CSAL. Tissues 
were extracted with 70% aqueous EtOH, isolated on BioRex-70 
lyophilized and derivatized with PFPA/HFIP. Analysis was 
performed on a 10M x 0.25 mm i.d., OV-17, 'NCOT, glass 
capillary column with electron-capture detection. GC 
conditions: Column temperature 155°C, detector temperature 
340°C, injector temperature 250°C, N2°2F 0.8 kg/cm
2 
and 
splitter set at 10/1. 
(B) Representative HPLC chromatogram of a 
hypothalamus from a rat injected ICV with 3-CSAL. Tissues 
were extracted with 70% aqueous EtOH, isolated on BioRex-70 
lyophilized and brought up in 0.5 ml of O.OlN HCL. Analysis 
was performed on a Bio-Sil c18 reverse phase 25 em 
column with electrochemical detection. HPLC conditions: 
Ion-suppression buffer (0.1 M NaH2Po4;1 mM Na 2EDTA, pH 
5.0) with a flow rate of 1.0 ml/min. 
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Figure 41. Summary of the site-specific in vivo 
a-methylation of various catechol-isoquinolines in the 
rRt CNS, expressed a percent of total a-methylation. 
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Figure 42. Levels of 5HT, 5HIAA, HVA and DOPAC (percent 
of control) in three rat brain regions 50 min following 
ICV administration of catechol isoquinolines (50 ug/animal). 
* = p ~ .05; ** = p _> 02. . , *** = P ~ .01; corpus striatum 
bS ; hippocampusl ; hypothalamus II . 
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Figure 43. Log of the tissue levels of 7M-SAL at different 
time points after rev injection ( 5 ug/ventricle ) i • 
hypothalamusi e corpus striatum. 
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Figure 44. Central effects of 7M-SAL on the levels of 
biogenic amines and acids. * = P > .05. 
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Figure 45. Possible tautomeric forms of DHIQs which 
can exist under physiological conditions. 
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Figure 46. W absorption spectra of A, 1-Me-6,7 DHIQ and 
B, 1-Me-7M-DHIQ; pH 2-4----; pH 7.0-13----. 
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Figure 47. Excitation and emission spectra of A, l-Me-
6,7-DHIQ and B, l-Me-7M-DHIQ. 
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Figure 48. Variation of fluo~escence intensity with pH of 
1-He-6, 7-DHIQ (0) and l-~1e-7M-DHIQ (D) · 
>-
1-
-(./') 
z: 
LL.I 
1-
z: 
-
LL.I 
> 
-~ 
-1 
LL.I 
0::: 
o-o-.o-o 
/ 
0 
0 
(J1 0'\ 
<.0 -0 
0 
0 
251 
Figure 49. UV absorption spectra of A, 1-He-6, 7-m·1 DHIQ 
and B, 1-He-6M-DHIQ; pH 1-9----; pH 10-13--. 
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Figure 50. Excitation and emission spectra of 1-Me-6,7-
DH DHIQ. 
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Figure 51. Variation of fluoresc~nce intensity with pH 
of 1-Me-6,7-DM DHIQ. 
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Figure 52. Cyclic voltanunograrns of 1-He-6, 7-DHIQ; A, pH 
3.0 (---); B, pH 5.0 (---); C, pH 7.4 <•-•); scan rate 
200 rnv/sec sensitivity 211A/crn. 
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Figure 53. Cyclic voltarnmograms of l-Me-7M-DHIQ; A, pH 
3.0 (---); B, pH 5.0 (---); C, pH 7.4 (A-~); scan speed 
200 mv/sec, sensitivity 2uA/cm. 
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Figure 54. Cyclic volta·mmograms of l-Me-6M-DHIQ; A, pH 
3.0 (---); B, pH 5.0 (--); C, pH 7.4 (•-•); scan speed 
200 rnv/sec, sensitivity 2~A/cm. 
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Figure 55. Representative GC chromatogram of head-space 
of control blood spiked with AcA, EtOH and N-propanol 
(internal standard) incubated at 37°C, using PoraPak 
QS column with flame ionization detection. 
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Figure 56. Comparison of structural similarities between 
DHIQs, pyrones, pyridones and tropolones. 
266 
(/) 
LJ.J 
z 
0 _J
 
0 c.. 
0 c:::: 
1
-
(/) 
LJ.J 
~ 0 ...... c:::: >-c.. (/) LJ.J z 0 c:::: >-c.. 
267 
268 
Figure 57. (A) Proposed alternative binding orientations 
of CA substrates at the catechol binding site of COMT, C-) 
meta-binding orientation and para binding orientation (---). 
(B) Proposed alternative binding orientations 
of catechol-isoquinoline substrates at the catechol-binding 
site COHT, para (7) binding orientation (--) and meta (6) 
binding orientation (---). H = proposed hydrophobic center; CA= 
CA binding center; SAM = SN1 binding site. 
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Figure 58. (A) Transition of a 1-Me-6-hydroxy-DHIQ with pH. 
{B) Transition of 1-Me-6-substituted-DHIQ with 
pH. 
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Figure 59. (A) Theoretical single peak voltammogram of a 
model oxidizable compound. 
(B) Theoretical cyclic voltammogram of a model 
oxidizable/reducible compound. 
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Figure 60. Cyclic voltammograms of model compounds show 
redox reactions which are; A, fast (reversible); B, 
intermediate (guasi-reversible; C, slow (irreversible) . 
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Figure 61. Possible reaction pathways for the electrochemical 
oxidation of DHIQs. 
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Figure 62. Possible metabolic routes for 1-CSAL in vivo. 
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AAD 
AcA 
ACN 
ADH 
ALDH 
AL203 
BBB 
BBr3 
CA.s 
CNS 
co2 
1-CSAL 
3-CSP...L 
COMT 
DP._ 
DBH 
DDC 
DHBA 
DHIQ 
dH20 
DHPA,cA 
DNLCA 
D20 
LIST OF ABBREVIATIONS 
Aromatic acid decarboxylase 
Acetaldehyde 
Acetonitrile 
Alcohol dehydrogenase 
Aldehyde dehydrogenase 
AluminUP.l oxide 
Blood-brain-barrier 
Borontribromide 
Catecholamines 
Central nervous system 
Carbon dioxide 
1-carboxysalsolinol 
3-carboxysalsolinol 
Catechol-0-methyl-transferase 
Dopamine 
Doparnine-S-hydroxylase 
L-Dopa decarboxylase 
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Dihydroxybenzylamine 
3,4-Dihydroisoquinoline 
Deionized-distilled water 
3,4-Dihydroxyphenylacetaldehyde 
3,4-Deoxynorlaudanosoline carboxylic acid 
Deuterium oxide 
DOPAC 
DOPEG 
EC 
EPI 
EtOAc 
EtOH 
GC 
GSH 
HBR 
HCHO 
HFBA 
HFIP 
5HIAA 
HoAc 
HSA 
5HT 
5HTOL 
5HTP 
HVA 
I2 
ICV 
IR 
KBr 
L-DOPA 
MAO 
3,4-Dihydroxyphenylacetic acid 
3,4-Dihydroxyphenylethylene glycol 
Election capture 
Epinephrine 
Ethyl acetate 
Ethanol 
Gas chromatograph 
Glutathione 
Hydrogen bromide 
Formaldehyde 
Heptafluorobutyric anhydride 
Heptafluoroisopropanol 
5-Hydroxyindoleacetic acid 
Acetic acid 
Heptane sulfonic acid 
Serotonin 
5-hydroxytryptophol 
5-hydroxytryphophan 
Homovanillic acid 
Iodine 
Intracerebroventricular 
Infra red 
Potassium ion 
Potassium bromide 
3,4-Dihydroxyphenylalanine 
Monoamine oxidase 
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6M-l-CSAL 
7M-l-CSAL 
6M-3-CSAL 
7M-l-CSAL 
3M-DA 
4M-DA 
1-Me-6,7-DHIQ 
1-Me-6,7-DMDHIQ 
l-Me-6M-DHIQ 
l-Me-7M-DHIQ 
MeOH 
MEOS 
MET 
Mg++ 
MOPEG 
NMLCA 
MS 
6M-SAL 
7M-SAL 
6M-4,7(0H) 2THIQ 
7M-4,6(0H) 2THIQ 
6-0-methyl-1-carboxysalsolinol 
7-0-methyl-1-carboxysalsolinol 
6-0-methyl-3-carboxysalsolinol 
7-0-methyl-3-carboxysalsolinol 
3-0-methyl-dopamine 
4-0-methyl-dopamine 
1-methyl-6,7-dihydroxy 3,4-dihydroiso-
quinoline 
1-methyl-6,7-dimethoxy 3,4-dihydroiso-
quinoline 
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1-methyl-6-methoxy-7-hydroxy-3,4-dihydro-
isoquinoline 
1-methyl-6-hydroxy-7-methoxy-3,4-dihydro-
isoquinoline 
Methanol 
Microsomal ethanol oxidizing system 
Metanephrine 
Magnesium ion 
3-methoxy-4-hydroxyphenylethylene glycol 
3-0-methylnorlaudanosolinecorboxylic acid 
Mass spectrum 
6-0-methyl-salsolinol 
7-0-methyl-salsolinol 
6-methoxy-4,7-dihydroxy-tetrahydroiso-
quinoline 
7-methoxy-4,6-dihydroxy-tetrahydroiso-
quinoline 
Nitrogen gas oxygen free 
Nitrogen gas extra dry 
Na+ 
NAD 
NADH 
NE 
6NH2 DA 
NLCA 
NMR 
NORMET 
NTs 
60HDA 
OSA 
OV-17 
OV-101 
PEA 
PFPA 
PIC 
PKU 
PNMT 
SAL 
SAM 
SCOT 
TCA 
Sodium ion 
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Nicotinamide-adenine-dinucleotide oxidized 
form 
Nicotinamide-adenine-dinucleotide reduced 
form 
Norepinephrine 
6-Amino-dopamine 
Norlaudanosalinecarboxylic acid 
Nuclear magnetic resonance 
Normetanephrine 
Neurotransmitters 
6-Hydroxy-dopamine 
Octane-sulfonic acid 
Polyphenylmethylsiloxane 
Polydimethoxysiloxane 
Phenethylamine 
Pentafluoropropionyl anhydride 
Paired-ion chromatography 
Phenylketonuria 
Phenethanolarnine-N-methyl-transferase 
Phosphorous pentoxide 
Reverse phase 
Room temperature 
Salsolinol 
S-adenosyl-L-methionine 
Support coated open tubular 
Citric acid cycle 
TFAA Trifluoroacetic anhydride 284 
TH Tyrosine hydroxylase 
THBC Tetrahydro-B-carboline 
THIQ Tetrahydroisoquinoline 
4,6,7-(0H) 3-THIQ 4,6,7-Trihydroxy-tetrahydroisoquinoline 
6,7-(0H) 2-THIQ 6,7-Dihydroxy-tetrahydroisoquinoline 
THP Tetrahydropapaveroline 
THPB Tetrahydroprotoberberine 
TLC Thin layer chromatography 
TMQ Tximetoquinol 
VMA Vanillyrnandelic acid 
WCOT Wall coated open tubular 
HPLC High performance liquid chromatography 
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